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than 4.5 µm the mean from five repeated measurements. 
 
Figure 4.19 The relationship between the normalised fluidisation energy (FENorm) of the 
carrier pre-blends and the DPI performance in terms of fine particle fraction of 
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emitted dose (FPFED) from formulations prepared with different fines and 
aerosolised with different devices. The data represents mean ± standard 
deviation, n=3. 
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Figure 5.10 Measured vs. the predicted output for A) fine particle fraction of emitted dose 
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Figure 6.5 The relationship between the proportion of particles deposited in the throat 
and the amount of drug recovered from the throat. The data for drug 
deposited in throat represents mean ± standard deviation. The data for 
proportion of particles below 29 µm is based on single measurement.  R2= 
0.999 
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ABSTRACT 
 
Dry powder inhalers (DPIs) are used for delivering drugs to the airways. In addition to the 
drug, the formulations often contain a coarse carrier, most commonly alpha lactose 
monohydrate. The presence of fine lactose particles in the formulation is known to 
improve the formulation performance. The active site, drug-fines agglomeration and 
increased cohesion theories have been suggested to explain improved DPI performance 
upon addition of fine excipient particles. This project aimed to investigate the validity of 
those theories.  
 
The viability of the active sites theory in explaining the improved DPI performance was 
investigated by studying the impact of loaded drug dose on the in vitro performance for 
formulation series prepared with coarse carriers with different surface characteristics. The 
formulations prepared with the rougher lactose carrier were seen to outperform the 
formulations prepared with the smoother carrier at all drug concentrations. These findings 
were concluded to be non-compatible with the active sites theory. 
 
The impact of addition of lactose fines with different size distributions on powder flow and 
fluidisation properties and in vitro performance was studied. Powder cohesion increased 
independent of size distribution of the fines, but did not necessarily correspond to 
improved performance. Therefore, the increased cohesion theory was concluded not to be 
the sole explanation for the improvement in DPI performance in the presence of lactose 
fines. Instead, the increase in performance could be preliminarily attributed to the 
formation of agglomerated systems. The formation and co-deposition of drug-fines 
agglomerates, and consequential improvement in the DPI performance was proved using 
morphologically directed Raman spectroscopy.  
 
The project also aimed to develop a universal model for predicting DPI performance 
based on the lactose properties for a wide range of carriers with different properties. No 
simple linear correlations between any the lactose properties and the final DPI 
performance were found. Therefore no single parameter can be used as a universal 
predictor for DPI performance. To establish more complex relationships, artificial neural 
networks were used for modelling the importance of different lactose properties in 
determining DPI performance. The proportion of fine lactose particles (<4.5 µm) was 
identified as the most important parameter. However, this parameter was capable of 
explaining only approximately half of the variation seen in the formulation performance. 
The current study showed that to obtain more accurate predictions for the purposes of 
quality-by-design approach, also other lactose properties need to be characterised.  
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CHAPTER 1 INTRODUCTION 
OVERVIEW 
 
Dry powder inhaler (DPI) formulations are used for delivering drugs to the lungs for the 
treatment of respiratory diseases. This thesis concentrates on understanding how the 
properties of lactose used as an excipient in carrier based DPI formulations govern the 
performance of the final product. The introduction can be roughly divided into three parts. 
During the first part, to appreciate the requirements of successful pulmonary drug delivery, 
the anatomy of the respiratory tract, the pharmacokinetic properties of the lung as a port 
of entry for the drug, the target diseases for respiratory drug delivery, the mechanisms of 
particle deposition in the lungs and the dosage forms currently available for delivering 
drugs to the lungs are introduced. To understand the physical phenomena governing dry 
powder inhaler formulation performance, the second part of the introduction covers the 
general properties of powders, interparticulate interactions, powder fluidisation and 
deagglomeration. The last part of the introduction is more specific to dry powder inhaler 
formulations. The available formulation strategies will be discussed. This is followed by an 
introduction to lactose and a review of literature on the relationship between lactose 
properties and the final formulation performance.  
 
1.1 DRUG DELIVERY TO THE LUNGS 
 
1.1.1 Anatomy of the respiratory tract  
 
The human upper airways consist of oral and nasal cavities, pharynx and larynx (Stevens 
et al. 1995). With regards to the delivery of orally inhaled drug products, the anatomy of 
the upper airways is dominated by a major change of direction in the pharynx, where the 
oral and nasal cavities are joined together.  
 
The structure of the lower airways is often referred to as the tracheobronchial tree (Newell 
2003). This is because the airways form a tree like structure with each of the parent 
airways splitting into two daughter airways for an average of 23 generations (Weibel et al. 
2005). A 3D visualisation of the tracheobronchial tree based on high resolution 
computerised tomography is shown in Figure 1.1 (Schmidt et al. 2004). The uppermost 
part of the lower airways is the trachea, analogous to the trunk of the tree. The next few 
generations are the bronchi and the deepest airways are the bronchioles. Bronchi and 
29 
 
bronchioles form the branches of the tree. The last seven generations of the airways are 
covered by alveoli, which are responsible for the large surface area of the lungs. The 
peripheral regions of the airways, covered by the alveoli, form the respiratory zone of the 
lung where the gas exchange takes place (Patton et al. 2007). Within the respiratory zone, 
the air flow is governed by diffusion. The airways above the respiratory airways are the 
conducting airways. The air flow in the conductive airways is convective (Weibel et al. 
2005). 
 
An important feature of the respiratory tract with regards to pulmonary drug delivery is that 
the more peripheral the airway within the tracheobronchial tree, the smaller the diameter. 
Trachea has a diameter of approximately 18 mm, the primary bronchi 12 mm and the first 
generation of bronchioles approximately 4 mm. The diameter of the airways connected to 
the alveoli is approximately 0.5 mm or less (Tsuda et al. 2008). The decrease in the 
airway diameter as the airways reach the peripheral lung regions is also visible in Figure 
1.1.  
 
 
FIGURE 1.1 3D VISUALISATION OF THE TRACHEOBRONCHIAL TREE OBTAINED FROM HIGH RESOLUTION 
COMPUTERISED TOMOGRAPHY MEASUREMENTS. REPRINTED FROM COMPUTERIZED MEDICAL IMAGING AND 
GRAPHICS, 28, SCHMIDT, A. et al., A DIGITAL REFERENCE MODEL OF THE HUMAN BRONCHIAL TREE, 203-
211, COPYRIGHT (2004), WITH PERMISSION FROM ELSEVIER 
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1.1.2 Pharmacokinetics of respiratory drug delivery 
 
The lungs are an appealing route for topical, and increasingly also for systemic, drug 
delivery. There are various reasons for this, all deriving from the favourable 
pharmacokinetics of pulmonary drug delivery. The large surface area of the lungs means 
that the drug delivered as an aerosol via the pulmonary route is dispersed sparsely on the 
epithelial surfaces available. This may result in rapid dissolution and absorption of the 
drug. The rapid absorption of the drug via the pulmonary route makes the lung an 
excellent route for administering drugs for symptoms where a quick onset of action is 
required, such as asthma exacerbations (Patton et al. 2004).  
 
Additionally, the first pass metabolic effect is avoided when the drugs are delivered via the 
pulmonary route, resulting in good bioavailability (Patton et al. 2004). Lungs also have 
very low enzymatic activity (Patton et al. 2007). Therefore, molecules that might be 
digested in the gastrointestinal tract before absorption can often successfully be delivered 
via the pulmonary route. Systemic side effects can also often be avoided when drugs are 
delivered via the lungs (Lipworth 1996).  
 
  
1.1.3 Traditional target diseases for respiratory drug delivery and inhaled drug 
therapies available for managing the diseases 
1.1.3.1 Asthma 
 
Asthma is a chronic disease affecting the airways. The patients often have a genetic 
tendency towards asthma. However, exposure to environmental factors, such as allergens 
and air pollutants, is also known to significantly contribute to the development of the 
disease by inducing irritation of the airways (Welte et al. 2006). According to the World 
Health Organization (WHO), approximately 235 million people worldwide suffer from the 
disease (WHO 2012). The symptoms of asthma include coughing, wheezing, tightness of 
the chest and shortness of breath. These symptoms are caused by two main 
mechanisms, bronchoconstriction and inflammation (Welte et al. 2006). In an asthmatic 
lung, bronchoconstriction and inflammation are expressed both in the conducting and 
peripheral airways (Hyde et al. 2009). 
 
Asthma can be controlled by a combination of long term control and quick-relief inhaled 
medication (Fanta 2009). The purpose of the long term control medication is mainly to 
reduce inflammation. The drugs used for this purpose are corticosteroids. However, the 
long term control of asthma can also include long term bronchodilation using long acting 
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β2-agonists (Fanta 2009). Quick relief medication on the other hand aims to relieve 
exacerbations caused by acute bronchoconstriction. Short acting β2-agonists are the most 
effective drugs for this purpose (Fanta 2009).  
 
1.1.3.2 Chronic obstructive pulmonary disease  
 
Chronic obstructive pulmonary disease (COPD) is an irreversible condition where the 
airways are progressively obstructed. The airway obstruction in COPD is caused by 
inflammation, structural changes within the airways and mucociliary dysfunction (Agusti 
2005). The airway obstruction results in a gradual decrease in lung function and 
worsening of the symptoms over time (William 2003). COPD mainly affects the small 
airways (Cazzola et al. 2007). The disease is aggravated by air pollutant particles, the 
greatest cause for the disease being cigarette smoke (William 2003).  It has been 
estimated that by year 2020 COPD will be the third most common cause of death in the 
world (Welte et al. 2006).  
 
At present, the only effective treatment for COPD is smoking cessation. However, the 
symptoms, which include chronic cough and abnormal sputum excretion, can be relieved 
by medication. The inhaled drugs used for relieving symptoms of COPD include 
bronchodilators for relieving the airway obstruction and corticosteroids for controlling 
inflammation (Hanania et al. 2005). The combination of long acting β2-agonist and inhaled 
corticosteroids has been shown to be beneficial for regulating the mucus hypersecretion 
(Hanania et al. 2005). 
 
 
1.1.4 Mechanisms of particle deposition in the lungs 
1.1.4.1  Inertial impaction 
 
Inertial impaction is the most important mechanism in determining the drug deposition in 
the lungs (Zeng et al. 2001a). Inertial impaction of the drug particles takes place when the 
momentum of the particles carried in the inspiratory air flow is too large to negotiate a 
change of direction in the airflow, for example when the respiratory tract branches to the 
next generation. As a consequence, the particles with too high a momentum will deposit in 
the respiratory tract by inertial impaction (Zeng et al. 2001a). Stokes’ number, Stk, is a 
dimensionless parameter and describes the likelihood of particle deposition in the 
respiratory tract by impaction according to Equation 1.1, where ρp is particle density, d is 
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the particle diameter, V is air velocity, η is the viscosity of air and R is the radius of the 
airway.  
 
ࡿ࢚࢑ ൌ ࣋࢖ࢊ૛ࢂ૚ૡࣁࡾ       EQUATION 1.1 
 
The larger the Stokes’ number for a particle, the more likely it is it will be deposited by 
inertial impaction (Zeng et al. 2001a). According to Equation 1.1, the particle deposition in 
the deeper regions of the lungs by inertial impaction can be improved by decreasing the 
particle size, density or air flow rate.  
 
1.1.4.2 Sedimentation 
 
Sedimentation of the particles in the airways is a time dependent process and maximising 
the drug deposition in the smaller airways and alveolar region by sedimentation is the 
reason patients are commonly instructed to hold breath after inhalation (Zeng et al. 
2001a). During sedimentation, particles settle in the airways under the influence of gravity 
as determined by their terminal settling velocity, Vts, as defined by the Stokes’ law (Zeng 
et al. 2001a).  Vts of a particle is defined by Equation 1.2, where ρp is the density of a 
particle, ρa is the density of air (ρp>ρa), d is the particle diameter, g is the acceleration due 
to gravity and η is the viscosity of air. 
 
ࢂ࢚࢙ ൌ 	 ሺ࣋࢖ି࣋ࢇሻࢊ
૛ࢍ
૚ૡࣁ 	    EQUATION 1.2 
 
Particles smaller than 10 µm sediment easier than predicted by the Stokes’ law (Zeng et 
al. 2001a). This is because slipping of the particles between each other may take place. 
Therefore, the Cunningham slip factor is applied for particles smaller than 10 µm (Zeng et 
al. 2001a). Stokes’ law is also valid only when the air flow is laminar (Zeng et al. 2001a). 
Reynold’s number, Re determines whether air flow is laminar (Re < 2000) or turbulent (Re 
> 4000) according to Equation 1.3, where ρa is the density of air, V is the air velocity, d’ is 
the diameter of the airway and η is the viscosity of air.  
 
ࡾࢋ ൌ 	 ࣋ࢇࢂࢊ
ᇲ
ࣁ      EQUATION 1.3 
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Turbulent airflow is characterised by fluctuations in the direction of the air flow. 
Consequentially, if the air flow in the respiratory tract is turbulent, inertial impaction 
becomes the prevalent mechanism of particle deposition instead of sedimentation (Zeng 
et al. 2001a).  
 
1.1.4.3  Diffusion 
 
Deposition of particles smaller than 1 µm in the airways takes place by diffusion. This form 
of deposition is a result of random movement of the particles, the Brownian motion. 
Brownian motion is caused by bombardment of the particles by surrounding gas 
molecules (Brown 1828). The phenomena is related to the size of the particles according 
to the diffusion constant, Dif, determined by Stokes-Einstein equation (Equation 1.4), 
where k is the Boltzmann constant, T is the absolute temperature, η is the viscosity of air 
and d is the diameter of the particle. 
  
ࡰ࢏ࢌ ൌ ࢑ࢀ૜࣊ࣁࢊ       EQUATION 1.4 
 
Brownian motion is inversely proportional to the particle size. Therefore, the smaller the 
particle size, the more likely the particles are to behave in a similar way to gas molecules, 
and will be exhaled before deposition (Ariyananda et al. 1996). To avoid exhalation of the 
drug particles, the particle size for inhalable drugs is generally recommended to be larger 
than 1 µm. 
 
1.1.4.4 Interception 
 
Particle deposition by interception takes place in the airways when the particle shape 
differs from a perfect sphere (Zeng et al. 2001a). The centre of gravity of an irregularly 
shaped particle may be within the streamlines of the air flow. However, owing to the 
irregular shape, the distal end of a non-spherical particle may be touching the walls of the 
airways earlier than determined by the impaction, sedimentation or diffusion for a 
spherical particle, thus resulting in particle deposition in a different region in the airways 
(Cai et al. 1988). In practice, for inhalation formulations, interception is not an important 
mechanism because the particle diameter is generally much smaller than the diameter of 
the airways. However, if the formulation contained elongated drug particles, the 
mechanism would become more important in determining the regional drug deposition in 
the lungs (Zeng et al. 2001a). 
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1.1.4.5  Electrostatic precipitation 
 
Upon inhalation, drug particles may develop a charge that is unlikely to dissipate between 
the inhalation event and the drug deposition in the respiratory tract (Zeng et al. 2001a). 
Two different mechanisms for particle deposition by electrostatic precipitation exist 
(Heyder 2004). The charged particles from the inhalation bolus can create an image 
charge on the grounded surface of the respiratory tract that attracts the particles. A less 
important mechanism is repulsion between particles with a charge of the same sign that 
results in particle deposition in the respiratory tract (Heyder 2004).  
 
 
1.1.5 Dosage forms for respiratory drug delivery 
1.1.5.1  Pressurised metered dose inhalers 
 
Worldwide, pressurised metered dose inhalers (pMDIs) are the most prescribed drug 
delivery systems for asthma and COPD (Dolovich et al. 2011). In a pMDI formulation the 
drug particles within the respirable range are suspended or solubilised in a propellant with 
the aid of a surfactant. The suspension/solution formulation is contained within a canister 
that holds multiple doses of the drug. The dose of the drug delivered by a single actuation 
is controlled by a metering valve. Upon actuation, the dose metered in the holding 
chamber is released and a jet of droplets containing the propellant and the drug is formed. 
The propellant then evaporates leaving behind drug particles or droplets within the 
respirable range (Ariyananda et al. 1996). Traditionally the propellants used in the pMDI 
products were chlorofluorocarbons (CFCs). However, due to environmental concerns 
related to ozone depletion, the use of CFCs was banned in the Montreal protocol set out 
in 1987 (McDonald et al. 2000). The propellants that have replaced CFCs in the pMDIs 
are hydrofluoroalkanes (HFAs). 
 
The advantages of pMDIs over other pulmonary drug delivery platforms are related to the 
formulation stability, device portability and cost effectiveness (Keller 1999). The main 
drawback of pMDIs is the requirement for co-ordination between the actuation of the dose 
and inspiration. Correct timing of the actuation and inhalation is essential to ensure that 
the high velocity aerosol jet exiting the device will be entrained in the inhaled air flow 
rather than impacted in the pharynx. However, drug deposition at the back of the throat 
due to the lack of co-ordination between the actuation and the inhalation can be reduced 
by using add-on devices, such as spacers or holding chambers (Keller 1999).  
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1.1.5.2  Nebulisers 
 
With nebulisers, respirable droplets of the drug are produced from solution or suspension 
formulations. Traditionally, two different technologies for forming the droplets from the 
liquid have been available, namely jet nebulisers and ultrasonic nebulisers (Dalby et al. 
2003). With jet nebulisers, a pressure differential between the liquid reservoir and the 
orifice of the liquid feed tube is created by using compressed gas. The pressure 
differential results in the liquid from the reservoir being drawn up the feed tube following 
Bernoulli’s principle. The liquid is then broken in to a fine mist of droplets at the outlet of 
the feed tube (Labiris et al. 2003). With ultrasonic nebulisers, the droplets are generated 
by a piezoelectric crystal that is vibrating at a high frequency (1-3 MHz).  As a result, a 
standing wave is formed on the surface of the liquid reservoir. A fountain of droplets is 
formed at the crest of the standing wave by cavitation and capillary wave formation (Dalby 
et al. 2003). The higher the frequency of the piezoelectric crystal, the smaller the resulting 
droplet size (Labiris et al. 2003).  
 
Due to the large size of the compressors and the nebulising masks, the use of nebulisers 
has mainly been restricted to hospital and ambulatory settings. The proportion of drug 
deposited from the nebulisers has also traditionally been low because of the lack of 
control over the aerosol formation relative to the patient’s breathing patterns. This has 
resulted not only in a large proportion of the drug being wasted but also in relatively long 
inhalation times for gaining the therapeutic dose, a factor that has also restricted the use 
of nebulisers in chronic disease management. However, the most recent developments in 
nebuliser technology in the form of multidose liquid inhalers and vibrating mesh nebulisers 
have resulted in more portable devices, shorter inhalation times and more efficient drug 
delivery (Dolovich et al. 2011). 
 
1.1.5.3 Dry powder inhalers 
 
Unlike pMDIs and nebulisers, DPI formulations do not contain a liquid phase. The drug is 
delivered to the patient’s lungs from a static powder bed instead. The current section will 
concentrate on the different devices available for delivering the dose from dry powder 
inhalers and the general mechanisms involved in delivering the dose to the patient’s 
lungs. The formulation aspects are central to the thesis and therefore will be discussed in 
more detail later on in the introduction. 
 
The first commercial DPI product, Aerohalor, was introduced in 1948 for the pulmonary 
delivery of penicillin (Sanders 2007). Since then, a variety of different device types has 
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been developed. Nowadays, the devices on the market can be classified according to the 
number of doses held within the device (single dose vs. multidose), the storage 
mechanism of the formulation in the device (capsule vs. blister vs. reservoir) and the 
fluidisation mechanism (active vs. passive). These forms of devices will be briefly 
introduced in the following. 
 
A DPI device can either hold a single or multiple doses of the drug (Smith et al. 2003). 
With single dose devices, the patient loads a capsule containing the dose into the device 
and primes the capsule before every inhalation. With multiple dose devices, the doses of 
drug are either held in a reservoir where the drug dose is metered upon priming the 
device, or in a blister strip where a single dose of the drug is exposed upon priming the 
device (Smith et al. 2003). The drug delivery mechanism of the device can be either 
passive or active. In traditional, passive DPI devices the drug delivery to the lungs relies 
on the patient’s inspiratory effort for delivering the dose of the drug from a static powder 
bed. In active DPIs, mechanical aids such as piezoelectric crystals or compressed air are 
used for delivering the dose of drug (Tobyn et al. 2004).  
 
With all these devices, three steps are required to achieve successful drug delivery to the 
lungs from the formulation contained within the device. Firstly, the powder containing the 
dose of the drug has to be fluidised. Secondly, the particles have to be deagglomerated to 
achieve drug particles within the respirable size range. Thirdly, the particles within the 
respirable range have to be entrained in the inspiratory airflow to be deposited in the site 
of action in the lungs (Telko et al. 2005). The significance of fluidisation of the dose in the 
drug delivery from DPIs is a relatively newly realised concept and was first mentioned as a 
requirement for successful drug delivery from DPIs by Telko et al. (2005). The importance 
of deagglomeration and entrainment has been recognised in the literature for longer 
(Ganderton 1997).  
 
The process of fluidising a static powder bed followed by simultaneous entrainment and 
deagglomeration of the formulation is illustrated in Figure 1.2. Deagglomeration and 
entrainment are presented as simultaneous processes in the schematic. This is because 
the proportion of the respirable fraction of drug from DPI formulations is often relatively 
low, between 20 and 30% of the loaded dose (Steckel et al. 1997). It is therefore 
reasonable to assume that some of the formulation will be entrained before 
deagglomeration and thus never reach the respirable particle size range. However, it is 
also known that powder deagglomeration takes place due to particle-particle and particle-
device impactions and turbulences in the inspiratory flow (Voss et al. 2002). Therefore, 
due to turbulences in the inspiratory air flow, some deagglomeration may also take place 
after the formulation has been entrained.  
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FIGURE 1.2 A SCHEMATIC SHOWING THE PROCESSES INVOLVED WITH DELIVERING THE DRUG FROM A 
STATIC POWDER BED CONTAINED IN A DPI PRODUCT.  THE POWDER BED IS FLUIDISED AND THE DRUG IS 
THEN SIMULTANEOUSLY DEAGGLOMERATED AND ENTRAINED  
 
The main advantage of DPIs compared to the pMDIs is that the delivery of the dose is 
breath actuated. Therefore, the issue of co-ordinating the inhalation with the actuation of 
the dose is avoided. However, the extent of drug delivery also relies on the inspiratory 
effort. Therefore, the delivered dose may be compromised, especially with patients with 
severe constriction in pulmonary capacity. In addition, the production of DPIs is relatively 
expensive compared to the production of pMDIs (Ariyananda et al. 1996).     
 
1.2   CHARACTERISTICS OF POWDERS  
 
1.2.1 The fourth phase of matter? 
 
Powders are granular materials consisting of solid particles of different sizes. In a dry 
powder, interstitial gas fills the voids between the particles (Rietema 1984). Powders 
exhibit properties of all the other three phases and under certain circumstances they can 
be compressed like gases, poured like liquids or deformed both plastically or elastically 
like solids (Rietema 1984). However, unlike gases, liquids and solids, powders are 
temperature independent (Heinrich et al. 1996). This is because the potential energy for a 
particle with a mass of m and diameter of d, is of the order of mgd, where g is the 
acceleration due to gravity. For a typical grain of sand, this value will be 1012 higher than 
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the thermal constant kT, where k is Avogadro’s constant and T the absolute temperature 
(Heinrich et al. 1996). The driving force of gravitation over the thermal effects explains, for 
example, how cereal segregates in a container as a result of the vibrations induced by 
transport despite the lower entropy of the system in the segregated state (Heinrich et al. 
1996).  
 
Powders also have a memory of past process history. The memory effect affects the 
properties of powders down the line (Valverde et al. 2003). For example, after 
segregation, the powder does not spontaneously return to its initial state after the factor 
that caused the segregation has been eliminated.  
 
Cohesion is a property of bulk powders that is defined as the powder’s resistance to flow 
(Geldart et al. 2007). Cohesion of a powder is determined by the magnitude of the 
interparticulate forces within the powder bulk. The major interparticulate forces 
contributing to the general powder flow and handling properties are introduced in the 
following.   
 
 
1.2.2 Particle-particle interactions in powders 
1.2.2.1  Van der Waals interactions 
 
Van der Waals interactions are named after a Dutch physicist who discovered that the 
attractive forces between molecules were responsible for the deviation of the behaviour of 
real gases from the ideal gas law. These interactions are a consequence of the attraction 
between molecules due to momentary changes in their electron densities exhibited even 
by molecules that do not carry a charge. In general, van der Waals interactions can be 
classified as dipole/dipole, dipole/non-polar and non-polar/non-polar interactions 
(Valderrama 2010). The van der Waals force, FvdW, between two identical spheres of 
radius Rs is defined by Equation 1.5, where A is the Hamaker constant and a is the 
separation distance between the bodies (Seville et al. 2000).  
 
ࡲ࢜ࢊࢃ ൌ ࡭ࡾ࢙૚૛ࢇ૛      EQUATION 1.5 
 
The contact between two spherical particles is illustrated in Figure 1.3A. Generally, the 
separation distance between particles becomes smaller as the particle size is diminished. 
In addition, the gravitational force becomes negligible compared to the van der Waals 
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interaction as particle size decreases (Visser 1989). As a result, van der Waals forces are 
very significant in fine powders.  
 
In reality, particles are seldom perfect spheres but exhibit surface roughness or irregular 
shapes instead. The van der Waals interactions will be significantly altered as a result of 
the changes in the surface morphology and contact geometry of the particles (Visser 
1989). Figure 1.3B illustrates a case of reduced van der Waals interaction due to 
decreased contact area derived from small scale surface roughness. Figure 1.3C and 
Figure 1.3D on the other hand illustrate cases of increased van der Waals interactions 
originating from increased contact area due to large scale surface roughness and non-
spherical contact geometry, respectively.  
 
 
FIGURE 1.3 SCHEMATICS OF VAN DER WAALS INTERACTION BETWEEN A) TWO IDEAL SPHERES WITH 
RADIUS OF R AND SEPARATION DISTANCE OF a, B) REDUCED VAN DER WAALS INTERACTION DUE TO 
DECREASED CONTACT AREA AND C) AND D) INCREASED VAN DER WAALS INTERACTION DUE TO 
INCREASED CONTACT AREA 
 
1.2.2.2  Electrostatic interactions 
 
In dry, gaseous environments particles of insulating material can accumulate electric 
charge due to contact charging, also known as triboelectrification (Bailey 1984). The 
process of triboelectrification includes charge transfer between insulating bodies carrying 
different potential to compensate for the potential difference. If the bodies are then 
separated before the charge can flow back, the bodies will remain charged (Karner et al. 
2011). Electrostatic charging of powders is often associated with pharmaceutical blending 
and powder transport during manufacturing, but also, importantly, with powder discharge 
from a dry powder inhaler device. This is due to the collisions between particles and 
different surfaces taking place during these processes, resulting in triboelectrification 
(Karner et al. 2011). The potential difference, and thus the magnitude of triboelectric 
charging, between two bodies is affected by the positions of the materials within the 
triboelectric series, which is a ranking of different materials according to their charge 
transfer properties (Shaw 1917). However, also surface roughness, particle size, 
mechanics of particle movement, mixing ratio of different components within the powder, 
speed of mixing, relative humidity, amorphous content of the materials and charge 
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dissipation properties of the materials, all of which are relevant variables for dry powder 
inhaler formulations, influence the magnitude of electrostatic charging (Karner et al. 2011). 
Charge accumulation influences the cohesion of powders because opposite charges will 
attract each other, thus increasing the strength of the interparticulate contacts (Visser 
1989).    
  
1.2.2.3  Capillary interactions 
 
Capillary interactions arise from condensation of liquid in the void spaces between the 
particles within a bulk powder (Seville et al. 2000). These interactions become significant 
at relative humidity of higher than 65% (Visser 1989). The maximum capillary force, Fc, 
between two spheres of radius Rs, both completely wetted by liquid with a surface tension 
of γ is defined by Equation 1.6.  
 
ࡲࢉ ൌ ૛࣊ࡾࢽ      EQUATION 1.6 
 
A schematic of a liquid bridge formed as a result of capillary condensation is presented in 
Figure 1.4. Capillary interactions have practical applications for example in granulation 
processes. This is because the magnitude of the capillary forces, and thus the strength of 
the granules, can be engineered by changing the amount, viscosity and surface tension of 
the liquid (Seville et al. 2000). 
 
 
FIGURE 1.4 SCHEMATIC OF A LIQUID BRIDGE FORMED AS A RESULT OF CAPILLARY CONDENSATION WITHIN 
THE VOID SPACE BETWEEN TWO SPHERICAL PARTICLES OF RADIUS R 
 
 
1.2.3 Powder fluidisation 
1.2.3.1  Definition  
 
Fluidisation is a phenomenon where particles within a powder bed are made free of 
internal friction by a counter force. As a result, the powder bed will enter a fluid-like regime 
(Horio 2010). In this regime the powder behaves like a fluid. Therefore, for example, less 
dense objects would float on the surface of a fluidised powder bed, the surface of the bed 
would stay horizontal even if the container was tilted and the particles would pour out of a 
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hole in the side of the vessel (Holdich 2002). In the fully fluidised state, bubbling on the 
surface of the powder bed is often observed. 
 
1.2.3.2  Fluidising a single particle 
 
A static particle of mass m experiences a downward force F due to the earth’s gravitation. 
The force experienced by a particle can be written as per Equation 1.7, where g is the 
acceleration due to gravity. 
 
ࡲ ൌ ࢓ࢍ       EQUATION 1.7 
 
If a fluid or gas flow is passed through the powder, the drag forces, FDrag, exerted by the 
fluid flow may exceed the weight of the particle. The excess of the upward component in 
the force balance means that the particle will become fully supported by the fluid flow, i.e. 
fluidised (Holdich 2002). This situation is illustrated in Figure 1.5. The statistical 
mechanics of a single fluidised particle are well understood and it is known that a single 
spherical fluidised particle undergoes Brownian motion whilst suspended in the gas flow 
(Ojha et al. 2004). 
 
FIGURE 1.5 A SCHEMATIC OF A SINGLE, SPHERICAL PARTICLE OF MASS m SUSPENDED IN AIR FLOW DUE 
TO A DRAG FORCE (FDrag) THAT IS LARGER THAN THE GRAVITATIONAL FORCE (F) EXPERIENCED BY THE 
PARTICLE. g IS THE ACCELERATION DUE TO GRAVITY 
 
1.2.3.3  Fluidising bulk powders 
 
In a free flowing bulk powder system where interparticulate forces are negligible, the drag 
force created by the flow of the fluidising gas has to overcome the gravitational downward 
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force experienced by the powder bed to initiate fluidisation (Holdich 2002). Therefore, the 
force balance for a single spherical particle presented in Figure 1.5 is also valid for a 
cohesionless powder bed of mass of m. However, powders often exhibit interparticulate 
contact forces. Therefore, for a cohesive powder, the strength of the interparticulate 
contacts within the powder bulk has to be taken into account in the force balance for 
fluidisation. In the presence of interparticulate contact forces, the downward force 
component can be written as per Equation 1.8, where σ is the strength of the 
interparticulate contacts within the bulk powder, also known as the tensile strength. 
 
ࡲ ൌ ࢓ࢍ൅ 	࣌      EQUATION 1.8 
 
It follows from Equation 1.8 that when a cohesive powder is being fluidised, the drag force 
exerted by the fluidising gas has to be greater than the gravitational and cohesive forces 
within the powder bed before fluidisation takes place.   
 
1.2.3.4  Classifying powders according to their fluidisation properties  
 
Geldart (1973) introduced a classification system for powders according to their 
fluidisation properties. The Geldart classification system is based on the particle size of 
the material to be fluidised and the density difference between the fluidising gas and the 
powder. Fluidised bed technology is a significant industrial application. The uses of the 
process range from catalytic conversion reactions to the food and agricultural industries 
(Horio 2010). To cater for all the different industrial applications of fluidised bed 
technology, Geldart’s classification covers particle sizes between 10 µm and 10 mm. 
 
The Geldart’s classification chart is presented in Figure 1.6. Powders consisting of fine 
particles belong to group C, which is a group for cohesive, difficult to fluidise powders. 
When these powders are fluidised, the fluidising gas cannot be evenly distributed 
throughout the powder bed. This is because the interparticulate forces within the powder 
are of much greater magnitude than the drag forces exerted by the fluidising gas (Molerus 
1982). Therefore, group C powders often exhibit channelling upon fluidisation or lift as a 
plug in a small diameter fluidisation vessel. Consequentially, group C powders have 
sometimes been allocated as being outside the applicability of fluidisation-based 
technologies (Molerus 1982). The classification chart shown in Figure 1.6 indicates that, 
independent of the density difference between the particles and the fluidising gas, 
powders consisting of particles finer than 20 µm always fall in this category. However, if 
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the density difference between the particles and the fluidising gas becomes smaller, also 
larger particles will exhibit poor fluidisation behaviour.  
 
Aeratable powders on the other hand belong to group A. Powders in this group are easily 
fluidised. Upon fluidisation, powders belonging to this group demonstrate bed expansion 
before entering the bubbling regime. In addition, if the fluidising gas supply is suddenly cut 
off, the bed collapse is slow (Geldart 1973). According to the original classification by 
Geldart (1973), the boundary between groups C and A is not definitive. However, a few 
years later Molerus (1982) was able to explain the border between groups A and C by the 
force balance between the drag forces caused by the fluidising gas and the 
interparticulate forces within the powder bed.   
 
Group B powders exhibit bubbling behaviour upon fluidisation. In contrast to group A 
powders, the bed collapses rapidly when the fluidising gas supply is cut off. According to 
Molerus (1982), group B powders are separated from group A powders because the 
magnitude of the interparticulate contacts in group B is negligible compared to the drag 
caused by the fluidising gas. Group D powders, in turn, form spouting beds (Geldart 
1973). The particles belonging to this group have a large particle size and possibly also a 
high density. The spouting behaviour of group D particles has been explained by the 
dominance of inertial forces acting on the fluidised particles over the drag forces induced 
by the fluidising gas (Molerus 1982). 
 
FIGURE 1.6 GELDART CLASSIFICATION OF POWDERS ACCORDING TO THEIR FLUIDISATION PROPERTIES 
BASED ON PARTICLE SIZE AND THE DENSITY DIFFERENTIAL BETWEEN THE PARTICLES AND THE FLUIDISING 
MEDIUM. C=COHESIVE, A=AERATABLE, B=BUBBLING AND D = SPOUTING. ADAPTED FROM GELDART 
(1973) 
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1.2.3.5  Particulate vs. aggregative fluidisation 
 
Powder fluidisation can also be classified as particulate or aggregative (Kwauk et al. 
2000). In particulate fluidisation, particles are homogeneously suspended within the fluid 
with the bed voidage between the particles remaining constant throughout the powder 
bed. Particulate fluidisation is usually only achieved if the fluid used as the fluidisation 
medium is a liquid. Aggregative fluidisation on the other hand is characterised by uneven 
voidage between unevenly sized agglomerates of powder. However, particulate and 
aggregative fluidisation are not two distinct classes, but end points for a continuous 
spectra of different behaviour of a fluidised powder bed (Kwauk et al. 2000).  
 
Following on from the fact that particulate fluidisation can only take place when the 
fluidisation media is a liquid, only aggregative fluidisation is relevant for DPI formulations. 
To understand the implications of aggregative fluidisation on the DPI performance, the 
following section of the introduction will discuss agglomeration and agglomerate 
breakage. 
 
 
1.2.4 Agglomerates and deagglomeration 
 
Agglomerate and aggregate are terms often used in parallel for describing loose 
assemblages of powders. As recommended by Nichols et al. (2002), the term 
agglomerate is used throughout the current thesis. Agglomerates are defined as systems 
where primary particles of different sizes are held together by interparticulate contact 
forces. Furthermore, each particle within an agglomerate has at least one point of contact 
with a neighbouring particle (Bika et al. 2001).  
 
Agglomeration has many applications, for example in the food, pharmaceutical, cement, 
mining and chemical industries (Mishra et al. 2001). In most of these applications, a 
delicate balance between stability and ease of disintegration of the agglomerate has to be 
achieved. This balance is especially important for dry powder inhaler formulations. 
Stability is required to avoid segregation of the formulation during storage and transport. 
Simultaneously, the contact forces have to be weak enough achieve deagglomeration 
upon inhalation (Boerefijn et al. 1998). In dry powder agglomerates, the void spaces 
between the particles are filled with interstitial gas. The proportion of interstitial gas within 
an agglomerate, defined as the porosity of an agglomerate, is an important property in 
determining the breakage properties of an agglomerate (Bika et al. 2001).  
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If the network of contact forces within a powder agglomerate is disturbed by mechanical 
impaction or turbulence, agglomerate breakage, also known as deagglomeration, will take 
place. However, this only happens if the energy of the impaction is sufficient to overcome 
the magnitude of the contact forces within the agglomerate. For agglomerates with strong 
interparticulate forces, such as liquid bridges in wet agglomerates, fracture planes are 
often observed across the agglomerate upon impaction. The size of the fragments is 
known to depend on the porosity of the agglomerate and the velocity of the impact 
(Subero et al. 2001). The mechanism of dispersion for weak agglomerates, which are 
often dry agglomerates held together by van der Waals forces, is less well described in 
the literature. Boerefijn et al. (1998) suggested that upon impaction, dry powder 
agglomerates disintegrated to primary particles and small clusters. Simulation results by 
Mishra et al. (2001) indicated that dry powder agglomerates with high porosity disintegrate 
and agglomerates with low porosity fracture upon impaction. The relationship between the 
agglomerate properties and the breakage pattern is relevant to DPI formulations, because 
the extent of deagglomeration, and thus drug delivery, can be changed by altering the 
powder properties.  
 
 
1.3 FORMULATION CHALLENGE AND STRATEGIES FOR DPI 
FORMULATIONS 
 
1.3.1 The challenge 
 
To summarise what has been discussed in the introduction so far, a schematic presenting 
the requirements for successful drug delivery to the lungs and the consequential 
challenges faced by a DPI formulator is shown in Figure 1.7. Ultimately, the requirements 
derive from the anatomy of the lungs. Asthma and COPD affect the bronchi and 
bronchioles. Therefore, the drug delivery is targeted in those regions of the lung. Due to 
the diameter of these peripheral airways and the particle deposition mechanisms within 
the lung, a particle size between 1 and 5 µm is required if drug delivery to the bronchi and 
bronchioles is to be achieved. Additionally, due to the favourable pharmacokinetic 
properties of the lung as the route of entry for drugs, only small doses of the drug are 
needed to obtain the required therapeutic effect.    
  
As outlined in Figure 1.7, the fine particle size and the small doses of drug required pose 
challenges for both the manufacturing process and the optimisation of DPI formulation 
performance. Fine powders exhibit high interparticulate contact forces and 
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consequentially, poor flow properties. Therefore, drug powders within the respirable range 
are difficult to handle during the manufacturing process. Additionally, the small doses 
required are difficult to weigh accurately and reproducibly.  
 
More importantly, from the formulation point of view, the drug delivery from DPIs relies on 
fluidising the dose. Particles within the respirable range belong to Geldart group C and 
cannot be fluidised. Therefore, the first challenge for a DPI formulator is to engineer the 
interparticulate contact forces within the formulation so that fluidisation can be achieved. 
Additionally, particulate fluidisation can only be achieved when a liquid is used as the 
fluidisation medium. Therefore only aggregative fluidisation is relevant for DPI 
formulations. Consequentially, the formulator has to also make sure that efficient powder 
deagglomeration takes place after fluidisation, so that a particle size of the drug within the 
respirable range is achieved.  
 
The formulation strategies available to a DPI formulator for achieving favourable powder 
properties for manufacturing the formulations and for fluidising and deagglomerating the 
dose of the drug will be introduced in the following.  
 
 
 
FIGURE 1.7 A SCHEMATIC ILLUSTRATING THE FORMULATION REQUIREMENTS FOR PULMONARY DRUG 
DELIVERY DERIVING FROM THE LUNG ANATOMY AND THE CONSEQUENTIAL CHALLENGES FOR 
FORMULATION AND PRODUCTION OF DPI PRODUCTS   
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1.3.2 Formulation strategies 
1.3.2.1  Carrier free formulations 
 
The simplest of the formulation strategies available to a DPI formulator is to alter the 
interparticulate contact forces of the drug powder so that the powder can be easily 
handled during processing and the dose can be fluidised upon inhalation. There are 
various options for achieving this. For example, larger, loosely bound agglomerates of the 
drug can be formed (Edwards et al. 1989). These agglomerates act as larger particles due 
to the increased significance of gravitational forces and relative decrease in the contact 
surface area between the agglomerates. This in turn will reduce the magnitude of the 
interparticulate forces within the bulk powder. Therefore, these agglomerated powders 
exhibit better flow properties, thus facilitating the manufacturing process and dose 
fluidisation. Providing the agglomerates are weak enough, they can be deagglomerated 
upon inhalation to achieve a particle size suitable for pulmonary drug delivery (Edwards et 
al. 1989; Hino et al. 1998). Turbuhaler Pulmicort is a commercially available product 
utilising this formulation approach. 
 
Another approach for preparing free flowing and easily fluidisable drug powders for DPIs 
is to use spray drying (Nolan et al. 2009; Steckel et al. 2004a) or spray freeze drying 
(Mueannoom et al. 2012) to produce hollow particles. The hollow particles have a low 
density. It follows from Equation 1.1 that the diameter of a low density particle can be 
larger than the diameter of a higher density particle to deposit at a similar site in the lungs. 
Therefore, respirable low density particles can be manufactured at larger particle sizes. 
Consequentially, the interparticulate forces within these powders are smaller and 
therefore manufacturing and fluidisation issues are somewhat solved. 
 
The surface properties of the drug particles can also be modified so that the 
interparticulate forces within the bulk powder are decreased. In practice, this often means 
producing small scale surface roughness on the surface of the drug particles. As a result 
of the decreased interparticulate forces, powders will exhibit improved flow and fluidisation 
properties. Surface modifications have been performed for example by crystallising 
vaporised solution of L-leucine on to the surface of drug particles (Raula et al. 2009).  
 
1.3.2.2  Binary formulations 
 
One of the formulation approaches widely used in DPI production is blending the cohesive 
Geldart group C drug powder with a Geldart group A powder that can be easily fluidised. 
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This results in interactive mixtures (Egermann et al. 1983), where the cohesive drug 
particles adhere on the surfaces of the easily fluidised large carrier crystals that act as the 
binary component in the formulation. The coarse carrier particles make up the bulk of the 
formulation allowing the resulting formulation to be fluidised upon inhalation. Bell et al. 
(1971) were the first to report the use of a coarse carrier for improving the flow properties 
of the cohesive drug. The most commonly used carrier in DPI formulations is α-lactose 
monohydrate, although studies where other sugars, such as mannitol, xylitol and glucose 
have been used as carriers have been published (Hamishehkar et al. 2010; Harjunen et 
al. 2003; Hooton et al. 2006).  
 
The approach of engineering the fluidisation properties of Geldart Group C powders by 
adding easy-to-fluidise particles is widely used within fluidisation science (Alavi et al. 
2005; Zhou et al. 1999). However, although the fluidisation properties of the drug 
delivered with DPIs can be adjusted by adding easy-to-fluidise coarse carrier particles, the 
challenge of detaching the drug particles from the surfaces of the coarse carrier and de-
agglomerating the drug upon inhalation remains somewhat unsolved. Consequentially, the 
respirable fraction delivered from these formulations is often only 20% or less of the drug 
dose (Steckel et al. 1997). The drug particles still remaining attached to the coarse carrier 
particles will deposit at the back of the throat. Therefore, optimising the drug delivery from 
DPI formulations would be advantageous for avoiding ingestion, rather than inhalation, of 
the drug. This would reduce potential systemic side effects caused by the absorption of 
the drug via the digestive system. Additionally, if the drug delivery from the DPI 
formulations was optimised, the loaded drug dose in the formulations could be lower 
whilst still delivering the same therapeutic dose of the drug. This would make the 
manufacturing of DPI formulations more economic.  
 
1.3.2.3  Ternary formulations 
 
To optimise the drug detachment from the surfaces of the coarse carrier, and thus 
improve the respirable fraction of the drug delivered from DPIs, ternary components can 
be added to the formulation. The ternary component can for example be either a force 
control agent or fine particle excipient.  
 
The exact mechanisms for how the ternary components alter the formulation performance 
remain unclear. However, it has been hypothesised that the force control agents, such as 
magnesium stearate, modify the surface energies of the large lactose carrier particles so 
that drug detachment becomes favourable (Begat et al. 2005). This is especially the case 
if the force control agent particles are dispersed on the surfaces of the large carrier 
49 
 
particles as a thin monolayer. Other mechanisms, such as the force control agent particles 
acting as micro-carriers or altering the powder structure to be more favourable for drug 
detachment and deagglomeration, have also been suggested (Tay et al. 2010). 
 
Similarly, the mechanism of action of the fine excipient particles is not currently fully 
understood. However, by the inclusion of fine excipient particles, a significant increase in 
the respirable fraction of the drug can be achieved compared to a binary formulation 
(Louey et al. 2003). The hypotheses for the mechanism accounting for the improved 
formulation performance include the active site, agglomerate formation and increased 
cohesion theories. The current thesis focuses on the role of lactose fines in regulating DPI 
formulation performance. Therefore, a thorough summary of these mechanisms will be 
given later in the introduction, after a general introduction to lactose and a review of all the 
research that has led to the development of these theories. 
 
1.4 LACTOSE AS A CARRIER IN DPI FORMULATIONS 
1.4.1 General introduction to lactose 
1.4.1.1 Chemistry 
 
Lactose is a naturally occurring disaccharide consisting of galactose and glucose moieties 
linked together with a glycosidic bond. The chemical structure of lactose is shown in 
Figure 1.8. In solution, the conformation of the hydroxyl group linked to C1 of the glucose 
ring can be either in α or β anomeric form. The position of this hydroxyl group is 
highlighted in Figure 1.8, with the hydroxyl group shown in α conformation. Mutarotation 
between the conformations takes place, and in the equilibrium, the proportion of α form is 
37.3% and β form 62.7 (Gänzle et al. 2008). Due to the hydroxyl group in the C1 position 
in the glucose ring, lactose is a reducing sugar. Consequentially, in the presence of water, 
Maillard reaction between lactose and molecules containing amino groups can take place 
over time (Narang et al. 2009). 
 
 
FIGURE 1.8 THE CHEMICAL STRUCTURE OF THE α ANOMERIC FORM OF LACTOSE WITH THE ANOMERIC 
HYDROXYL GROUP HIGHLIGHTED 
50 
 
1.4.1.2 Production 
 
Lactose is crystallised out from whey that is a by-product of cheese manufacturing. If the 
crystallisation is performed below 93.5 °C, the crystalline form of α-lactose, α-lactose 
monohydrate, is obtained. If the crystallisation is performed above 93.5 °C, the lactose will 
crystallise in the β-anhydrous form (Gänzle et al. 2008). The most common crystal shapes 
of lactose are tomahawks, pyramids and prisms (Clydesdale et al. 1997). However, the 
crystal habit of lactose depends on the crystallisation conditions, especially the rate of 
crystal growth. Therefore, also other morphologies of lactose crystals can be obtained 
(Gänzle et al. 2008). Amorphous, non-crystalline lactose can also be obtained for example 
by spray, freeze or roller drying of the solution containing the lactose. The resulting 
proportions of α-lactose monohydrate and β-anhydrous lactose within the amorphous 
lactose glass are identical to the solution from which the crystallisation was performed 
(Gänzle et al. 2008).  
 
After crystallisation, lactose can be further processed for example by sieving, milling, air 
classification or micronisation to produce lactose with desirable physicochemical and 
physical attributes. Therefore, there are various commercial grades of lactose on the 
market, some of which have been specifically designed for inhalation purposes (Pilcer et 
al. 2012).  
 
1.4.1.3  Lactose as an excipient in DPI formulations  
 
Traditionally excipients have been defined as ingredients present in pharmaceutical 
formulations that do not provide the patient with direct therapeutic value. Excipients are 
added to drug products mainly for two reasons. The first one is to facilitate the 
manufacturing of the drug product. The second objective of the use of excipients is to 
increase the patient compliance to the treatment by making the dosage forms more 
pleasant. This includes for example increasing the size of a tablet so that it can be easily 
handled or coating tablets so that they will be easier to swallow (Parker 2009). However, 
in some cases, rather than defining excipients as inert materials present in the 
formulations, it has been realised that the excipients also exhibit functionality, often 
altering the pharmacological properties of the final products (Pifferi et al. 1999).  
 
Lactose has traditionally been used as filler, binding agent and diluent in tablet and 
capsule based formulations (Edge et al. 2006). In the advent of the era of DPIs, the 
excipient was adopted for use in inhalation formulations. This was mainly due to the good 
availability, inexpensive price and compatibility with most of the inhaled therapy small 
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molecules (Telko et al. 2005). The α-monohydrate form is the most commonly used 
lactose in inhalation formulations. The only restriction on the use of lactose in inhalation 
formulations is the reducing properties of the molecule. Therefore, lactose cannot be used 
as an excipient in formulations containing peptides, proteins or other molecules containing 
amino groups (Edge et al. 2006). 
 
Favourable toxicological properties also contributed towards the adoption of lactose as an 
excipient for DPI formulations. The pulmonary deposition of lactose in humans has been 
proven to be non-toxic, although in some cases mild irritation of the airways and non-
severe bronchoconstriction have been reported (Thoren et al. 2001). The lactose that is 
small enough to be deposited in the lungs has been shown to be rapidly absorbed and 
excreted in urine (Baldrick et al. 1997). Upon inhalation, the lactose particles outside the 
respirable range are deposited in the oropharynx, and consequentially ingested. However, 
the amounts of lactose typically contained within a dose of DPI formulation are not 
sufficient for triggering the symptoms of lactose intolerance. This is because grams of 
ingested lactose are needed for the symptoms to appear (Baldrick et al. 1997).  
 
The pharmacopoeial requirements for inhalation grade lactose are summarised in the 
lactose monograph of the Handbook of Pharmaceutical Excipients (Edge et al. 2006). All 
the parameters specified, such as specific optical rotation, heavy metal content and 
microbial content, are related to ensuring the chemical identity and purity of the lactose. 
However, the physical and physicochemical properties, such as particle size, have not 
been strictly specified. Therefore, a wide range of different lactose grades are 
commercially available. The lactose monograph of the Handbook of Pharmaceutical 
Excipients highlights the variety of the marketed grades in terms of particle size 
distributions (Edge et al. 2006). The differences in the physical and physicochemical 
properties of the commercially available lactose grades result in a wide variation in the 
functionality of lactose sourced from different manufacturers or processed in different 
ways. In fact, some studies have even addressed the issue of batch-to-batch variability of 
the carrier lactose affecting the final performance of the DPI formulations, especially at 
low drug loadings (Steckel et al. 2004b). The following sections of the introduction aim to 
summarise how the different physical and physicochemical properties of the lactose 
carrier influence the performance of DPI formulations. 
 
 
 
 
 
52 
 
1.4.2 The link between the properties of the coarse lactose carrier and the DPI 
performance 
1.4.2.1 Crystalline form 
 
An early study reported that the crystalline form of coarse lactose did not have an impact 
on the in vitro performance of a steroid formulation. Similar performances were obtained 
from formulations prepared with α-lactose monohydrate, chemically dehydrated α-
anhydrous lactose and β-anhydrous lactose (Robertson et al. 1996). Larhrib et al. (1999) 
reported that the 63-90 µm sieved fraction of anhydrous lactose outperformed equivalent 
sieved fractions of α-lactose monohydrate as the carrier for salbutamol sulphate. 
However, the fine lactose content and surface roughness of the anhydrous form of the 
lactose used in the study were significantly different from the monohydrate carriers. 
Therefore, the findings of the study are somewhat inconclusive with regards to the role of 
the crystalline form of the lactose carrier. Subsequently, Pitchayajittipong et al. (2010) 
studied the impact of the crystalline form of lactose sourced from different manufacturers 
on the formulation performance of budesonide. The study indicated that the source of 
lactose was more important in regulating the performance than the crystalline form. This 
finding was attributed to the powder bulk properties, such as fluidisation properties, 
dominating over the chemical identity of the lactose carrier in determining the DPI 
performance.  
 
Traini et al. (2008) reported differences in the delivery of salbutamol sulphate from 
formulations prepared with different polymorphic forms of lactose. The α-monohydrate 
form produced the highest performance. The findings of this study were attributed to the 
surface energies of the carrier particles with the α-monohydrate having the lowest surface 
energy, resulting in lower drug-excipient interactions and thus greater drug detachment. 
 
1.4.2.2 Moisture content 
 
The water loss on drying has been shown to contribute to the in vitro performance of 
salmeterol xinafoate. The effect of increasing moisture content of the carrier on the 
formulation performance was shown to be two-fold. Firstly, the drug losses in the device 
were increased. Secondly, the amount of drug lost due to adhesion to the large carrier 
particles was reduced. The former finding was attributed to the increased adhesive forces 
upon increasing water content preventing a complete emptying of the device. The latter 
observation on the other hand was attributed to the water molecules acting as lubricant on 
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the surface as long as the relative humidity was kept at too low a level for capillary 
interactions to take place (Podczeck 1998) 
 
1.4.2.3  Surface morphology 
 
Several studies have reported the impact of the surface roughness of the coarse lactose 
carrier on the DPI formulation performance. Kawashima et al. (1998) found that 
microscale roughness on the surface of the lactose carrier was advantageous for the 
detachment of pranlukast hydrate from DPI formulations. The study also reported that 
both large scale surface roughness and smooth surfaces of the carrier lactose crystals 
had a negative effect on the formulation performance. The decrease in performance in the 
latter two cases was attributed to the increased interparticulate forces due to increased 
contact area between the drug particles and the carrier lactose (Kawashima et al. 1998). 
Similar conclusions were made by Young et al. (2009), who prepared lactose composite 
carriers with different degrees of surface roughness. The study reported an improvement 
in the delivery of salbutamol sulphate upon increasing microscale surface roughness of 
the carrier. The differences in the resulting contact geometry between the carrier surface 
and the drug particles were concluded to affect the drug detachment from the carrier 
surfaces. Similarly, Kaialy et al. (2012a) reported an increased delivery of salbutamol 
sulphate upon increasing surface roughness of the carrier. In this study different 
commercial, 63-90 µm sieved grades of lactose were used as the carriers. 
 
In contrast, studies by Zeng and co-workers indicated that smoother lactose carriers 
produced higher in vitro performance for salbutamol sulphate, also known as albuterol 
sulphate (Zeng et al. 2000a; Zeng et al. 2001b; Zeng et al. 2001c).  A study by de Boer et 
al. (2003) on the other hand concluded that small scale surface roughness on the surface 
of commercial coarse grade lactose carriers had very negligible effect on the detachment 
of budesonide from the carrier surfaces.  
 
1.4.2.4  Particle shape 
 
Kaialy et al. (2012a) have reported that the more irregular the shape of the coarse carrier, 
the better the in vitro performance of salbutamol sulphate from commercial, 63-90 µm 
sieved fractions of lactose. Numerous studies have also shown that increasing the 
elongation of the coarse carrier particles improved the respirable fraction of salbutamol 
sulphate (Dhumal et al. 2008; Kaialy et al. 2012a; Larhrib et al. 2003a; Larhrib et al. 
2003b; Zeng et al. 2000a). The authors of most of these studies unanimously concluded 
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that the elongated shape of the carrier crystals was aerodynamically favourable. As a 
result, elongated carrier particles would stay suspended in the air flow for a longer period 
of time. Consequentially, the drag forces had more time to act to detach the drug particles 
from the surfaces of the carrier particles.   
 
To investigate the impact of extremely elongated particles, lactose and different crystal 
forms of mannitol were used as the carriers for salbutamol sulphate in a study by Kaialy et 
al. (2011). Depending on the crystallisation conditions, the particle shape of mannitol was 
greatly altered. Needle like mannitol particles with an elongation ratio of approximately 6 
were obtained when crystallisation was performed in ethanol. The study demonstrated 
that even in extreme cases, the more elongated the carrier particles, the better the fine 
particle dose from the formulations. However, it was also demonstrated that the drug 
emission and powder flow properties were adversely affected as a result of increasing 
elongation.  
 
1.4.2.5  Particle size 
 
A study by Zeng and co-workers showed that the emission of salbutamol sulphate from 
DPI formulations improved upon increasing the particle size of the coarse carrier. 
However, in the same study it was shown that the drug deagglomeration efficiency 
decreased simultaneously with the increase in the carrier particle size. The different size 
fractions of lactose used in that study were recrystallized from Carbopol gel and therefore  
exhibited smooth carrier surfaces (Zeng et al. 2001c). However, in a later study, similar 
results were reported for commercial grades of coarse lactose carriers with a decrease in 
the in vitro delivery of salbutamol sulphate upon increasing median particle size (Louey et 
al. 2003).  
 
Le et al. (2012a) fractionated a commercial grade of coarse lactose to different size 
fractions by sieving. The different sieve fractions were then used as carriers for fluticasone 
propionate. It was demonstrated that the smaller size fractions produced a higher in vitro 
performance than the larger size fractions. The finding was attributed to lower adhesion 
energy between the smaller size fractions of lactose and the drug particles.  
 
1.4.2.6  Complications 
 
A complication in establishing the link between the coarse lactose properties and the 
formulation performance is that the effects of the various properties of the lactose 
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discussed above are not independent of each other. For example, Donovan et al. (2010) 
compared the formulation performance of budesonide prepared with sieved fractions of 
anhydrous and granular tablet grades of lactose. The former had a smooth surface and 
the latter exhibited large scale surface roughness. It was found that the anhydrous, 
smooth carrier outperformed the granular carrier with the rough surface when the carrier 
size was small. However, the opposite was observed for the coarser sieve fractions with 
the rough carrier outperforming the smooth carrier. The findings were attributed to the 
different drug detachment mechanisms, drag forces or impaction, prevailing for different 
carrier systems. According to the authors, detachment by drag forces is the most 
important mechanism in conventional DPI formulations. However, impaction became an 
important mechanism upon increasing the particle size of the carrier. Consequentially, the 
drug particles that were accommodated by the surface roughness of the granular carriers 
were dislodged more efficiently from the larger size fractions of the carrier upon impaction 
(Donovan et al. 2010). 
 
A further complication in gaining an understanding between the lactose carrier properties 
and DPI performance is that studying the impact of an isolated variable with lactose 
carriers is difficult. This is because lactose is a natural product and altering one 
parameter, such as particle surface roughness, will very likely also change the overall 
particle morphology and particle size. Therefore, another approach recently used for 
collecting the pieces for the bigger picture is developing model systems where the 
different variables can be independently isolated. Ooi et al. (2011) used three different 
monodisperse size fractions of spherical polystyrene beads with similar surface 
characteristics as the carrier for salbutamol sulphate. The results of the study indicated 
that smaller carriers outperformed the larger size carriers. The finding was attributed to 
the higher number of collisions taking place in the formulations prepared with smaller 
carriers upon aerosolisation, leading to a greater extent of drug detachment from the 
surfaces.  
 
 
1.4.3 Influence of lactose fines 
 
The relationship between the different properties of the coarse carrier and the 
performance of binary DPI formulations was discussed above. Clearly, the interplay 
between the different physical and chemical properties of the coarse carrier and the drug 
detachment is complex. As was discussed earlier in the introduction, one of the 
formulation strategies to improve the drug detachment from the surface of the coarse 
carrier is to add a ternary component, such as fine particle lactose, to the formulation. The 
following sections of the introduction aim to summarise the research that has been 
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conducted on the impact of adding lactose fines as the ternary component on the DPI 
performance. 
 
1.4.3.1  Intrinsic fines 
 
Some coarse carriers contain a small proportion of lactose fines. These fines are termed 
intrinsic fines. The role of intrinsic lactose fines in regulating DPI performance has been 
shown in numerous studies. Zeng et al. (1998) showed that the in vitro performance of 
salmeterol xinafoate could be reduced by removing intrinsic fine lactose particles from the 
coarse carrier by air sieving. The reduction in the performance was shown to be reversible 
by the addition of a fine lactose component to the formulation after air jet sieving. 
Similarly, Islam et al. (2004) reported a decrease in the in vitro performance of salmeterol 
xinafoate after surface smoothing a coarse lactose using wet decantation. However, the 
impact of surface modification was concluded to have a much less significant impact on 
the in vitro performance than the removal of intrinsic fines, which also took place during 
the wet decantation. Again, the performance was found to be reversible to the original 
level by the addition of fine particle lactose to the surface smoothed carriers (Islam et al. 
2004). A decrease in the performance of budesonide (Dickhoff et al. 2006) and salbutamol 
sulphate (Boshhiha et al. 2009) formulations has also been reported after surface 
smoothing by removing the intrinsic lactose fines by wet decantation. Le et al. (2012b) 
showed a decrease in the in vitro performance of fluticasone propionate and terbutaline 
sulphate upon the removal of intrinsic lactose fines by air jet sieving.  
 
Steckel et al. (2006) used a different approach of creating intrinsic fines by milling 
commercial grade lactose carriers. The commercial and milled products were sieved to 
produce identical size fractions. The fractions of the milled carriers outperformed the 
equivalent fractions of commercial grades as carriers for bechlometasone dipropionate 
and salbutamol sulphate, proving the role of intrinsic fines in improving the DPI 
performance. Xu et al. (2010) used milled and sieved grades of α-lactose monohydrate as 
the carriers for salbutamol sulphate and disodium cromoglycate. The upper ends of the 
particle size distributions of the lactose carriers were similar. However, the proportion of 
intrinsic fines within the milled grade carriers was higher than in the sieved grades. The 
milled grades of lactose were seen to outperform the sieved grade of lactose as a carrier 
for both the drugs, once again addressing the importance of the intrinsic fines. 
 
 
 
57 
 
1.4.3.2  Particle size of the fines 
 
Zeng et al. (1999) reported that micronised lactose fines were more efficient in improving 
the in vitro performance of salbutamol sulphate than intermediate size lactose fines. A few 
years later, the same research group concluded that it was the presence of micronised 
lactose fines (<10 µm) that was ruling the DPI performance of salbutamol sulphate 
formulations, not the properties of the coarse lactose carrier (Zeng et al. 2001b). Harjunen 
et al. (2002) showed that the presence of crystalline, micronised lactose fines improved 
the formulation performance of budesonide. However, in the same study, it was shown 
that the performance of a formulation containing the micronised lactose fines was greatly 
decreased upon storage (Harjunen et al. 2002). Similarly, a study by Guenette et al. 
(2009) showed that the lactose fines below 10 µm had the greatest positive effect on the 
in vitro delivery of salbutamol sulphate. However, again, the formulations prepared with 
this fraction of fines were the most affected upon storage. 
 
A study by Adi et al. (2006) specified the optimum size of the fines more accurately by 
showing that an added fine fraction with a volume median diameter (VMD) of 7.9 µm was 
the most effective in improving the delivery of salmeterol xinafoate. Fines with a VMD of 
3.3 µm were shown to be less efficient as were larger fines with VMD of 17.7 and 33.3 
µm. The two largest fractions were in fact suggested to act as secondary carriers (Adi et 
al. 2006). Following on from this study, the impact of the polydispersity of the fine fractions 
with similar VMDs was investigated (Adi et al. 2009). The study concluded that the 
optimum particle size of the fines was between 5 and 10 µm. The finding was attributed to 
fines between these sizes forming agglomerates with favourable deagglomeration 
properties (Adi et al. 2009).   
 
1.4.3.3  Adding sequence of the fines 
 
Zeng et al. (1999) found that the in vitro performance of salbutamol sulphate was better 
from a formulation where the lactose fines were added to the formulation before 
salbutamol sulphate compared to a formulation prepared with an opposite mixing order. 
The same observation was made in a different study for a hydrophobic drug, 
bechlometasone dipropionate (Zeng et al. 2000b). However, the optimum mixing order for 
bechlometasone dipropionate was shown to be initially mixing the lactose fines and the 
drug, followed by blending the resulting pre-blend with the coarse lactose carrier (Zeng et 
al. 2000b). In contrast, Louey et al. (2002) found that the mixing order of the fine ternary 
component and salbutamol sulphate did not have an impact on the performance of the 
final formulation.   
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A study by Jones et al. (2010) pointed out that the mixing process and the drug 
concentration played a role in the results of blending order studies for salbutamol 
sulphate. It was reported that with short mixing times (15 min), neither the mixing order 
nor the drug concentration had an impact on the formulation performance. With longer 
mixing times (30 min), formulations with low drug contents produced better performance 
by adding the fines before the drug. The performance at high drug concentrations on the 
other hand was not affected by the mixing order. The authors concluded that the different 
drug concentrations used in the previous studies by Zeng et al. (1999) and Louey et al. 
(2002) were likely to explain the discrepancies between the studies, which both used 
mixing time of 30 minutes. 
 
1.4.3.4 Concentration of the fines 
 
A study by Guchardi et al. (2008) indicated that the optimum concentration of fine particle 
lactose <10 µm was 5% for formoterol fumarate. Louey et al. (2003) concluded that, for 
salbutamol sulphate, the optimum concentration of micronised lactose fines was 
approximately 10 wt-%. At higher concentrations than this, a decrease in the formulation 
performance was reported.  
 
1.4.3.5 Addition of non-lactose fines 
 
Sorbitol and mannitol fines have been employed as the fine particle component. However, 
the chemical identity of the fines has been shown to be insignificant for determining the 
performance of salbutamol sulphate formulations for inhalation (Tee et al. 2000). 
 
 
1.4.4 Mechanisms for lactose fines improving the DPI performance 
1.4.4.1  Active sites theory 
 
The active site theory was originally proposed by Ganderton (1991; 1992) based on the 
concept of ordered mixing introduced by Hersey (1975). According to the theory, the 
surfaces of the coarse lactose crystals contain highly energetic spots where the drug 
particles strongly adhere (Staniforth 2000). These spots, termed the active sites, have 
been suggested to be regions with morphological defects such as asperities on clefts, 
chemical impurities or amorphous material on the surface of the large lactose crystals 
(Pilcer et al. 2011). According to the theory, upon the addition of the ternary component, 
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the fine excipient particles occupy these active sites. When the drug is added to the 
formulation, the drug particles attach to the surfaces with lower interaction energy. Due to 
the lower energy, the drug particles are easily detached from the surface upon inhalation. 
The active sites theory is illustrated in Figure 1.9. 
 
 
FIGURE 1.9 A SCHEMATIC ILLUSTRATING THE ACTIVE SITE THEORY AND THE IMPACT OF THE ACTIVE SITES 
ON THE DRUG DETACHMENT FROM THE CARRIER IN BINARY AND TERNARY DPI FORMULATIONS 
 
Since the introduction of the active sites theory, numerous studies have found supporting 
evidence in favour of the hypothesis. The authors of the studies where the DPI formulation 
performance was reduced upon the removal of intrinsic fines and reversed back to the 
original level by adding fines have explained the findings with the active site theory 
(Steckel et al. 2006; Zeng et al. 1998).  
 
Parallel studies by Young et al. (2005) and El-Sabawi et al. (2006) used a commercial and 
a surface smoothed grade of lactose as the carriers for salbutamol sulphate. By dose 
titration for the drug it was shown that initially, at low drug concentrations, no improvement 
in the formulation performance was achieved upon increasing the drug concentration. This 
was attributed to the continuous process of filling the active sites below the saturation 
concentration. However, at higher drug concentrations, once all the active sites had been 
filled and the excess drug was binding to the low energy binding sites, an improving trend 
in the formulation performance was apparent. The concentration where the improvement 
started was termed as the critical concentration. It was shown that the critical 
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concentration was lower for the surface smoothed lactose than for the commercial grade 
of lactose. This was explained by the lower number of active sites on the surface of the 
smoothed lactose (El-Sabawi et al. 2006; Young et al. 2005).  
 
The active site theory was also supported by a study, where in addition to the in vitro 
deposition of formoterol fumarate, the deposition profile for lactose was determined. The 
results of the study indicated that the amount of lactose fines associated with the coarse 
lactose did not change after approximately 4 wt-% fines concentration. This was attributed 
to lactose fines having saturated the active sites at this concentration. Any fines added 
above this concentration were attached to the low energy binding sites and therefore were 
detached upon dose fluidisation (Guchardi et al. 2008).  
 
However, although many studies have supported the active sites theory, other studies 
have reported opposite findings. Louey et al. (2002) investigated the role of lactose and 
glucose fines on the in vitro performance of salbutamol sulphate. The results of the study 
were concluded to be inconsistent with the active site theory for two reasons. Firstly, if the 
active sites theory was true, the mixing order of the drug and fines should have an impact 
on the performance, because the component that was added first would occupy the active 
sites. However, the mixing order of the fines and the drug had no impact on the 
performance. Secondly, the active sites are defined as high energy binding sites. 
However, using AFM, the addition of fines was found to increase the surface energy of the 
lactose carrier. The increase in the surface energy of the carrier system upon the addition 
of fine excipient particles has also been reported based on inverse gas chromatography 
measurements by Ho et al. (2010).  
 
1.4.4.2 Drug-fines agglomeration theory 
 
The drug-fines agglomeration theory is another traditional view for the mechanism for the 
improvement in DPI performance in the presence of a ternary component. This theory was 
originally proposed by Lucas et al. (1998), who found that the performance of a carrier 
based bovine serum albumin (BSA) formulation improved in the presence of fine particle 
lactose. According to the theory, the improved DPI performance in the presence of 
excipient fines can be explained by agglomerate formation between the drug and the fine 
particle excipient. Upon inhalation, these agglomerates are more likely to detach from the 
carrier surfaces. The theory can be verified by calculating the drag force (FDrag) 
experienced by a particle or an agglomerate on a surface of a coarse carrier crystal as per 
Equation 1.9 (Begat et al. 2004a), where CDrag is drag coefficient, ρa is the density of air, 
ΦAgg the diameter of the agglomerate and V the air velocity. 
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ࡲࡰ࢘ࢇࢍ ൌ ࡯ࡰ࢘ࢇࢍ ࣊ૡ ࣋ࢇ઴࡭ࢍࢍ૛ ࢂ૛    EQUATION 1.9 
 
It follows on from Equation 1.9 that the drag force experienced by any particle or an 
agglomerate is directly proportional to the square of its diameter. Therefore, the 
detachment of the agglomerates from the surfaces is more likely than the detachment of 
primary drug particles. The detached agglomerates may be of respirable size, or may 
deagglomerate to produce a respirable particle size. The drug fines agglomeration theory 
is illustrated in Figure 1.10. 
 
 
FIGURE 1.10 THE DRUG – FINES AGGLOMERATE FORMATION THEORY ILLUSTRATED 
 
The drug-fines agglomeration theory has also been supported by numerous studies. 
Podczeck (1999) reported that the fine particle lactose was more efficient in improving the 
in vitro performance of salmeterol xinafoate when formulated with a large lactose carrier 
with a rough surface than one with a smooth surface. In this study, the finding was 
attributed to the tendency of the fines and the drug to form agglomerates on a rough 
surface and monolayers on smooth surface (Podczeck 1999). 
 
The agglomerate formation theory is further supported by a study where wet granulation 
techniques were used for producing spherical agglomerates of an inhaled steroid. The 
study showed that the agglomerated systems formulated with a coarse lactose carrier 
produced higher respirable fractions than formulations prepared with the primary particles 
of the crystalline drug (Ikegami et al. 2000). Even though the study was not aimed at 
finding support for the agglomerate formation theory, in retrospect, it proves the 
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significance of the increased size of the drug for the likelihood of detachment from the 
coarse lactose surfaces. 
 
In the study conducted by Louey et al. (2002) that found contra-indicatory evidence for the 
active sites theory discussed earlier, it was also reported that the addition of drug was 
seen to increase the amount of detached lactose fines. This finding suggested a 
synergistic action between the two types of fines. Because of the finding, the authors 
concluded that formation of agglomerates or multilayers had to be playing a role in 
determining the performance of the DPI formulations (Louey et al. 2002). This theory was 
further supported by a study by Islam et al. (2004) who showed that the in vitro 
performance of salmeterol xinafoate decreased as the theoretical ratio between the 
number of salmeterol xinafoate and fine lactose particles decreased. 
 
Jones et al. (2008) used a cohesive-adhesive balance (CAB) approach to determine the 
interaction energies between fine excipient particles and micronised drug particles. The 
study concluded that when the drug-excipient interaction was adhesive, i.e. the drug 
preferred adhering to the excipient rather than to another drug particle, the formulation 
performance improvement was due to agglomerate formation between the drug and the 
fines.  
 
1.4.4.3  Increased cohesion theory 
 
The most recent theory suggested for being responsible for improving the DPI formulation 
performance upon the addition of fine particle lactose is the increased cohesion theory. 
During the years, it has been shown that the inclusion of fine particle lactose in DPI 
formulations increases the cohesive strength of the bulk powder (Thalberg et al. 2004). 
However, Shur et al. (2008a) were the first to realise the potential connection between the 
increased cohesion of the carrier upon the addition of lactose fines and the improved final 
formulation performance. According to the increased cohesion theory, the drag forces 
created by the inspiratory effort are not able to initiate the fluidisation until a critical air flow 
velocity, the minimum fluidisation velocity, has been reached. The minimum fluidisation 
velocity, on the other hand, is dependent on the extent of interparticulate contact forces 
within the formulation (Shur et al. 2008a).  
 
According to the increased cohesion theory, a carrier with low interparticulate contact 
forces, such as coarse grades of lactose, will be entrained in the air flow gradually, 
resulting to an erosion mechanism for fluidisation. A cohesive formulation on the other 
hand resists the fluidisation for longer, and once the fluidisation takes place, it follows the 
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fracture mechanism. This results in large agglomerates being formed upon fluidisation 
(Shur et al. 2008a). The kinetic energy of an agglomerate formed upon fluidisation, EKin, is 
defined by Equation 1.10, where ρAgg is the density of the agglomerate, ΦAgg is the 
diameter of the agglomerate and V is the air velocity (Begat et al. 2004a). 
 
ࡱࡷ࢏࢔ ൌ 	 ࣊૚૛ ࣋࡭ࢍࢍ઴࡭ࢍࢍ૜ ࢂ૛     EQUATION 1.10 
 
Equation 1.10 shows that the kinetic energy of an agglomerate is related to the cube of 
the diameter of the agglomerate. Therefore, the larger the agglomerate formed upon 
fluidisation, the more kinetic energy is stored in the agglomerate. Consequentially, the 
larger the agglomerate, the more likely that deagglomeration will take place, because the 
collisions between the device and the formulation will be more energetic (Shur et al. 
2008a).   
 
Shortly after the study by Shur et al., another research group confirmed that fluidisation 
could take place via the erosion or fracture mechanisms (Tuley et al. 2008). A paper by 
Watling et al. (2010) reported that the severity of the fracture could be qualitatively 
classified as mild or severe. With mild fracture the powder bed entrained as numerous 
small plugs and with severe fracture as one large plug. The mechanism of fracture could 
be anything between these two endpoints and was shown to be related to the powder 
flowability. It was concluded that the more cohesive the powder, the more severe fracture 
it exhibited upon fluidisation. 
 
 
1.4.5 Predicting DPI performance on the basis of lactose properties 
 
It is hoped that increasing the understanding of the mechanisms by which the lactose 
properties affect the performance of DPIs will permit improvements in formulation design. 
In particular, models that would enable predicting the DPI performance on the basis of the 
properties of lactose are currently being established. This is because the United States 
Food and Drug Administration (FDA) recently published the recommendations for the 
Process Analytical Technologies (PAT) (FDA 2004) and Quality by Design (QbD) 
initiatives (FDA 2006). The PAT initiative encourages the industry to follow and apply the 
most recent scientific discoveries in the product development and manufacturing 
processes to improve the quality of the pharmaceutical products supplied to the consumer 
(FDA 2004). The QbD initiative on the other hand encourages the industry to characterise 
the raw materials that go into the products and to use statistical tools for establishing 
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relationships between the properties of the raw materials and the product performance 
(FDA 2006).  
 
With regards to the lactose used as the carrier in DPI formulations, several studies have 
reported correlations between the properties of the lactose and the resulting formulation 
performance. Traditionally, the proportion of fines present in the carrier has been a good 
measure for estimating the formulation performance.  Islam et al. (2004) suggested that 
the proportion of fine lactose particles (<5 µm) in the carrier could be used as an 
indication of the final formulation performance. Guchardi et al. (2008) on the other hand 
suggested, that for every 1% increase in the proportion of lactose particles below 10 µm, 
an improvement of 3% in the fine particle fraction for formoterol fumarate was achieved.  
Similarly, Guenette et al. (2009) reported a linear relationship between the proportion of 
particles finer than 10 µm in the carrier and the fine particle dose of salbutamol sulphate. 
 
In addition to the proportion of fines present in the carrier, other techniques and 
parameters have been reported to be useful in understanding the relationship between the 
carrier properties and the formulation performance. Louey et al. (2001) suggested atomic 
force microscopy would be a suitable tool for predicting DPI formulation performance on 
the basis of the adhesion forces between the lactose carrier and the drug particles. The 
surface energy of the carrier lactose as determined by inverse gas chromatography has 
been shown to be inversely proportional to the formulation performance of budesonide 
(Saleem et al. 2008) and salbutamol sulphate (Traini et al. 2008). A linear relationship 
between the formulation performance of salbutamol sulphate and the tapped and true 
densities of the lactose carriers crystallised in different conditions was reported by Kaialy 
et al. (2012b). 
 
In terms of powder flow and fluidisation properties, Le et al. (2010) reported a correlation 
between the air permeability of DPI formulations and the fine particle fraction produced.  
However, the method required preparation and characterisation of the final formulation. 
Therefore, the value of the method as a quality by design tool can be questioned. 
Pitchayajittipong et al. (2010) successfully correlated the increasing energy required to 
fluidise the carrier and the resulting improved formulation performance of budesonide.  
 
1.5  AIMS OF THE STUDY 
 
Despite all the research that has taken place over the years, there is still debate as to the 
mechanism by which the lactose fines affect the DPI performance. Furthermore, the 
majority of the correlations between the carrier properties and the DPI formulation 
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performance reported in the literature are based on relatively small datasets and the 
window across which most of the models are capable of modelling the relationship is 
relatively narrow. Therefore, to date, a universal model for predicting DPI performance on 
the basis of the characteristics of the lactose carrier still remains to be introduced. 
 
Therefore, the aim of this project is two-fold. Firstly, the validity of the active site, 
agglomerate formation and the increased cohesion theories in governing the DPI 
performance was to be investigated. Secondly, the project also aimed to establish a 
universal relationship between the properties of the lactose carrier and the final DPI 
formulation performance when a wide range of different lactoses were used as the 
carriers.  
 
In Chapter 3 the impact of loaded drug dose on the formulation performance and 
fluidisation characteristics was investigated. The aim of this chapter was to study the 
validity of the active sites theory and the increased cohesion theories in governing the DPI 
performance.  
 
In Chapter 4 the impact of increasing concentration of lactose fines on the flow and 
fluidisation characteristics of the lactose carriers and the formulation performance were 
studied. This chapter aimed to test the validity of the increased cohesion theory and also 
to screen potential properties of the lactose that could be used for predicting the DPI 
performance. 
 
In Chapter 5 the importance of different lactose characteristics in governing the DPI 
performance was investigated by the means of multivariate statistical analysis methods 
and artificial neural networks. The chapter aimed at building a more holistic picture of the 
lactose characteristics that govern the DPI performance.  
 
In Chapter 6 the regional deposition of the drug in the impactor was studied in more detail 
by using complementary techniques in parallel with conventional in vitro testing of DPI 
formulations. This chapter aimed to relate the lactose characteristics to the regional drug 
deposition within the impactor. 
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CHAPTER 2 GENERAL MATERIALS AND METHODS 
OVERVIEW 
 
The aim of the current chapter is to introduce the theoretical background of the 
experimental methods central to the PhD project. In addition, the details of the 
experiments conducted are given in this chapter. In the later chapters, a brief materials 
and methods section is given, but the current chapter should be referred to for more 
detailed description of the experimental setup and the theoretical background of the 
frequently used methods. The theoretical background and the experimental details of the 
methods specific to each of the results’ chapters will be outlined in the chapters 
themselves. 
2.1 RAW MATERIALS 
2.1.1  Inhalation grade lactose 
2.1.1.1 Coarse grades of lactose 
 
Lactohale® (LH) is the brand of inhalation grade lactose manufactured by DFE Pharma 
(Borculo, Netherlands). Two different coarse grades of Lactohale supplied by DFE 
Pharma were used in the study, LH100 (Batch #625484) and LH206 (Batch #632599). 
The former is a sieved grade of coarse lactose and the latter a coarse but lightly milled 
lactose grade. Additionally, a sieved grade of coarse lactose SV010 (Batch #10523871) 
manufactured at a different plant of DFE Pharma was used in the studies. 
  
2.1.1.2  Lactose fines 
 
The fine grades of lactose used in the study were also Lactohale products donated by 
DFE Pharma (Borculo, Netherlands). LH300 (Batch #632955) is a micronised grade of 
lactose, LH230 (Batch #632868) a finely milled fine lactose and LH210 (Batch #632309) a 
coarsely milled fine lactose. In addition, Sorbolac 400 (Batch #0137, Meggle, Germany), 
which is a milled, fine grade of lactose with a broad particle size distribution, was used 
during the studies. 
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2.1.1.3  Preparation of lactose pre-blends 
 
The fine fractions of lactose were added to the coarse carriers in-house using low shear 
mixing to prepare pre-blends. The fines were added to the coarse carriers at 
concentrations of 2.5, 5, 10 and 20 wt-%. The total mass of the pre-blends was 100 g. The 
fine grades of lactose were sandwiched between the coarse carrier in two (2.5% blends) 
or 3 layers (5, 10 and 20% blends). A stainless steel cylindrical vessel with internal 
dimensions of 100 mm (inner diameter) by 150 mm (depth) was used for preparing the 
blends. With 100 g of lactose, the headspace in the vessel was approximately two thirds 
of the volume of the vessel, depending on the fines content of the pre-blend. Blending on 
a Turbula mixer (Glen Creston, Middlesex, UK) at 46 rpm was applied for 60 minutes. The 
pre-blends were stored at 44% RH and 20±2°C for at least a week before any further work 
was carried out.  
 
2.1.2 Model drugs 
 
Micronised fluticasone propionate (FP, Batch #R362400) (GlaxoSmithKline, Singapore) 
and micronised budesonide (Batch #364R, AstraZeneca, Lund, Sweden) were used as 
the model drugs during the project. Both these molecules are corticosteroids used for 
reducing airway inflammation.  
 
2.1.3 Other chemicals 
 
All the solvents (methanol, acetonitrile, cyclohexane and hexane) used during the study 
were purchased from Sigma (Gillingham, UK) and were of HPLC grade. Similarly, silicone 
oil and lecithin granules were purchased from Sigma. The water was reverse osmosis 
purified (Millipore, France).  
 
2.2 PHYSICAL AND PHYSICOCHEMICAL CHARACTERISATION OF THE 
LACTOSE CARRIERS  
2.2.1 Particle size 
2.2.1.1 Theory 
 
Measuring the particle size distributions of raw the materials of inhalation formulations is 
important for various reasons. Firstly, it was shown in the introduction that for achieving 
successful drug delivery to the lungs it has to be ensured that the particle size of the drug 
is within the respirable range (Section 1.1.4) Secondly, it was discussed in the introduction 
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(Section 1.4.2.5) that the particle size of the coarse carrier itself has an impact on the drug 
detachment from the carrier surface. Thirdly, the proportion of fine lactose particles 
present in the carrier is known to correlate with the final formulation performance (Section 
1.4.5).  For these reasons, particle sizing is one of the most fundamental characterisation 
techniques in inhalation product manufacturing. 
 
When a monochromatic ray of light with an intensity of I0 interacts with a particle, the light 
can be absorbed, refracted or scattered. Laser diffraction is a particle sizing technique 
based on measuring the angle of the scattered light, θ, as a result of an interaction with a 
particle. The smaller the particle, the larger the angle of scattered light. Also, the smaller 
the particle, the smaller the intensity of the scattered light, Is (Newton 1982). These 
principles are illustrated in Figure 2.1, where the angle and the size of the arrows 
scattered from the particles represent the scattering angle and the intensity of the 
scattered light, respectively. 
 
 
FIGURE 2.1 THE PRINCIPLE OF LASER DIFFRACTION WITH SMALL PARTICLES SCATTERING THE INCIDENT 
LIGHT I0  AT A LARGE ANGLE θ AT LOW INTENSITY IS (TOP) AND LARGE PARTICLES SCATTERING THE LIGHT 
AT SMALL ANGLE AT HIGH INTENSITY (BOTTOM) 
 
Measuring the scattering data for a sample is based on the first principles described 
above. However, the scattering pattern for a polydisperse ensemble of particles can be 
complex (Newton 1982). To convert the measured scattering data into a particle size 
distribution, calculations with different assumptions have to be made. Two different 
theories, the Fraunhofer and Mie theories, are predominantly used for obtaining the 
particle size distributions from the scattering data. The Fraunhofer theory assumes the 
particles are much larger than the wavelength of the incident light. Additionally, the theory 
assumes no interactions other than scattering take place upon the interaction between the 
light and a particle. Mie theory requires more computational power to be solved but 
provides a more accurate model for analysing the scattering data by taking into account 
also the refraction and absorption of the light by a particle (Newton 1982).  
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To obtain laser diffraction data of high quality, the particles have to be dispersed to 
primary particles. However, simultaneously, the concentration of the particulate matter in 
the measurement zone has to be maintained low enough. That is because multiple light 
scattering, which is a phenomenon taking place in concentrated suspensions, results in 
the measured particle size being smaller than the true particle size. The phenomenon 
occurs when the light already scattered by one particle hits another particle and as a 
result is scattered again (Kokhanovsky et al. 2001). This phenomenon is illustrated in 
Figure 2.2. 
 
FIGURE 2.2 MULTIPLE LIGHT SCATTERING IS A PHENOMENON WHERE THE SCATTERED LIGHT (IS) AT AN 
ANGLE θ IS RE-SCATTERED ON ITS WAY TO THE DETECTOR DUE TO A HIGH CONCENTRATION OF 
PARTICULATES. THIS RESULTS IN MEASUREMENT OF LOWER LIGHT INTENSITY IS2 AND A LARGER 
SCATTERING ANGLE θ2 THAN THE TRUE VALUES. CONSEQUENTIALLY,  A PARTICLE SIZE SMALLER THAN 
THE REAL SIZE IS REPORTED 
 
2.2.1.2 Measurement methodology 
 
The particle sizing experiments were conducted using a Helos laser diffraction unit in 
conjunction with Windox 5 software, both from Sympatec GmbH (Clausthal-Zellerfield, 
Germany). The system uses a 632.8 nm wavelength He-Ne laser as the light source. The 
optical bench was equipped with R3 and R4 Fourier lenses for focusing the diffraction 
patterns of equally sized particles to the same position on the array of detector rings. 
These lenses cover particle size ranges between 0.9 and 175 µm and 1.8 and 350 µm, 
respectively. The principle of using Fourier lens for focusing the scattering is illustrated in 
Figure 2.3.  
 
FIGURE 2.3 PRINCIPLE OF OPERATION OF THE FOCUSING LENS AND DETECTING THE SCATTERING FROM 
PARTICLES OF IDENTICAL SIZES ON THE SYMPATEC LASER DIFFRACTION SYSTEM 
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The high resolution Fraunhofer model provided by the Windox software (HRLD) was used 
for calculating the particle size distributions from the raw scattering data. According to the 
manufacturer, the HRLD calculation mode is able to take the background noise into 
account more accurately when converting the measurement data to the size distribution 
than the standard Fraunhofer model provided by the software.  
 
The lactose powders were measured using the R4 lens and dispersed dry using the 
Rodos dry powder disperser in conjunction with the Vibri dry powder feeder (both from 
Sympatec). Before the measurements, the vacuum was switched on and the background 
scattering was recorded for 10 seconds. The sample was then introduced to the 
measurement zone with a steady flow rate. This was obtained by adjusting the gap 
between the funnel and the powder feeder tray to 2 mm. The feed rate was adjusted such 
that an optical concentration of between 0.5% and 5% was achieved. For most of the 
powders, the feed rate required to achieve this was approximately 30%. To ensure a high 
signal to noise ratio, no data was recorded until the threshold value of 0.5% for optical 
concentration was exceeded. A pressure titration was performed to assess the disperser 
pressure at which the particles were fully dispersed and no attrition took place. On the 
basis of the results, a disperser pressure of 2 bar was selected for measuring the lactose 
samples.  
 
The particle size distributions of the drugs were measured using the R3 lens and the 
Cuvette wet dispersion system. The aliquots of the materials were dispersed in 
cyclohexane that contained 0.1% lecithin to aid the dispersion. The stir speed using the 
magnetic flea was set to 1500 rpm. Prior to the measurements, the background scattering 
caused by the dispersant was recorded for a period of 10 seconds. To achieve the 
primary particle size, ultrasound at 50% intensity of the maximum with the internal probe 
of the disperser system was applied for 1 minute for budesonide and for a total of 5 
minutes in one minute intervals for fluticasone propionate. After every minute of 
sonication, a pause of one minute was applied to allow thermal gradients within the 
dispersant to dissipate. After the sonication, the final optical concentration was between 3 
and 10%. 5 repeated measurements of 5 seconds duration were recorded for both the 
samples. 
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2.2.2 Scanning electron microscopy 
2.2.2.1 Theory 
 
Knowledge of the powder structure is important if an understanding of the different 
theories regulating the DPI performance in the presence of lactose fines is to be achieved. 
However, at present, suitable techniques for characterising the powder structure at the 
bulk level are scarce. Therefore, scanning electron microscopy (SEM) is often used for 
qualitative assessment of the formulation structure in DPI manufacturing.  
 
When a conductive specimen is irradiated with a finely focused electron beam, secondary 
electron scattering and backscattering take place upon the interaction between the 
specimen surface and the electron beam. The backscattered electrons are defined as the 
electrons that scatter from the sample specimen through the same surface as they 
entered the specimen. Secondary electrons on the other hand are any low energy 
electrons scattered from the specimen. SEM is a surface visualisation technique based on 
detecting the secondary and backscattered electrons (Goldstein et al. 1992). The basic 
components of a scanning electron microscope are an electron source, condenser lenses, 
a deflection system, an objective lens, secondary electron and backscattering detectors 
and the sample holder, all held under vacuum. (Goldstein et al. 1992). A schematic of the 
instrumental setup and data collection is presented in Figure 2.4 and will be discussed in 
detail in the following paragraphs. 
 
The electron source creates an electron beam with up to 40 keV of energy. However, the 
spatial resolution of SEM is affected by the diameter of the electron beam. The diameter 
of the beam produced by the electron source, also termed as the spot size, is too large to 
obtain high resolution images. Therefore, condenser lenses are used for focusing the 
beam and thus reducing the spot size. A beam with a small diameter has a high energy 
density. Consequentially, smaller spot sizes result in a high enough intensity for the 
scattered electrons. This way, good spatial resolution is ensured. For optimal resolution, 
the electron beam fine tuning on to the specimen surface is done by adjusting the focus 
with the objective lens (Goldstein et al. 1992).  
 
The magnification of the scanning electron micrograph is adjusted by the deflection 
system. The system consists of two pairs of electromagnetic coils that split the electron 
beam to create a raster on the sample surface. The magnification of the image is 
determined by the ratio between the raster size of the display and the raster size on the 
surface of the specimen. Therefore, to enable the determination of the magnification, the 
deflection system of a SEM is also connected to the scan generator and the display. 
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Assuming the size of the display is fixed, higher magnifications result from reducing the 
raster distance on the specimen surface (Goldstein et al. 1992).  
 
The detectors for the secondary and backscattered electrons consist of collector plates, a 
scintillator and an amplifier. The collector plates are positively charged screens that attract 
the scattered electrons. The collected electrons are then accelerated and sent to the 
scintillator. Upon contact between an electron and the scintillator, light is emitted. This 
light is sent to a photomultiplier tube and converted to an amplified electrical signal that is 
then displayed on the screen (Goldstein et al. 1992).   
 
 
FIGURE 2.4 SCHEMATIC PRESENTATION OF CONFIGURATION OF A SCANNING ELECTRON MICROSCOPE 
 
2.2.2.2  Measurement methodology 
 
Pharmaceutical powders are electrical insulators. Therefore, SEM imaging of these 
materials is impossible unless a conductive coating is applied. The materials under 
investigation in the current study were mounted on conductive, sticky carbon tabs. The 
samples were then coated with gold under vacuum using an Edwards Sputter Coater 
(Edwards, Israel). Sputter coating is a process where atoms are created from a target by 
means of highly energetic collisions with neutral molecules or atoms under vacuum. 
These atoms are then deposited on the surface of the specimen to be coated (Goldstein 
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et al. 1992). A coating time of 5.5 minutes was applied for sample preparation in the 
current study.  
 
A JEOL-6480LV scanning electron microscope (Jeol, Tokyo, Japan) was used for imaging 
the samples. The acceleration voltage applied was 10 keV. The spot size was set to 15 
and the samples were observed at a magnification of 900x.  
 
 
2.2.3 Bulk and tapped density, Hausner ratio and the Carr Index 
2.2.3.1 Theory 
 
One aim of the project was to assess the impact of increasing cohesion of the carrier on 
the DPI formulation performance. The Hausner ratio (HR) and Carr index (CI) have 
traditionally been used as measures of powder flow properties within the pharmaceutical 
industry. Both these parameters are calculated based on the bulk and tapped densities of 
the powders. 
Bulk density (ρB) of a powder describes how closely the particles pack when allowed to 
settle under gravity. The bulk density is determined by the force balance between the 
gravitational and interparticulate forces within the bulk powders (Mohammadi et al. 1997). 
It was discussed in the introduction (Section 1.2.3.3) that in free flowing powders, the 
magnitude of the gravitational forces is significantly higher than the magnitude of the 
interparticulate forces. Consequentially, gravitational forces prevail in free flowing powders 
and the particles in the bulk powder pack closely, resulting in a high bulk density. In 
contrast, in cohesive powders the interparticulate forces dominate over the gravitational 
forces. This results in a more open packing structure, and consequentially in a low bulk 
density, for cohesive powders. 
When the tapped density (ρT) of a powder is measured, the force balance between 
gravitational and interparticulate forces is altered by the mechanical forces induced by the 
vibrations (Mohammadi et al. 1997). For free flowing powders, the application of 
mechanical forces does not significantly change the packing characteristics of the bulk 
powder. This is because gravitational forces were significantly larger than the 
interparticulate forces in the first place. Therefore, no significant changes in the packing 
densities of free flowing powders are seen as a result of tapping. In contrast, for cohesive 
powders, the mechanical forces induced by the tapping combined with the gravitational 
forces experienced by the particles are often enough to overcome the interparticulate 
forces. This results in a more compact packing structure, and thus a higher density, upon 
tapping. 
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The Hausner ratio is a parameter describing the friction of the particles as they move past 
each other in a bulk powder (Hausner 1967). The Hausner ratio is defined by the ratio 
between the tapped and bulk density of the powder as per Equation 2.1. 
 
ࡴࡾ ൌ ࣋ࢀ࣋࡮     EQUATION 2.1 
Shortly after the Hausner ratio was reported in the literature, it was realised that the 
parameter correlated with the parameters describing the flow properties of powders. 
Cohesive powders demonstrate higher values of Hausner ratio than free flowing powders 
(Grey et al. 1969).  
The Carr index was introduced at a similar time to the Hausner ratio (Carr 1965). The Carr 
index is calculated on the basis of the bulk and the tapped densities of the powder 
according to Equation 2.2. The higher the value of Carr index, the more cohesive the 
powder is. 
 
࡯ࡵ ൌ ࣋ࢀି࣋࡮࣋ࢀ ∗ ૚૙૙     EQUATION 2.2 
 
2.2.3.2 Measurement methodology 
 
The bulk and tapped densities were measured using the FT4 powder rheometer (Freeman 
Technology, Tewkesbury, UK). For the measurement of bulk density, a 25 mm diameter, 
20 ml volume split measurement vessel was placed on the measurement table of the 
instrument and the weight of the vessel was tared. The vessel was then filled with the 
powder under investigation. A conditioning cycle was then run to remove the influence of 
the filling procedure on the powder packing. For measuring the bulk density, after the 
conditioning cycle, the measurement vessel was split and the split mass recorded. For 
measuring the tapped density, the measurement vessel was placed on a jolting volumeter 
(J. Engelsmann, Germany)) and 250 taps were applied. The measurement vessel was 
then transferred back on to the measurement table of the FT4, the vessel was split and 
the split mass recorded. All the measurements were performed in triplicate for all the 
powders. The results were calculated by dividing the mass of the powder in the 
measurement vessel after the cell had been split by 20 ml, which was the volume of the 
split cell. 
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2.3 METHODS FOR CHARACTERISING THE POWDER FLOW AND 
FLUIDISATION PROPERTIES  
 
2.3.1 Importance of characterising powder flow properties 
 
It was discussed in the introduction of the thesis (Section 1.2.1) that powders exhibit 
properties of gases (compressibility), liquids (fluidised state, pouring), and solids (plastic 
and elastic deformation). It was also shown that, for example, the fluidisation behaviour of 
the powders is closely related to the cohesion of the powder bulk. Therefore, to be able to 
predict the behaviour of powders under different processing conditions, knowledge of the 
powder flow properties is of paramount importance.  
 
In addition, it was discussed in the introduction that powders have a memory of the past 
consolidation history (Section 1.2.1) Therefore, the measurement methodology will greatly 
affect the results obtained. Consequentially, it is important to understand the conditions 
that prevail in the powder during the characterisation and the process; it is unlikely that the 
flow properties of a powder measured under high consolidation stresses describe the 
fluidisation behaviour of the powder very accurately. To simulate different powder 
handling process conditions, such as flow in hoppers or the fluidisation behaviour, as 
precisely as possible, different powder flow characterisation techniques are commercially 
available. These techniques can be divided in to two classes, namely static and dynamic 
methods (Krantz et al. 2009). During static measurements the powders are consolidated. 
During dynamic testing no consolidation stresses are applied on the powder and the 
particles are free to move during the measurements (Krantz et al. 2009).  
 
For the carriers and the DPI formulations themselves, low to moderate consolidation 
stresses are encountered during manufacturing and storage. Therefore, characterising the 
formulations at low consolidation stresses or using dynamic methods should give the 
results that are the most relevant to the final product performance. However, dynamic 
methods are often empirical whereas static methods are based on well described 
principles. Therefore, also static characterisation was performed in the current study. 
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2.3.2 Static characterisation – Schulze Ring Shear tester 
2.3.2.1 Theory 
2.3.2.1.1  Mohr circles 
 
When a Newtonian liquid is stored in a bulk container, the pressure applied on the surface 
of the liquid is evenly distributed against the container walls (Schulze 2010). If the walls 
are removed, the system will spontaneously return to the equilibrium state where the 
vertical and horizontal forces are equal, i.e. to a puddle of liquid. In contrary, in powders, 
the horizontal stress is always a result of applying vertical stress (Schulze 2010). 
Therefore, for example, in the absence of stress from above, a sand castle will retain its 
shape. However, if weight is applied on the top of the sand castle, the sand castle will 
deform in the horizontal direction. Yet a sandcastle may be ruined, but it will rarely be 
completely flattened by consolidating the top. That is because the force balance found in 
liquids is inexistent in powders. Therefore, stresses can be found in powders even at rest 
(Schulze 2010). The magnitude of horizontal stresses σh for liquid and powder stored in a 
container compared to the vertical stress σv applied on the surface are illustrated in Figure 
2.5. 
 
 
FIGURE 2.5 THE RELATIONSHIP BETWEEN THE VERTICAL STRESS σv AND HORIZONTAL STRESS σh IN 
NEWTONIAN LIQUID (LEFT) AND IN BULK POWDER (RIGHT) 
 
The rheological properties of liquids under pressure and shear stress are simply defined 
by the force balance with the forces distributed evenly throughout the liquid. Due to the 
lack of the force balance, defining the rheological properties of powders under 
consolidation and shear stress is more complicated. However, the stresses within the 
powder bulk can be described using Mohr stress circles (Schulze 2010). The principle of 
Mohr circles is illustrated in Figure 2.6. The bottom left corner of the schematic shows a 
powder in a container under vertical consolidation stress σv. The powder in the container 
is sheared at shear stress of τ. As a result of the shear stress, different shear planes 
appear in the powder bulk. The schematic in the top left corner of Figure 2.6 is a 
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magnification of one of the sections of the powder created by the shear plane. The shear 
plane has formed at an angle α in the powder bulk. The Mohr circle for this shear plane is 
presented on the right hand side of the schematic. The relationship between the powder 
segment and the Mohr circle will be discussed in the following. 
 
In the diagram for the Mohr circle, the y-axis represents the shear stress τ and the x-axis 
the consolidation stress σ. In the powder segment, the planes X and Y do not experience 
any shear stresses τ. Therefore, these two planes are described as points on the x-axis of 
the Mohr circle diagram, where τ is 0. It was discussed above that the horizontal stresses 
in powders are always a consequence of the vertical stresses, and therefore of smaller 
magnitude. Consequentially, σh is closer to the origin in the Mohr circle diagram than the 
σv. Both the centre and the radius of the Mohr circle are defined using the average 
between the horizontal and vertical consolidation stresses (Schulze 2010). This is also 
illustrated in Figure 2.6. 
 
The plane A in the powder segment that is shown on the top left of Figure 2.6, is a shear 
plane confining the segment highlighted in light blue in the insert on the bottom left of the 
schematic. The shear plane A has formed at an angle of α as a consequence of the shear 
stress τα. This plane experiences a consolidation stress of σα. The magnitude of the 
consolidation stress experienced by a shear plane within the bulk powder is always 
smaller than the vertical consolidation stress σv but larger than the horizontal 
consolidation stress σh. When the values of the shear stress τα and consolidation stress σα 
for a shear plane within the powder bulk are plotted against each other, a point on the 
perimeter of the Mohr circle is obtained. If the same procedure is repeated for all the 
possible shear plane angles, the perimeter of the Mohr circle will be fully defined (Schulze 
2010).  
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FIGURE 2.6 THE PRINCIPLE OF MOHR CIRCLES AND THE RELATION OF THE PARAMETERS TO THE POWDER 
UNDER STRESS. A, X AND Y ARE PLANES DESCRIBING THE POWDER SEGMENT HIGHLIGHTED LIGHT BLUE IN 
THE SCHEMATIC ON THE BOTTOM LEFT, A CLOSE UP OF WHICH IS PRESENTED ON THE TOP LEFT OF THE 
SCHEMATIC. α DEFINES THE ANGLE BETWEEN PLANES X AND A. σv, σh, AND σα ARE CONSOLIDATION 
STRESSES ENCOUNTERED BY THE POWDER SEGMENT IN VERTICAL, HORIZONTAL AND NORMAL TO PLANE A 
DIRECTIONS CORRESPONDINGLY. τα IS  THE SHEAR STRESS ACTING ON PLANE A. THESE PARAMETERS 
FULLY DEFINE THE MOHR CIRCLE SHOWN ON THE RIGHT OF THE SCHEMATIC. 
  
 
An important consequence of the Mohr stress circle analysis of powder properties is that 
the powder properties can only be defined if at least two of the parameters are known 
(Schulze 2010). Following on from the definition of the Mohr stress circle, the simplest 
way for constructing the Mohr stress circle for a powder would be using the average of the 
vertical and horizontal consolidation stresses, σv and σh, to define the centre and the 
radius for the circle. However, in practice, defining these values is not straightforward. 
Therefore, a reverse approach for determining the Mohr stress circle for a powder from a 
yield locus that can be easily measured is often applied. The yield locus and the 
relationship between the yield locus and the Mohr circles will be introduced in the 
following. 
 
 
2.3.2.1.2  Yield locus 
 
Returning to the example of the sandcastle, another important feature of a sandcastle is 
that the more consolidated the sand in the container before the bucket is turned over, the 
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stronger the resulting sand castle. This example illustrates that the magnitude of the 
consolidation stress applied has a significant impact on the flow properties of the powder, 
with higher consolidation stresses resulting in a powder more resistant to deformation and 
flow. Therefore, when characterising powder flow properties, the results will strongly 
depend on the magnitude of the consolidation stresses experienced by the powder before 
the testing. Therefore, in static powder testing, the powder properties are characterised by 
defining a yield locus for a powder. The yield locus describes the properties of the powder 
after application of a particular consolidation stress (Schulze et al. 2003).  
 
The process of constructing the yield locus for a powder is illustrated in Figure 2.7. The 
powder is first consolidated under a pre-defined pre-shear consolidation stress σPre. The 
sample is then sheared until a steady state flow is obtained. The steady state flow is 
defined as a state where neither the density nor the shear required for maintaining the 
movement of the powder change over time. This is illustrated as the flat plateau in the 
shear vs. time curve during the first phase, as shown on the left hand side diagram in 
Figure 2.7. The shear and the consolidation stresses are then eased off before a pre-
defined consolidation stress σShear, lower than the σPre, is applied and the powder is 
sheared until failure to resist the flow. The failure to resist flow is characterised by the 
sharp decrease in the required shear stress, and is illustrated in the second phase of the 
diagram on the left hand side in Figure 2.7. The powder is then returned to the initial state 
by repeating the pre-shear step before another shearing phase at a different, pre-defined 
consolidation level is applied. The yield locus that is shown on the right in Figure 2.7, is 
achieved by plotting the pairs of values for the consolidation stresses σ and the 
corresponding values of shear stresses τ against each other (Schulze et al. 2003).  
 
 
FIGURE 2.7 OBTAINING STEADY STATE FLOW UNDER A PRE-SHEAR STRESS σPre AND SUBSEQUENT 
SHEARING OF THE SAMPLE AT A LOWER, PRE-DEFINED CONSOLIDATION STRESS σShear UNTIL FAILURE 
(LEFT) AND THE CONSTRUCTION OF THE YIELD LOCUS ON THE BASIS OF THE PRE-SHEAR AND SHEAR 
EXPERIMENTS. ADAPTED FROM SCHULZE ET AL. (2003) 
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2.3.2.1.3 The relationship between the yield locus, the Mohr circle and the powder 
flow properties 
 
Based on the measured yield locus, two different Mohr stress circles for a powder under a 
certain stress can be constructed (Schulze et al. 2003). These circles are shown in Figure 
2.8. The larger of the circles is constructed by using the end point of the yield locus, i.e. 
the pre-shear point (τPre, σPre). This point on the yield locus is shown in the right hand side 
of Figure 2.7. This point is the intersect for the tangent between the yield locus and the 
larger Mohr circle. The larger Mohr circle defines the vertical consolidation stress of the 
powder at the pre-sheared state, i.e. at steady flow. This is indicated as the point σ1 in 
Figure 2.8. The smaller Mohr stress circle intersects the origin of the graph and is 
tangential to the yield locus. This stress circle represents the stresses in the powder if 
stored in a container without walls. Therefore, the principal stress labelled as σc in Figure 
2.8 is defined as the unconfined yield strength.  
 
 
FIGURE 2.8 CONSTRUCTING THE MOHR CIRCLE FOR A POWDER ON THE BASIS OF THE YIELD LOCUS. THE 
THREE LABELLED POINTS CORRESPOND TO THOSE IN FIGURE 2.7.  σ1 IS THE CONSOLIDATION STRESS AND 
σc THE UNCONFINED YIELD STRENGTH 
 
Because the powder properties are heavily dependent on the consolidation stress, the 
powder flow properties from static tests are often reported as the flow function, ffc. The 
flow function of a powder is defined as the ratio between the consolidation stress σ1 and 
the unconfined yield strength σc as per Equation 2.3 (Schulze et al. 2003). 
 
ࢌࢌࢉ ൌ ࣌૚࣌ࢉ     EQUATION 2. 3 
 
The larger the value of ffc for a powder, the better the flow properties it exhibits (Schulze 
et al. 2003). The classification of powder flow properties according to values of ffc is 
summarised in Table 2.1. 
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TABLE 2.1 CLASSIFICATION OF POWDER FLOW PROPERTIES ON THE BASIS OF FLOWABILITY NUMBER ffc  
(SCHULZE 2010) 
 ffc Powder flowability
<1 Not flowing 
1-2 Very cohesive 
2-4 Cohesive 
4-10 Easy flowing 
>10 Free flowing 
 
2.3.2.2 Measurement methodology 
 
The samples were characterised using the RST-XS ring shear tester controlled by RST-
Control 95 software (both from Dietmar Schulze, Germany). The 30 ml annular shear cell 
was filled with the powder under investigation and the surface of the powder was 
subsequently evened out by a spatula. The filled shear cell was then mounted on the 
measurement table of the instrument and the lid of the shear cell was carefully placed on 
top of the sample without compacting the powder. For applying the normal force, the 
loading rod was then inserted. The tie rods were connected to the shear cell and the 
loading beams that measure the shear force. The pre-shear consolidation stress (σPre) 
was set to 1 kPa in the software and the sample was then sheared until steady state flow 
was achieved. The shear stress at this stage was measured and used as τPre. The sample 
was then consolidated at 750, 500 and 250 Pa and the corresponding shear stresses 
measured for each of the consolidation stresses. Before each of the measurements, the 
pre-shear step was repeated to return the sample to its initial state. The yield locus and 
the corresponding Mohr stress circles were then constructed using the instrument 
software. The results were reported as the flowability number ffc. The measurements were 
performed in triplicate for all the samples characterised. 
 
 
2.3.3 Dynamic characterisation – FT4 powder rheometer 
2.3.3.1 Theory 
 
In static powder testing the movement of particles relative to each other is limited due to 
the consolidation stresses from above. In contrast, in dynamic powder characterisation, 
the powder is not consolidated during the measurements. This means the particles can 
move freely relative to each other in the powder bulk during the measurements (Krantz et 
al. 2009). This situation is similar to a dose of DPI formulation in a capsule, where the 
powder occupies the volume of the capsule, which is often considerably larger than the 
volume of the powder containing the dose. Therefore, dynamic methods are anticipated to 
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be suitable for characterising the flow properties that are relevant to fluidisation and 
deagglomeration behaviour of DPI formulations and excipients.  
 
The approach of the FT4 powder tester for determining the flow properties of powders is 
empirical and cannot be described theoretically like the static methods. Different 
measurements can be performed using the FT4 powder rheometer (Freeman 2007). 
These include, for example, measurements of the powder flow of the bulk or aerated 
powders or the compressibility of the powders. All the measurements reported in the 
current thesis are based on determining the torque (τ) and a downward force (F) required 
to keep a blade moving though a powder bed at a constant speed and helical angle as a 
function of height (h) of the blade within the powder bed. This principle of the 
measurements is illustrated in Figure 2.9. The force and torque profiles as a function of 
the blade height are then integrated to produce total energy for initiating powder flow 
(Freeman 2007).  
 
 
FIGURE 2.9 THE PRINCIPLE OF CHARACTERISING THE RESISTANCE OF A POWDER TO FLOW USING THE FT4 
POWDER RHEOMETER WITH THE TORQUE (τ) AND FORCE (F) MEASURED AS A FUNCTION OF THE BLADE 
HEIGHT (h) 
 
The flow patterns of the powder, and thus the measured energies, during the 
measurements are influenced by the helical angle of the blade movement, α, and the 
blade tip speed. These parameters can be altered for the measurements, so that relevant 
information for the powder properties under process conditions of practical interest can be 
recorded. The blade tip speed and the helical angle trigonometrically define the rotational 
and vertical speed for the blade assembly, as illustrated in Figure 2.10.  
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FIGURE 2.10 THE BLADE TIP SPEED AND THE HELICAL ANGLE α DEFINE THE ROTATIONAL AND VERTICAL 
SPEED OF THE BLADE ASSEMBLY 
 
 
The blade geometry is designed so that different powder flow patterns can be initiated 
depending on the direction of the helical movement. An anti-clockwise motion of the blade 
with a positive helical angle produces a bulldozing action. Clockwise movement of the 
blade, corresponding to negative helical angles, results in a gentle displacement of the 
powder (Freeman 2007). The clockwise motion of the blade, illustrated on the right in 
Figure 2.11, is used for erasing the packing history of the powder by gently displacing the 
powder before the measurements are performed. This step, termed the conditioning cycle, 
results in a loosely packed and constant initial state of powder packing before the 
measurements are performed. Therefore, it removes the operator influence on the results 
(Freeman 2007). 
 
The bulldozing action of the anti-clockwise movement of the blade, shown on the left in 
Figure 2.11, results in the forces created by the blade movement being transferred 
throughout the powder bulk (Freeman 2007). The powder packing structure and its 
influence on the extent of the force transmission zone ahead of the blade are essential in 
understanding the results of powder characterisation when using the FT4 powder 
rheometer. Free flowing powders normally have higher bulk densities than cohesive 
powders (Thalberg et al. 2004). As discussed earlier in the chapter (Section 2.2.3.1), this 
means that the particles in free flowing powders are more closely packed than in cohesive 
powders. Therefore, free flowing powders have less air within the powder bulk structure.  
Only particles will create resistance to the blade movement and any air trapped in 
between the particles does not resist the blade movement. Therefore, when the blade is 
moved though a free flowing powder at a constant speed, the force transmission zone 
ahead of the blade is larger than it would be for a cohesive powder. 
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FIGURE 2.11 THE ANTI-CLOCKWISE MOTION OF THE BLADE PRODUCING A BULLDOZING ACTION (LEFT) AND 
THE CLOCKWISE MOTION OF THE BLADE RESULTING IN A GENTLE DISPLACEMENT OF THE POWDER (RIGHT). 
THE IMAGES ARE COURTESY OF AND REPRODUCED WITH THE PERMISSION OF FREEMAN TECHNOLOGY 
 
 
The normalised basic flow energy (BFENorm) measurement characterises the resistance of 
one gram of the powder to flow at a constant speed (Freeman 2007). The more cohesive 
the powder, the lower the basic flow energy. This may appear unintuitive at first. However, 
as discussed above, this can be explained by the packing structure and resulting extent of 
the force transmission zone ahead of the blade. Therefore, the force and torque required 
to maintain a constant speed of the blade in a free flowing powder is higher than in a 
cohesive powder, resulting in a higher value of BFENorm (Freeman 2007).   
 
Flow rate index (FRI) is a dimensionless parameter describing how different powders 
react to changes in the rate at which they are moved around. The more cohesive the 
powder, the more sensitive it is to the changes in the flow rate (Freeman 2007). Cohesive 
powders have low packing density and therefore more air entrapped within the powder 
bulk. When the blade is moved though a cohesive powder slowly, the air within the 
powder bulk ahead of the blade has enough time to escape from the structure as a result 
of the forces created by the blade movement. Consequentially, the force transmission 
zone ahead of the blade is extended at slow tip speeds. Therefore, at slow tip speeds, the 
force and the torque required to keep the blade moving though the powder bulk at 
constant speed are higher than at higher tip speeds. In contrast, the force and torque 
required for maintaining a constant tip speed in free flowing powders is not affected to 
such a great extent by changes in the tip speed. This is because the powders have less 
entrapped air in the first place. Therefore, the extent of the force transmission zone is not 
altered upon changing the flow rate.  
 
The normalised fluidisation energy (FENorm) defines the energy required to keep the blade 
moving through one gram of fluidised powder bed at a constant speed. Particulate and 
aggregative fluidisation were discussed in the introduction of the thesis (Section 1.2.3.5). 
The results of the fluidisation energy measurements can be explained by the combination 
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of the force transmission zone ahead of the blade and the extent of particulate fluidisation 
in the powder. To illustrate this, the following example should be considered. If the 
aeration test was performed without any powder in the measurement cell but with the 
fluidising gas flow enabled, no resistance would be encountered by the blade. Therefore, 
the measured flow energy would be zero. Following this, the closer to full particulate 
fluidisation the powder is, the lower the measured fluidisation energy will be. This is 
because the more completely fluidised the powder is, the less likely it is that a fluidised 
particle will encounter another one as the blade is moved through the bed of fluidised 
powder. Therefore, the blade encounters very little resistance and the measured 
fluidisation energy is low. The larger the fluidised agglomerates, the more likely it is that 
the agglomerates will interact with each other as a result of the impelling action of the 
blade. Therefore, the force transmission zone will be large and the measured energy high. 
 
Dynamic flow index (DFI) describes the reactivity of the powder to an air flow through the 
powder bed. The value of DFI is calculated as a ratio between normalised basic flow 
energy (BFENorm) and the normalised fluidisation energy (FENorm) of a powder. The higher 
the value of DFI, the more the powder structure is affected by the fluidising gas flowing 
through the powder bulk. Free flowing powders have high bulk densities but are easily 
aerated upon passing fluidising gas through the powder bed. Cohesive powders on the 
other hand have a loose packing structure and the gas permeation through the powder 
bulk is not as complete as for free flowing powders.  
 
2.3.3.2 Measurement methodology 
 
The BFENorm and FRI were measured during the same test procedure. For the 
measurement, the powder was loaded in the 25mm bore diameter, 20 ml volume split 
vessel. At first, a downward conditioning cycle was run at a tip speed of -40 mm/s and a 
helical angle of 5° to remove the packing history of the powder. This was followed by an 
upward conditioning cycle at a tip speed of 40 mm/s and a helical angle of 5°. After the full 
conditioning cycle, the measurement cell was split and the split mass recorded. 
Consecutive cycles of conditioning and measuring the BFE were then repeated seven 
times to assess the stability of the powder under agitation. The downward BFE 
measurement cycle was performed at a tip speed of -100 mm/s and helical angle of -5°. 
After each of the BFE measurements, the blade was moved upward at a tip speed of 40 
mm/s and helical angle of -5°. If the BFE measured during the repeated measurements 
remained stable, the BFE recorded in the 7th test was divided by the split mass to 
calculate the BFENorm.  To measure the FRI, four additional measurement cycles at tip 
speeds -100, -70, -40 and -10 mm/s were run with an unaltered conditioning cycle 
86 
 
between each of them. The FRI is calculated as the ratio of the flow energy measured at a 
tip speed of -10mm/s over the flow energy measured at -100 mm/s tip speed. 
 
The FENorm and DFI were measured during the same measurement program. Also for 
these measurements, the powder was loaded in the 25mm bore diameter, 20ml volume 
split vessel. At first, a conditioning cycle was repeated 8 times at a tip speed of -60 mm/s 
downward and 60 mm/s upward and helical angles of 5° and -5°, respectively, to remove 
the packing history of the powder. The high number of conditioning cycles was seen to 
improve the reproducibility of the measurements. The improvement was attributed to 
obtaining a uniform powder structure and thus avoiding the formation of rat holes in the 
cohesive powders. After the conditioning cycles, the measurement cell was split. The 
cycle of the conditioning and the measuring of the flow energy was then repeated at 
different air velocities, controlled by the Aeration Control Unit (ACU) accessory of the FT4. 
The air velocity was adjusted such that, during the conditioning cycle, the air velocity was 
equal to the air velocity of the following measurement. The measurement cycles at the 
different air velocities were performed at a tip speed of -100 mm/s and a helical angle of   
-5°, followed by an upward motion at a tip speed of 60mm/s and a helical angle of 10°.  
 
2.3.4 Dynamic characterisation - Fluidisation and defluidisation properties by 
pressure drop measurements 
 
2.3.4.1  Theory 
 
The fluidisation properties of powders can also be dynamically studied by measuring the 
pressure drop across the powder bed when fluidising gas is passed through a column of 
powder (Valverde et al. 1998). Unlike the powder testing based on measuring the torque 
and force required to move an impeller blade through powder, characterising the cohesion 
of powders by pressure drop measurements during fluidisation and defluidisation is an 
accepted and theoretically well-established technique (Castellanos 2005). The pressure 
drop generated across the powder bed is caused by interparticle forces and the friction 
between the particles and the fluidising gas (Holdich 2002). Figure 2.12 presents a typical 
pressure drop curve for a cohesive powder as the velocity of the fluidising gas is 
increased and decreased in a stepwise fashion. During the fluidisation branch (solid line), 
the pressure drop initially increases linearly as the velocity of the fluidising gas is 
increased.  The slope upon increasing the velocity of the fluidising gas is defined by the 
Carman-Kozeny law (Carman 1956). The law describes the relationship between the 
pressure drop and the void fraction within the powder bed with larger void fractions 
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resulting in a smaller slope. Therefore, the slope describes the packing structure of the 
bulk powder.  
 
For a free-flowing powder with very weak interparticulate forces the pressure drop 
continues to increase up to the fluidising gas velocity labelled (a) in Figure 2.12. At this 
point, for a free-flowing powder, the weight of the powder is fully supported by the drag 
force exerted by the fluidising gas and the powder becomes fully fluidised. The pressure 
drop measured across the powder bed equals the weight of the powder bed per cross-
sectional area of the fluidising vessel. However, for cohesive powders, interparticulate 
forces have to be overcome before fluidisation can occur. Therefore, the pressure drop for 
a cohesive powder would continue to increase above the weight of the powder to the gas 
velocity labelled as (b) in Figure 2.12. At this point, the pressure drop is equal to the 
weight of the powder and the strength of the cohesive forces within the powder bed 
(Valverde et al. 2000).  With increasing air flow velocities, the pressure drop returns to a 
level equal to that of the weight of the powder bed. Thus, this overshoot in the pressure 
drop, indicated by the arrow labelled as σ, provides an indication of the strength of the 
cohesive forces within the powder bed (Valverde et al. 1998). Some studies, however, 
have shown that the pressure drop hysteresis is also related to the wall friction created 
between the particles and the walls of the fluidising vessel and that the friction must 
therefore be taken into account (Loezos et al. 2002). 
 
The dashed line in Figure 2.12 illustrates the pressure drop of the powder bed when the 
fluidising gas velocity is decreased stepwise. The pressure drop hysteresis is absent on 
this defluidisation branch. This is because all the cohesive forces within the powder bed 
have been overcome during the fluidisation of the powder. The particles are re-forming a 
packing structure as they settle under gravity when the drag forces exerted by the 
fluidising gas become inadequate to maintain the particles suspended.  
 
The gas velocity at which the powder becomes fully fluidised is the minimum fluidisation 
velocity (Umf). In some previous studies, the minimum fluidisation velocity has been used 
as a measure of powder cohesion both experimentally (Wright et al. 1998) and 
theoretically (Weber et al. 2006). These studies concluded that the higher the minimum 
fluidisation velocity, the more cohesive the powder. Depending on the powder properties, 
the minimum fluidisation velocity can be defined as three different points, indicated by a 
(Castellanos 2005), b (Shur et al. 2008a) and c (Delebarre et al. 2004) in Figure 2.12. 
Typical DPI formulations exhibit a certain degree of cohesion. Therefore, during the 
current study, point b was used as the minimum fluidisation velocity.  
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FIGURE 2.12 SCHEMATIC OF A PRESSURE DROP CURVE DURING FLUIDISATION (SOLID LINE) AND 
DEFLUIDISATION (DASHED LINE) EXPERIMENTS OF A COHESIVE POWDER AS A FUNCTION OF THE FLUIDISING 
GAS VELOCITY. POINTS a, b AND c HIGHLIGHT THE DIFFERENT DEFINITIONS FOR THE MINIMUM 
FLUIDISATION VELOCITY AND σ REPRESENTS THE COHESIVE STRENGTH OF THE POWDER. THE EQUATION 
DESCRIBES THE THEORETICAL PRESSURE DROP FOR A POWDER BED WITH A MASS OF m AND CROSS-
SECTIONAL AREA OF A 
 
To the author’s knowledge, the FT4 rheometer has not been previously used for 
measuring the pressure drop of powders. Therefore, the steps followed during method 
development will be described in detail with supporting results in Chapter 3, section 3.5. 
 
2.4 DRUG CONTENT ASSAY BY HPLC 
2.4.1  Theory 
 
To assess the performance of the DPI formulations, an analytical method is required for 
quantifying the amount of drug in various samples. High performance liquid 
chromatography (HPLC) was used for assaying the drug contents in the current study. 
 
HPLC is a widely used analytical technique where analytes in a solution are separated 
and quantified. As in any chromatographic technique, the separation of analytes in HPLC 
is based on the distribution coefficient of the analyte (D), which is defined as the ratio 
between the affinity of the analyte to the stationary phase (As) and to the mobile phase 
(Am). In HPLC, the stationary phase is packed in a column, through which the mobile 
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phase is pumped. Once eluted, the concentration of the analytes can be quantified by 
using, for example, spectrophotometric, fluorescence or mass spectrometric methods 
(Lough et al. 1995).  
 
The stationary phase material, such as octadecyl silane (ODS), for HPLC is often 
immobilised on the surface of material consisting of small silica particles. These particles 
are packed in the column in such a way that the column has a low permeability. 
Therefore, pumps are required to maintain a constant flow of the mobile phase through 
the column. However, because of the low permeability, pumping the mobile phase creates 
a pressure differential between the inlet and the outlet of the column. In HPLC, the 
pressure differential is the driving force for the mobile phase movement through the 
column. Despite the high packing density of the column, a descent flow rate of the mobile 
phase is achieved due to the pressure differential. Consequentially, more efficient 
separation can be achieved with HPLC in equivalent time when compared with traditional, 
gravity driven open column liquid chromatography (Lough et al. 1995). The higher the 
pressure the pump can create, the smaller the particle size of the stationary phase can be. 
This improves the separation efficiency due to the increased surface area of the stationary 
phase. For the same reason, increasing the column length in HPLC improves the 
separation of analytes (Lough et al. 1995) 
 
Retention time is the time that it takes for an analyte to be eluted. In a mixture of analytes, 
a large enough difference between the retention times for the different analytes is needed 
if a baseline resolution is to be achieved. The retention time is dependent on the analyte 
interactions with the stationary and mobile phases. Therefore, the resolution of the 
method can be influenced by altering the composition of one of the phases. The choice of 
stationary phase materials is often limited and some of the less common columns are very 
expensive. Therefore, the easiest and the most economical way of modifying the retention 
times of analytes to achieve a complete separation is changing the composition of the 
mobile phase. For example, if the stationary phase is non-polar, non-polar analytes will 
have longer retention times than polar analytes. The retention times of non-polar 
molecules can be increased by adding water to the mobile phase. This causes the analyte 
molecules to favour the hydrophobic stationary phase over the hydrophilic mobile phase. 
Similarly, the addition of water in the mobile phase has an opposite effect on the retention 
times of polar analytes, decreasing the retention time (Lough et al. 1995).  
 
Once separated within the column, the analytes can be quantified by using, for example, 
UV spectrophotometry or mass spectrometry for detection. The area under the curve or 
the peak height, depending on the method of detection, is proportional to the amount of 
the analyte in the sample. If standards with known amounts of the analyte are run with the 
90 
 
samples, the amount in the samples can be quantified based on the calibration (Lough et 
al. 1995).   
 
 
2.4.2 Measurement methodology 
 
In the current study, HPLC was used for quantifying the concentration of drug in binary 
mixtures with lactose. Due to the chemical similarity of the drug molecules used, 
principally the same method could be used for both budesonide and fluticasone 
propionate. The samples were dissolved in a mobile phase that consisted of 20% water, 
35% acetonitrile and 45% methanol.  The mobile phase was pumped through the system 
at a flow rate of 1.5 ml/min using a Jasco PU-980 pump (Jasco, Tokyo, Japan). 100 µl of 
the samples were injected into the system using a Jasco AS-950 autosampler (Jasco, 
Tokyo, Japan). The 250 mm long Hypersil-ODS column with an inner diameter of 4.6mm 
and packing material particle size of 5 µm (Thermo Scientific, Loughborough, UK) was 
held at 40°C using a Jasco CO-965 column oven (Jasco, Tokyo, Japan). The eluted drug 
was detected using a Jasco UV-975 detector (Jasco, Tokyo, Japan) at a wavelength of 
244 nm for budesonide and 235 nm for fluticasone propionate. The retention time for 
budesonide was 3.75 min and 3.25 min for fluticasone propionate. 
 
The amount of drug in the unknown samples was determined based on calibration for the 
area under the curve versus the concentration of standard samples that were run in every 
sample rack.     
 
2.5  PREPARATION OF DRY POWDER INHALER FORMULATIONS 
 
2.5.1 Background 
 
To study the impact of the carrier properties on the final formulation performance, model 
formulations were prepared. The following section of the chapter describes the processes 
involved in manufacturing the blends and assuring the quality of the blending. 
 
Powder mixing is a fundamental process in DPI formulation, where the aim is to prepare a 
uniform formulation from two or more components. When mixing two powders that consist 
of equally sized, free flowing particles of equal density and that exhibit no significant 
interparticulate forces, mixing takes place by randomisation via diffusion or convection 
(Hersey 1975). However, in binary DPI formulations, the size difference between the drug 
particles and the large lactose carrier particles is often two orders of magnitude. 
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Therefore, the principles of random mixing are not applicable for the system. In a ternary 
DPI formulation, the situation is further complicated by the presence of the third 
component that can be polydisperse in size. For describing these kind of mixtures, Hersey 
(1975) was the first to introduce the concept of ordered mixing. In these mixtures, the 
blending takes place as a result of particle-particle interactions, also known as adhesive 
forces. The fine particle component is distributed on the surface of the large particles due 
to adhesive forces, such as electrostatic, capillary or van der Waals forces, taking place 
between the components. Therefore these mixtures have been later more appropriately 
termed as adhesive mixtures (Dickhoff et al. 2002).  
 
For mixing to take place, movement of particles is required so that relocation of the 
particles within the mixture can take place. The particles can be moved around in a mixer 
for example by tumbling, shearing, fluidising or scooping (Harnby 2000). The energy input 
of the process can also be altered. Particles in free flowing powders can be moved around 
easily. Therefore, preparing uniform blends of free flowing powders is relatively simple. 
However, ensuring the stability of the final mixture is difficult, because the particles can 
easily segregate due to the lack of interparticulate forces. In cohesive powder mixing, the 
challenge is to break the network of the interparticulate contact forces within the original 
powder, so that the particles within the agglomerates can be relocated. However, due to 
the existence of the interparticulate forces, mixtures prepared with cohesive powders are 
often less prone to segregation. Having said that, if segregation takes place in an 
adhesive mixture, the mixing quality can be severely affected because the size of the 
segregated agglomerates can be large (Harnby 2000).  
 
The quality of the blending can be assessed by taking random samples and measuring 
the content of one of the components in these samples. The variation in the content in 
terms of how close the assessed amount is to the theoretical amount and the standard 
deviation in the content of a component between the samples describes the quality of the 
blending (Williams 1968).  
 
 
2.5.2 Preparation of the formulations  
2.5.2.1 Blending  
 
The formulations investigated during the current study were prepared using low shear 
convective mixing. A Turbula mixer was used for preparing the blends at a speed of 46 
rpm. Before formulating, the lactose blends were passed through a 850 µm aperture sieve 
to break any large agglomerates formed upon the storage of the pre-blends. The required 
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amounts of drug and lactose were weighed. One quarter of the lactose was transferred to 
the blending vessel described earlier (Section 2.1.3). The drug was added to the top of the 
lactose and one quarter of the lactose was added on top of the drug. This was blended for 
10 minutes. The remaining half of the coarse lactose was then added before blending the 
formulation for 45 minutes. After the blending, the formulations were passed through a 
250 µm sieve and stored at 20 ± 2°C and 44% RH for at least a week before the content 
uniformity of the blends was assayed.  
 
2.5.2.2 Content uniformity 
 
The quality of the blending was ensured by taking 10 aliquots of each of the formulations 
and assessing the drug content in the aliquots. Aliquots equal to the capsule fill weight 
(12.5 or 25 mg) were taken in volumetric flasks (50 or 100 ml) and dissolved in the mobile 
phase by placing the volumetric flasks in an ultrasonic bath for 60 minutes to dissolve the 
lactose. After the sonication, the solutions were allowed to cool to the room temperature 
before the volumetric flasks were topped up to the mark with the mobile phase. Aliquots 
were then taken in HPLC vials and the drug content assayed using HPLC. The mean 
dose of drug in each of the aliquots was calculated based on the linear response from the 
standard samples of known concentrations that were analysed in the same measurement 
sequence as the samples. The quality of the blending was deemed to be satisfactory if the 
variation coefficient of the drug dose was less than 6% in the 10 samples assayed. The 
nominal dose was ensured to be between 90 and 110% of the loaded dose.   
 
2.5.2.3  Capsule filling 
 
After the satisfactory dose content uniformity and nominal dose had been assured, the 
formulations were loaded in capsules. Size 3 Quali-V hydroxypropylmethylcellulose 
(HPMC) capsules (Qualicaps, Spain) were filled by hand. A fill weight of 12.5 or 25 mg 
was applied for different studies. The amount used in each particular study will be 
specified in the results chapters.  
 
2.6 IN VITRO TESTING OF THE FORMULATIONS 
2.6.1  Theory 
 
In the industry, the in vitro formulation testing is used for assessing the formulation 
performance for formulation development and quality control purposes. In the current 
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study, the in vitro assessment of performance of the model formulations prepared was 
performed to relate the impact of the addition of lactose fines to the formulation 
performance. In addition, the properties of the lactose were to be related to the final 
formulation performance of the model formulations. 
 
2.6.1.1  Devices  
 
It has been reported in the literature that the resistance of the device is an important factor 
in determining the extent of deagglomeration for DPI formulations (Olsson et al. 1994).  
Therefore, three different devices were used during the studies. The Rotahaler 
(GlaxoSmithKline), Cyclohaler (Teva) and Handihaler (Boehringer Ingelheim) are all 
capsule based, single dose, breath actuated devices with low, medium and high 
resistance to air flow, respectively (Srichana et al. 1998a).  
 
2.6.1.2  Next generation impactor testing  
 
2.6.1.2.1  General introduction  
 
The aerodynamic particle size distribution of the drug aerosolised from an inhaled product 
is crucial in determining the lung deposition characteristics of the drug. The deposition of 
the drug could be investigated in vivo using a combination of radiolabelled drug and 
medical imaging (Carvalho et al. 2011). However, this method is impractical for testing 
every released formulation. Instead, as specified by the pharmacopoeias (European 
Medicines Agency 2007), aerodynamic particle size classification systems are used for 
testing the extent of drug delivery from DPI products.   
 
In the early days of inhalation testing, methods that were widely used for characterising 
the size distributions and the lung deposition of environmental pollutant particles were 
adopted for inhalation product development and release testing (Broadhead et al. 1995). 
However, these impactors are often limited in their capability of being used at different air 
flow rates, are most suitable for sampling of dilute aerosols and are labour intensive 
(Marple et al. 1995). To try and address these issues, the first impactor that was 
specifically designed for inhalation testing was the Marple-Miller impactor (Marple et al. 
1995). However, although an improvement in usability in pharmaceutical applications and 
a wider selection of flow rates compared to the predecessors was achieved with the 
Marple-Miller impactor, there still was room for improvement. Consequentially, a 
consortium of pharmaceutical companies involved in inhalation product manufacturing 
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listed the “must have” and “would like to have” features of a pharmaceutical impactor. The 
ultimate aim of the consortium was to develop a universal impactor capable of operating 
over a range of flow rates and less labour intensive to operate, with the possibility of 
automating the testing procedure (Marple et al. 2003a).  As a result, the Next Generation 
Impactor (NGI) was developed.   
 
 
2.6.1.2.2  The general layout and the principle of operation 
 
A photograph of the NGI equipped for DPI testing is shown in Figure 2.13. The NGI set-up 
for DPI testing consists of an induction port that mimics the oropharyngeal region of the 
respiratory tract, the pre-separator that mimics the upper airways and the impactor body 
that contains the collection cups for the fine particles. The principle of operation for the 
system aims to mimic the inhalation manoeuvre and consequential regional particle 
deposition within the lungs of the patient. This is achieved by connecting the impactor to a 
vacuum pump at the distal end of the impactor body, as highlighted in Figure 2.13. The 
primed device with the dose of drug loaded is connected to the induction port using a 
mouthpiece. Air is then drawn through the system. As a consequence, the dose of the 
drug is fluidised, deagglomerated and entrained in the airflow. The entrained particles are 
separated in the impactor according to their aerodynamic properties, mainly their inertia. 
The design principles of the NGI by which the separation of the particles is achieved will 
be introduced in detail in the following.  
 
 
FIGURE 2.13 THE NEXT GENERATION IMPACTOR LAYOUT FOR DPI TESTING WITH THE USP INDUCTION 
PORT AND A PRE-SEPARATOR.  THE IMAGE IS COURTESY OF AND REPRODUCED WITH THE PERMISSION OF 
COPLEY SCIENTIFIC  
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2.6.1.2.3  The induction port 
 
The United States Pharmacopoeia (USP) induction port is a very crude model of the 
oropharyngeal region. It is generally believed that particle deposition in the USP throat is 
governed by the inertial moment of the particles (Longest et al. 2008). Particles that are 
large have a high inertia and therefore are impacted in the 90° bend, mimicking the back 
of a human throat. Finer particles, in contrast, have lower inertia. These particles are 
therefore able to negotiate the sudden change in the direction of the air flow. However, the 
most recent developments in the in vitro testing of inhalation products include the 
introduction of an anatomically realistic induction port. The induction port is based on 
medical imaging of human mouth and throat region (Ilie et al. 2008). 
 
 
2.6.1.2.4  The pre-separator 
 
The pre-separator aims to mimic the upper airways of the respiratory tract. The pre-
separator is only used as an add-on part of the impactor for testing DPI formulations with 
the purpose of collecting the large carrier lactose particles and any drug adhering to the 
surfaces of these particles. The particle deposition in the pre-separator is believed to be 
governed by gravitational forces rather than impaction (Marple et al. 2003b). This is 
because the carrier lactose particles are generally large enough to be affected by 
gravitational forces. 
 
 
2.6.1.2.5 The impactor body 
 
The impactor body where the collection cups are housed acts as an air classifier. The air 
classifier separates the particles by impaction according to their aerodynamic diameters. 
Large particles have large inertia and are therefore unable to react to sudden changes in 
the direction of the airflow. Consequentially these particles get deposited on the impaction 
surface. In contrast, small particles with lower inertia remain suspended in the airflow 
(Marple et al. 2003a). This basic principle of an impactor stage is illustrated in Figure 2.14. 
By placing a series of impactor stages and changing the aerodynamic design parameters 
of the different stages, particles with different aerodynamic diameters can be separated. 
The design principles according to which this is achieved with the Next Generation 
Impactor will be discussed in the following. 
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FIGURE 2.14 THE PRINCIPLE OF PARTICLE IMPACTION WITH LARGE PARTICLES UNABLE TO NEGOTIATE THE 
SUDDEN CHANGE IN THE DIRECTION OF AIRFLOW WHILST SMALL PARTICLES ARE CARRIED IN THE AIRFLOW 
 
The first design principle in achieving reliable particle classification by impaction is to 
ensure the air flow throughout the impactor is laminar. This is because particle deposition 
by impaction in turbulent air flow, characterised by constant, random changes in the 
direction of the airflow, may occur earlier than would be predicted on the basis of the 
aerodynamic properties of a particle. Reynold’s number (Re) is a parameter describing the 
extent of turbulence within the air flow. In a straight tube, laminar flow is characterised by 
a Reynolds number between 500 and 3000. The Reynolds number is defined by Equation 
2.4, where ρ is the density, u is the velocity, µ is the viscosity of the fluid and d’’ the 
diameter of the tube through which the fluid is flowing (Marple et al. 2003a) 
 
ࡾࢋ ൌ ࢛࣋ࢊ
ᇲᇲ
ࣆ      EQUATION 2.4 
 
A schematic of the design and the principle of operation for an impactor stage is shown in 
Figure 2.15. The particles are carried in the air flow that has a flow rate of Q through n 
nozzles of diameter W. The distance between the nozzle orifice and the impaction plate is 
S. The average velocity of the air though each of the nozzles (V0) is defined by Equation 
2.5 (Marple et al. 2003a). 
 
ࢂ૙ ൌ 	 ૝ࡽ࣊࢔ࢃ૛      EQUATION 2.5 
 
By replacing the air velocity u and the diameter of the pipe d in Equation 2.4 by the air 
velocity through the nozzles V0 as determined by Equation 2.5 and the diameter of a 
nozzle W, respectively, the Reynolds number for the air flow through the nozzles can be 
written as per Equation 2.6 (Marple et al. 2003a) 
 
ࡾࢋ ൌ ૝࣋ࡽ࢔࣊ࣆࢃ      EQUATION 2.6 
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Assuming no changes in the air flow velocity, the denominator in Equation 2.6 is constant. 
Therefore, it follows from Equation 2.6 that the air flow through the impactor can be kept 
laminar by increasing the number of nozzles n in the nozzle orifice upon decreasing the 
nozzle diameter W. This is the reason the NGI stages have an increasing number of 
smaller holes the lower the stage. This is illustrated in Table 2.2, where the number and 
diameter of the nozzles on the different stages of the NGI are summarised.  
 
 
 
FIGURE 2.15 A SCHEMATIC OF THE SETUP OF A NOZZLE OF THE NEXT GENERATION IMPACTOR WITH THE 
PARAMETERS THAT GOVERN THE PARTICLE IMPACTION 
 
The second design principle for the NGI ensures good particle collection efficiency. To 
achieve high particle collection efficiency, the impaction distance S for a stage should be 
between 1 and 10 times the nozzle diameter W. Therefore, in impactor design, in addition 
to the Reynolds number, which is affected by the number n and the size W of the nozzles, 
attention has to be paid to the W/S ratio (Marple et al. 2003a). The values of S for the 
different NGI stages are also listed in Table 2.2.  
 
TABLE 2.2 THE AERODYNAMIC DESIGN OF THE NEXT GENERATION IMPACTOR STAGES IN TERMS OF 
NUMBER OF NOZZLES (n), THE DIAMETER OF EACH OF THE HOLES (W) AND THE DISTANCE BETWEEN THE 
NOZZLE ORIFICE AND THE IMPACTION SURFACE (S). ADAPTED FROM MARPLE et al. (2003a) 
Stage N W (mm) S (mm) 
1 1 14.300 15.000 
2 6 4.880 9.764 
3 24 2.185 6.555 
4 52 1.207 3.621 
5 152 0.608 1.824 
6 396 0.323 1.001 
7 630 0.206 1.000 
MOC 4032 0.070 0.500 
 
 
The theoretical mean particle size (d50) of the material collected on the different impactor 
stages is defined by Equation 2.7, where ρp is the particle density and √St50 is the square 
root of Stokes’ number calculated for a stage based on the mean cut off diameter of the 
stage. For particles depositing by inertial impaction, the square root of Stokes’ number 
98 
 
√Stk50 should have a value of close to 0.495 when the Reynolds number is between 500 
and 3000 and the W/S ratio between 1 and 10 (Marple et al. 2003b). It follows from 
Equation 2.7 that the d50 decreases when the nozzle diameter W is decreased.  
 
ࢊ૞૙ ൌ ටૢ࣊ࣆ࢔ࢃ
૜
૝࣋࢖ࡽ ඥࡿ࢚࢑૞૙    EQUATION 2.7 
 
The d50 can be calculated using Equation 2.7. However, for routinely defining the d50 of the 
different stages at different flow rates, a calibration of the system was performed upon the 
release of the system design (Marple et al. 2003b). As a result of the calibration, Equation 
2.8, where A and B are constants that are listed for the different stages in Table 2.3, was 
introduced for calculating the cut off values for the different stages at different flow rates. 
 
ࢊ૞૙ ൌ ࡭ቀ૟૙ࡽ ቁ
࡮
     EQUATION 2.8 
 
In addition to the constants A and B, the calculated d50 values based on Equation 2.8 for 
the different stages at 30, 60 and 90 litres per minute air flow rates are listed in Table 2.3. 
 
TABLE 2.3 THE CONSTANTS A AND B USED FOR CALCULATING THE CUT-OFF DIAMETERS OF THE NEXT 
GENERATION IMPACTOR STAGES AT DIFFERENT FLOW RATES AND THE CALCULATED VALUES OF d50 AT 
FLOW RATES OF 30, 60 AND 90 LITRES PER MINUTE  
Stage A B d50 (µm) 30 l/min 60 l/min 90 l/min 
1 8.06  0.54 11.72 8.06  6.48 
2 4.46  0.52 6.40 4.46  3.61 
3 2.82  0.50 3.99 2.82  2.30 
4  1.66  0.47 2.30 1.66  1.37 
5 0.94  0.53 1.36 0.94  0.76 
6 0.55  0.60 0.83 0.55  0.43 
7 0.34  0.67 0.54 0.34  0.26 
 
 
2.6.1.2.5  Mean mass aerodynamic diameter, geometric standard deviation and 
fine particle mass 
 
The mean mass aerodynamic diameter (MMAD) determines the average particle size of 
the material collected from the impactor stages and the geometric standard deviation 
(GSD) the width of the distribution. Both these parameters are calculated from the 
cumulative impactor stage-by-stage deposition data (European Medicines Agency 2007). 
The cumulative mass of the drug recovered from the stages, starting from the Stage 8, is 
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plotted against the logarithm of the d50 for the stage. This plot is shown in Figure 2.16. The 
MMAD is the size of the 50th percentile of the cumulative distribution. The GSD is defined 
on the basis of the 16th (y) and the 84th (x) percentiles of the distribution as per Equation 
2.9.  
ࡳࡿࡰ ൌ ට࢞࢟ EQUATION 2.9
The fine particle mass (FPM) describes the amount of respirable particles aerosolised 
from a formulation. This is often defined as the mass of particles finer than 5 µm. The 
mass of particles <5 µm can be obtained from the cumulative drug mass versus stage cut-
off size plot shown in Figure 2.16 either by extrapolation or regression. However, 
according to the pharmacopoeial specifications (European Medicines Agency 2007), only 
the data points falling between 16th and 84th percentiles should be used for both obtaining 
the fine particle mass and defining the MMAD. This is because the points outside these 
limits may skew the distribution in case of abnormal particle deposition pattern on the 
highest or the lowest stages.  
FIGURE 2.16 THE DEFINITION OF THE MEAN MASS AERODYNAMIC DIAMETER (MMAD) AND  THE 16TH AND
THE 84TH PERCENTILES (Y AND X, RESPECTIVELY) OF THE CUMULATIVE STAGE-BY-STAGE DRUG
DEPOSITION PLOT AS A FUNCTION OF THE STAGE CUT-OFF SIZE USED FOR CALCULATING THE GEOMETRIC
STANDARD DEVIATION (GSD) 
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2.6.2 Methodology 
2.6.2.1  Determination of air flow rates on different devices 
The flow rates required to produce a 4 kPa pressure drop across the mouthpiece without 
the capsules placed in the devices were measured using the TPK critical flow controller 
(Copley Scientific, Nottingham, UK). The device was connected to the dose content 
uniformity sampling apparatus (DUSA, Copley Scientific, Nottingham, UK) via a 
mouthpiece. The flow rate was adjusted such that the P1 on the TPK was 4 kPa. The 
equivalent flow rate was then read from a DFM2000 flow meter (Copley Scientific, 
Nottingham, UK). The measured flow rates producing the 4 kPa pressure drop were 160 
l/min for Rotahaler, 100 l/min for Cyclohaler and 54 l/min for Handihaler. The NGI is 
calibrated between flow rates of 30 and 100 l/min. Therefore, to obtain reliable in vitro 
performance data for the model formulations, a flow rate of 90l/min was used for 
Rotahaler and Cyclohaler.  
2.6.2.2  Next Generation Impactor testing 
To prevent re-bounce of particles to the air flow after impaction, the NGI collection cups 
and the base plate of the pre-separator were coated with silicone oil before each run. 
This was done by covering the surfaces with 1 v/v-% silicone oil in hexane solution. The 
hexane was then allowed to evaporate leaving behind a thin coat of oil.  
The impactor was then assembled and 15 ml of the mobile phase was added in the insert 
cup of the pre-separator. The flow rate was then adjusted to the correct value, determined 
by the device used, by the Copley TPK critical flow controller. Once the flow rate had been 
adjusted, the ratio between the P2 and P3 measured by the TPK was inspected. To 
ensure sonic flow through the impactor, and consequentially no sudden changes in the air 
flow pattern within the impactor altering the particle deposition, was maintained, the value 
of P2 has to be at least twice as high as for P3.  
Once the flow rate had been adjusted, the flow meter was replaced by a mouthpiece. The 
device was primed and attached to the mouthpiece. The valve of TPK was then opened 
for either 2.7 s (90l/min flow rate) or for 4.4 s (54 l/min flow rate) so that 4 litres of air was 
drawn through the impactor during the test. The actuation was repeated between 2 and 10 
times. The number of actuations in each of the studies will be specified in the results 
chapters. 
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After all the doses had been actuated, the capsules, device, mouthpiece and throat, pre-
separator and the stages were washed in the mobile phase. Aliquots of the wash solutions 
were taken for assessing the drug content in the different parts of the impactor by HPLC. 
For each of the formulations, the test was performed in triplicate. 
Fine particle mass (<5 µm), MMAD and GSD were determined as described in section 
2.6.1.2.5. The fine particle fraction of emitted dose (FPFED) is defined as the ratio between 
the fine particle mass and the dose of the drug recovered after the capsule and device. 
Fine particle fraction of recovered dose (FPFRD) is the ratio between the fine particle mass 
and the total dose of the drug recovered from the analysis. 
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CHAPTER 3  THE EFFECT OF LOADED DOSE ON IN VITRO 
PERFORMANCE AND THE FLUIDISATION PROPERTIES OF DRY 
POWDER INHALER FORMULATIONS  
3.1 INTRODUCTION 
Previous studies have highlighted the dependency of dry powder inhaler performance on 
the loaded drug dose (El-Sabawi et al. 2006; Young et al. 2005). It was found that initially, 
as the salbutamol sulphate loading increased from 0.02 to 0.27 wt-%, the in vitro 
performance decreased to a minimum value. However, at higher drug loadings (>0.27 wt-
%), a linear increase in in vitro deposition performance was obtained (Young et al. 2005). 
Furthermore, the drug loading with the minimum in DPI performance was observed to be 
dependent on the degree of surface roughness of the large lactose carrier, with the 
smoother lactose carrier reaching a minimum in in vitro performance at a lower drug 
concentration of 0.13 wt-%. The findings of these studies were explained by the active site 
theory (Staniforth 2000) based on Hershey’s (1975) concept of ordered mixtures. The 
smoother lactose would have fewer high energy binding sites on the surface, and 
consequentially require a lower drug loading to occupy all the active sites before the drug 
was bound to low energy binding sites, where it could be more easily detached upon 
fluidisation (El-Sabawi et al. 2006).  
Based on the results of Young et al. (2005) and El-Sabawi et al. (2006), Muresan and 
Hebbink (2009) developed a theoretical model for in vitro performance governed by the 
active site theory. In their model they were able to predict the number of active sites on a 
lactose carrier surface and the probability of drug detachment from the normal surface. It 
was found that for the surface etched lactose used by El-Sabawi et al. (2006) the number 
of active sites was significantly lower and the probability of drug detachment higher than 
for the ‘as-received’ lactose used by Young and co-workers (2005). 
Recently, Le et al. (2012c) investigated the impact of loaded dose on DPI performance 
with formoterol fumarate. In their study, the formoterol fumarate concentrations were 
varied between 0.09 and 0.17 wt-%. A linear increase in the fine particle fraction was 
reported upon increasing the drug concentration. The increased performance upon 
increasing formoterol fumarate content was speculated to be caused either by the 
saturation of active sites or agglomerate formation between the drug particles and intrinsic 
lactose fines of the carrier (Le et al. 2012c).  
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This chapter aims to investigate the validity of the active site hypothesis in improving dry 
powder inhaler performance. To do that, model DPI formulations of fluticasone propionate 
with two different coarse lactose carriers were prepared and the in vitro performance of 
the formulations assessed. 
It is also known that there are two different fluidisation mechanisms for dry powders, 
namely erosion and fracture (Shur et al. 2008a; Tuley et al. 2008). Free flowing, Geldart 
group A powders (Geldart 1973) fluidise following the erosion mechanism whereas 
cohesive, Geldart group C powders fluidise via a fracture mechanism. It was anticipated 
that the trends in the formulation performance observed by Young and co-workers (Young 
et al. 2005) and El-Sabawi et al. (El-Sabawi et al. 2006) may also be explained by 
possible change in the fluidisation mechanism from erosion to fracture, which may lead to 
a consequential change in drug de-agglomeration efficiency. Therefore, in the current 
study, the fluidisation mechanisms of selected model formulations were assessed using 
high speed imaging. 
Increased cohesion of DPI carriers has also been reported to correspond to improved DPI 
performance (Shur et al. 2008a). To investigate the role of this hypothesis in governing 
the DPI performance, a method to characterise the fluidisation and defluidisation 
properties of the formulations was developed according to the theory described in Chapter 
2, section 3.4, and the formulations were characterised. 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
The coarse lactose carriers used in the study were LH100 and SV010, both supplied by 
DFE Pharma, Netherlands. The drug was micronised fluticasone propionate (FP), 
manufactured by GlaxoSmithKline (Jurong, Singapore). The solvents were obtained from 
Fisher (Loughborough, UK) and Sigma Aldrich (Gillingham, UK) and were of HPLC 
quality. Water was reverse osmosis purified (Millipore, France). 
3.2.2 Particle sizing 
A Sympatec Helos laser diffraction system (Sympatec, Germany) was used for particle 
sizing experiments in conjunction with Windox 5 software. The coarse lactose materials 
and the DPI formulations were dispersed dry at 2 bar disperser pressure using the Rodos 
T4 dry dispersion unit with a Vibri powder feeder. The gap width was adjusted to 2 mm 
104 
and the feed rate such that an optical concentration of between 0.5 and 5% was achieved. 
Five replicate measurements were recorded. The Geldart group C powder, FP, was 
dispersed wet using the Cuvette dispersion system and 0.1% lecithin in cyclohexane as 
the dispersant. A small aliquot of FP was suspended in the dispersant. The suspension 
was ultrasonicated for 5 minutes in one minute intervals before five consecutive 
measurements were recorded at an optical concentration of between 5 and 10%. The 
results reported are based on the average of five repeated measurements. 
3.2.3 Scanning electron microscopy 
Scanning electron micrographs of the powder samples were obtained with a Jeol JSM-
6480LV SEM (Jeol, Tokyo, Japan) system using an acceleration voltage of 10 kV and a 
spot size of 15. Samples were mounted on sticky carbon tabs and excess powder was 
removed by a gentle tap. This approach was used to avoid any fines being dusted off from 
the surfaces of the large carrier particles. Prior to SEM analysis, samples were coated 
with gold for 5.5 minutes by an Edwards SB150 sputter coater (BOC Edwards, UK). 
3.2.4 Preparation of carrier based DPI formulations 
Carrier based DPI formulations were prepared in quantities of 40 g in a 500 cm3 stainless 
steel vessel. The desired amount of drug and lactose were weighed and the drug was 
sandwiched between half of the lactose and blended for 10 minutes in a Turbula blender 
(Glen Creston Ltd, Middlesex, UK) at 46 rpm. The remaining lactose was then added and 
the formulation blended for a further 45 minutes. Once the blending was complete, the 
formulation was passed through a 250 µm aperture sieve to break any large agglomerates 
remaining within the blend.  
The quality of the blending was assured by examining the drug content uniformity of the 
formulations. This was done by sampling 10 random aliquots of 25 mg and quantifying the 
drug content in the aliquots according to the HPLC assay described in the general 
materials and methods of the thesis (Chapter 2.4.2).  
3.2.5 In vitro testing of the formulations 
Size 3 hydroxypropylmethylcelluloce (HPMC) capsules (Qualicaps, Spain) were manually 
filled with 25 mg of the formulations. A Cyclohaler DPI device was used for aerosolising 
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the formulations into a Next Generation Impactor (Copley Scientific, Nottingham, UK) 
equipped with a pre-separator. Air was drawn through the impactor at 90 l/min for 2.7 
seconds as controlled by a TPK critical flow controller (also from Copley Scientific). A total 
of 10 capsules were aerosolised for the low concentration formulations (≤ 0.4 wt%) and 5 
capsules for the high concentration (> 0.4 wt%) formulations. Due to the low amount of 
drug in the low drug loading formulations, stages 6, 7, and 8 were grouped and washed 
together in 10 ml of the mobile phase. This was done to ensure the drug content of the 
low dose formulations could be reliably determined with the HPLC assay described in 
Chapter 2.4.2. The limit of detection for FP for the HPLC assay was determined to be 0.01 
µg/ml and the response was linear between concentrations of 0.01 and 50 µg/ml.  
3.2.6 High speed imaging of the fluidisation event 
High speed imaging of the fluidisation events of low, medium and high drug concentration 
formulations were recorded by using an Oxford Lasers Firefly high speed imaging system 
(Oxford Lasers, Oxford, UK). The formulations were fluidised using the Sympatec Rodos 
T4 dry dispersion system at 0.1 bar disperser pressure and the Aspiros sample feeder. 
The test tube was filled with approximately 25 mg of the powder under investigation and 
the powder was dispersed from the test tubes. High speed imaging footage of the powder 
fluidisation event was recorded at 8000 frames per second.  
3.2.7 Powder fluidisation and defluidisation properties 
The powder fluidisation and defluidisation properties of the formulations were measured 
using the FT4 powder rheometer. A powder bed of between 12 and 13 g in a 25 mm bore 
diameter, 30 ml measurement vessel with a standard aeration base was first conditioned 
by fully fluidising the powder. The air supply was then switched off and the powder bed 
was allowed to settle under gravity. This was done to erase the consolidation history of 
the powder caused by the storage and loading of the powder into the vessel. This allowed 
a reproducible state of powder packing to be achieved prior to subsequent 
measurements. The air velocity of the fluidising gas (dry pressurised air supply) was 
linearly increased in small increments. The pressure differential required to maintain the 
requested air velocity was measured by the Aeration Control Unit (ACU) of the system. 
Once an air velocity of 15 mm/s was achieved, the air velocity was decreased gradually 
and the pressure differential at each air velocity recorded for the defluidisation curve.  
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3.2.8 Flow rate index 
The flow rate index (FRI) is a flow descriptor that can be measured on the FT4 powder 
rheometer. This parameter was also measured, but a different measurement program 
based on measuring the torque and force required to keep the impeller blade moving 
through the powder bed at a constant tip speed was applied. A detailed description of the 
measurement for determining the FRI can be found in the general materials and methods 
section of the thesis (Chapter 2.3.3.2). Briefly, a 25 mm inner diameter, 20 ml split cell 
was filled with powder before a conditioning cycle was run to remove the packing history 
of the powder. The cell was then split to gain a constant volume of powder between 
repeated experiments.  The FRI was obtained by measuring the torque and force required 
to move the blade through the powder bed at a tip speed of 100 and 10 mm/s. Flow rate 
index is the ratio between the flow energies at the two different tip speeds as defined by 
Equation 3.1: 
ࡲࡾࡵ ൌ ࡲ࢒࢕࢝	ࢋ࢔ࢋ࢘ࢍ࢟	ࢇ࢚	૚૙	࢓࢓/࢙ࡲ࢒࢕࢝	ࢋ࢔ࢋ࢘ࢍ࢟	ࢇ࢚	૚૙૙	࢓࢓/࢙ EQUATION 3.1
3.3 RESULTS AND DISCUSSION 
3.3.1 Characteristics of the raw materials 
The particle size measurements for the Geldart Group A classified coarse carriers, in 
terms of the 10th, 50th and 90th percentiles of the probability density function distribution 
and proportion of particles finer than 4.5 µm, are summarised in Table 3.1. In addition, 
theoretical surface area measurements of the carriers based on the particle sizing data 
are shown in Table 3.1. Comparing the d10, d50 and d90 of LH100 and SV010, it was 
seen that SV010 has slightly larger particle size than LH100. This can also be seen in 
Figure 3.1 where the particle size distributions of the raw materials are presented. 
However, Table 3.1 indicates that LH100 and SV010 are very similar in terms of their 
proportion of fine particles and the surface area of the powders. The similarity of the fines 
content in the carriers is a significant feature because it is known from previous studies 
that the proportion of fines is more important in determining the DPI performance than the 
particle size distribution as a whole (Guenette et al. 2009). 
The particle size of the Geldart Group C fluticasone propionate is also shown in Figure 
3.1. The particle size of the material was within the respirable range with values of d10, 
d50 and d90 of 0.89, 2.13 and 4.07 µm, respectively.  
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TABLE 3.1 THE 10TH, 50TH AND 90TH PERCENTILES OF THE DENSITY PARTICLE SIZE DISTRIBUTIONS (d10,
d50 AND d90 CORRESPONDINGLY) AND THE PROPORTION OF PARTICLES FINER THAN 4.5 µm FOR THE
LACTOSE CARRIERS USED IN THE STUDY. THE DATA FOR d10, d50 AND d90 REPRESENTS MEAN ±
STANDARD DEVIATION, N=5. THE DATA FOR <4.5 µm REPRESENTS MEAN, N=5. 
Carrier d10 ± S.D.  (µm) 
d50 ± S.D. 
(µm) 
d90 ± S.D. 
(µm) 
<4.5 µm 
(%) 
LH100 37.74 ± 1.06 99.79 ± 0.71 157.01 ±  1.81 1.4 
SV010 51.33 ± 2.04 111.24 ± 1.39 176.83 ± 5.95 1.5 
FIGURE 3.1 PARTICLE SIZE DISTRIBUTIONS OF THE COARSE CARRIERS LH100 AND SV010 AND
FLUTICASONE PROPIONATE (FP) USED IN THE STUDY 
Representative scanning electron micrographs of the raw materials are presented in 
Figure 3.2. Comparing the morphology of LH100 (A) and SV010 (B), it appears that 
LH100 exhibits the smoother surfaces of the two carriers. Despite the same proportion of 
intrinsic fines (% of particles <4.5 µm), LH100 appears to have less of the fines attached 
to the surface than SV010. The explanation for this could be that the fines are tightly 
adhered to the surface of SV010 and therefore cannot be removed upon dry dispersion. In 
addition, the volume of the fines is very low compared to the volume of the bulk powder. 
Thus, subtle differences in the amount of fines in the two carriers may not be accurately 
reflected by volume based particle size distributions. It is known that LH100 and SV010 
are produced at different DFE Pharma plants (DFEPharma 2011). The differences in the 
morphology of the LH100 and SV010 materials are most likely caused by different 
manufacturing processes used at the two sites. A scanning electron micrograph of FP is 
shown in Figure 3.2C. The micrograph indicates that FP is very fine and agglomerated.  
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FIGURE 3.2 900X MAGNIFICATION SCANNING ELECTRON MICROGRAPHS OF A) LH100 B) SV010 AND C)
FLUTICASONE PROPIONATE 
A
B
C 
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3.3.2 Physical properties of the carrier based DPI formulations 
The particle size measurements together with the proportion of particles finer than 4.5 µm 
and the surface area of the series of carrier based DPI formulations with an increasing 
amount of FP, dispersed dry, are presented in Table 3.2. It can be seen that the d90 of 
the formulations remain somewhat unaltered across the entire concentration range for 
both carriers, as does d50. A decrease in the value of d10 can be observed for both 
formulation series. For the LH100 series the d10 dramatically decreases for the 2 wt-% FP 
formulation, while for the SV010 series this decrease occurs at 1 wt-% FP concentration.  
However, the most remarkable observation of these data, shown in Table 3.2, is the 
amount of fine particles detaching from the surface of the carriers upon dry dispersion as 
the drug concentration is increased. This is graphically presented in Figure 3.3, where the 
percentage of particles < 4.5 µm measured for the formulations is plotted as a function of 
the loaded drug dose. It can be seen that a larger proportion of fines are detached from 
the SV010 formulations across the entire concentration range with respect to the LH100 
formulations. As expected, this trend is reflected in the surface area of the powders as 
calculated from the particle sizing data. This is an interesting finding because, by using 
pressure titration, the disperser pressure was set such that the primary particle size 
should have been achieved during the measurements 
De Boer et al. (2005) and Dickhoff et al. (2005) used an air classifier technology for 
studying the drug detachment from DPI formulations prepared at different drug 
concentrations with lactose carriers having different surface characteristics. The major 
findings from their studies suggested that the surface discontinuities on the lactose carrier 
surface, in the form of rugosities or adhering intrinsic lactose fines, provided shelter from 
the press-on forces induced during formulation blending. This resulted in improved drug 
detachment from lactose carriers with a rougher surface. They also saw an improved 
detachment at higher drug loadings and attributed this to the press-on forces being more 
efficient at low drug concentrations (de Boer et al. 2005; Dickhoff et al. 2005). The findings 
of the current study with more fines detaching from the surface of SV010, which exhibited 
the rougher surface of the two coarse carriers used, could possibly also be explained by 
the lower magnitude of press-on forces acting on SV010 during formulation blending. 
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TABLE 3.2 THE 10TH, 50TH AND 90TH PERCENTILES OF THE DENSITY PARTICLE SIZE DISTRIBUTIONS (d10,
d50 AND d90 CORRESPONDINGLY) AND THE PROPORTION OF PARTICLES FINER THAN 4.5 µm FOR THE
FLUTICASONE PROPIONATE (FP) FORMULATIONS INVESTIGATED IN THE STUDY.  THE DATA FOR d10, d50
AND d90 REPRESENTS MEAN ± STANDARD DEVIATION, N=5. THE DATA FOR <4.5 µm REPRESENTS MEAN,
N=5. 
Formulation 
(+ wt-% FP) 
d10 ± S.D. 
 (µm) 
d50 ± S.D. 
(µm) 
d90 ± S.D. 
(µm) 
<4.5 µm 
(%) 
LH100 37.74 ± 1.06 99.79 ± 0.71 157.01 ± 1.81 1.40 
 +0.02 45.43 ± 2.15 103.13 ± 0.62 158.26 ± 1.28 1.29 
 +0.05 43.41 ± 0.22 100.96 ± 0.80 152.89 ± 4.43 1.23 
 +0.08 44.99 ± 1.23 101.71 ± 1.23 151.00 ± 4.90 1.34 
 +0.1 45.49 ± 0.45 101.36 ± 0.45 148.49 ± 0.65 1.27 
 +0.15 44.25 ± 0.77 101.83 ± 0.93 154.65 ± 4.35 1.56 
 +0.2 48.99 ± 2.98 102.79 ± 1.50 148.22 ± 2.16 1.38 
 +0.4 45.79 ± 1.06 102.95 ± 0.99 156.17 ± 4.21 1.54 
 +1 41.69 ± 0.85 102.43 ± 0.76 157.14 ± 0.57 2.28 
 +2 31.51 ± 4.55 101.03 ± 1.15 160.68 ± 1.75 4.47 
SV010 51.33 ± 2.04 111.24 ± 1.39 176.83 ± 5.95 1.50 
 +0.02 52.86 ± 0.27 110.34 ± 0.32 167.31 ± 0.39 1.68 
 +0.05 54.50 ± 0.54 111.45 ± 1.31 173.97 ± 7.50 1.49 
 +0.08 57.05 ± 2.55 113.07 ± 0.26 178.60 ± 3.00 1.31 
 +0.1 56.15 ± 2.17 112.97 ± 1.02 178.97 ± 4.17 1.43 
 +0.2 51.76 ± 0.83 110.24 ± 1.59 172.00 ± 7.39 1.87 
 +0.3 51.53 ± 1.61 111.52 ± 0.40 180.03 ± 1.50 1.69 
 +0.4 50.89 ± 1.20 111.77 ± 0.80 181.01 ± 0.88 2.14 
 +1 44.80 ± 2.15 107.99 ± 1.29 169.07 ± 6.66 3.39 
 +2 30.80 ± 2.75 109.89 ± 0.54 183.72 ± 1.24 5.73 
FIGURE 3.3 THE PROPORTION OF PARTICLES FINER THAN 4.5 µm (%<4.5 µm) MEASURED WHEN THE
FORMULATIONS WERE DISPERSED DRY AT 2 BAR DISPERSER PRESSURE AS A FUNCTION OF FLUTICASONE
PROPIONATE CONTENT OF THE FORMULATIONS (LOADED DOSE) 
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The distribution of the drug particles on the surface of the coarse lactose particles can be 
observed by SEM. Representative scanning electron micrographs of the LH100 
formulations are shown in Figure 3.4. Very few fines are attached to the surface of LH100 
up to 0.2 wt-% concentration (Figure 3.4A to Figure 3.4F). At 0.4 wt-% concentration 
(Figure 3.4G) more fines are seen on the surface. As the drug concentration is increased 
further to 1 and 2 wt-% (Figure 3.4H and Figure 3.4I), not only more particles but also 
agglomerated fine particles are seen adhering to the surface of the coarse lactose.  
Scanning electron micrographs of the SV010 formulations are presented in Figure 3.5. In 
the SV010 formulations, the drug particles start forming agglomerates on the surface of 
the SV010 at lower concentrations (0.4 wt-%, Figure 3.5G), than on the surface of the 
LH100 (1 wt-%, Figure 3.4H). The drug coating on the surface of SV010 formulations at 1 
and 2 wt-% concentrations (Figure 3.5H and, Figure 3.5I) is also more uniform than the 
equivalent LH100 formulations (Figure 3.4H and Figure 3.4). The micrographs indicate 
that all the formulations exhibit characteristics of ordered mixtures (Hersey 1975) with 
fines adhering to the surfaces of the larger particles with hardly any free fines present in 
the blends.  
The presence of fine particle agglomerates at lower concentrations of the SV010 
formulations may be an explanation for the increased amount of fine particles <4.5 µm 
detaching from the surface, as shown in Figure 3.3. The agglomerates will experience 
greater drag forces during dispersion and are therefore more likely to be detached from 
the surface of the large lactose particles than individual particles (Begat et al. 2004a). 
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FIGURE 3.4 900X MAGNIFICATION SCANNING ELECTRON MICROGRAPHS OF A) 0.02% B) 0.05% C) 0.08% 
D) 0.1% E) 0.15% F) 0.2% G) 0.4% H) 1% AND I) 2% FLUTICASONE PROPIONATE FORMULATIONS WITH 
LH100 AS THE CARRIER  
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FIGURE 3.5 900X MAGNIFICATION SCANNING ELECTRON MICROGRAPHS OF A) 0.02% B) 0.05% C) 0.08% 
D) 0.1% E) 0.2% F) 0.3% G) 0.4% H) 1% AND I) 2% FLUTICASONE PROPIONATE FORMULATIONS WITH 
SV010 AS THE CARRIER  
A 
B 
C 
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3.3.3 In vitro performance of the formulations 
 
The results from dose content uniformity determination for the different formulations are 
summarised in Table 3.3. The actual dose in the formulations is close to the formulated 
dose. These data indicate that no significant amount of either the drug or the carrier was 
lost during the blending procedure due to adhesion to the blending vessel walls.  The 
variation in the dose in ten random samples was generally seen to be at an acceptable 
level with the variation coefficient being less than or close to 6%. The variation coefficient 
is plotted as a function of the loaded drug dose in Figure 3.6. The figure highlights that at 
lower drug concentrations a high variation and fluctuations in the dose content uniformity 
were apparent for both the carriers. However, at higher drug concentrations, a plateau 
level in the dose variation was reached. Remarkably, the plateau level was lower for the 
formulations prepared with SV010 than for LH100 formulations. This indicates the FP 
particles were more evenly distributed in the formulations prepared with SV010 than in the 
formulations prepared with LH100. As discussed above, based on the SEM images, the 
SV010 formulations were seen to form agglomerated systems at lower drug 
concentrations. These findings suggest that agglomerate formation promotes even drug 
distribution within the formulations. 
 
TABLE 3.3 THE ACTUAL DOSE OF FLUTICASONE PROPIONATE IN THE DIFFERENT FORMULATIONS IN TERMS 
OF WEIGHT PERCENTAGE (WT-%) AND DOSE IN MICROGRAMS. THE DATA REPRESENTS MEAN ± STANDARD 
DEVIATION, n=10). THE COEFFICIENT OF VARIATION (%CV) FOR THE DOSE WITHIN THE TEN SAMPLES FOR 
THE DIFFERENT FORMULATIONS IS ALSO TABULATED. 
Carrier Blend (wt-%) 
Dose ± S.D. 
(wt-%) 
Dose ± S.D. 
(µg) %CV
LH100 
0.02 0.02 ± 0.00 5.16 ± 0.20 4.39 
0.05 0.05 ± 0.00 12.06 ± 0.41 2.90 
0.08 0.07 ± 0.00 18.71 ± 0.56 2.37 
0.1 0.09 ± 0.00 23.63 ± 0.38 1.03 
0.15 0.14 ± 0.01 35.12 ± 2.35 6.28 
0.2 0.20 ± 0.01 50.15 ± 1.23 2.55 
0.4 0.39 ± 0.01 99.04 ± 1.74 1.61 
1 0.97 ± 0.02 242.80 ± 4.57 1.81 
2 2.02 ± 0.07 507.46 ± 19.93 3.67 
SV010 
0.02 0.02 ± 0.00 5.14 ± 0.19 3.49 
0.05 0.05 ± 0.00 12.29 ± 0.28 1.71 
0.08 0.08 ± 0.00 19.86 ± 0.78 3.84 
0.1 0.10 ± 0.00 23.98 ± 0.31 1.18 
0.2 0.20 ± 0.00 50.75 ± 0.82 1.35 
0.3 0.30 ± 0.02 74.09 ± 4.30 5.33 
0.4 0.40 ± 0.01 99.77 ± 2.19 3.16 
1 0.96 ± 0.01 241.52 ± 2.33 0.76 
2 1.96 ± 0.03 494.71± 10.07 1.33 
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FIGURE 3.6 THE VARIATION IN THE DRUG CONTENT (DOSE CV)  FOR THE FORMULATIONS PREPARED WITH 
LH100 AND SV010 AS THE CARRIERS AS A FUNCTION OF THE FLUTICASONE PROPIONATE 
CONCENTRATION (LOADED DOSE) 
 
The emitted dose of drug from the different formulations is shown in Table 3.4. These data 
are plotted against the loaded drug dose in Figure 3.7. In the case of both formulation 
series, a linear response was observed. The R2 values were 0.9926 and 0.9952 for the 
LH100 and SV010 formulation series, respectively. These data are in an agreement with 
the earlier studies investigating the impact of loaded drug dose on DPI performance, 
where it was found that the drug loading did not have an impact on the proportion of 
salbutamol sulphate being left behind in the device and capsule (El-Sabawi et al. 2006; 
Young et al. 2005). 
 
TABLE 3.4 THE MEAN EMITTED DOSE ± STANDARD DEVIATION FOR THE DIFFERENT FORMULATIONS DURING 
IN VITRO TESTING (n=3) 
Carrier Blend (wt-%) ED ± S.D. (µg) Carrier
Blend 
(wt-%) ED ± S.D. (µg)
LH100 
0.02 5.20 ± 0.22 
SV010 
0.02 4.84 ± 0.21 
0.05 11.76 ± 0.11 0.05 10.89 ± 0.37 
0.08 17.47 ± 0.21 0.08 17.75 ± 0.06 
0.10 20.60 ± 0.97 0.10 21.89 ± 0.15 
0.15 32.45 ± 0.15 0.20 47.09 ± 0.66 
0.20 42.97 ± 0.17 0.30 64.35 ± 0.44 
0.40 85.74 ± 0.94 0.40 84.30 ± 0.82 
1 201.11 ± 2.80 1 192.28 ± 2.17 
2 363.86 ± 1.13 2 359.66 ± 5.04 
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LH100 formulations 
SV010 formulations 
FIGURE 3.7 THE RELATIONSHIP BETWEEN THE EMITTED DOSE AND THE FLUTICASONE PROPIONATE 
CONCENTRATION (LOADED DOSE) OF THE FORMULATIONS FOR THE LH100 (TOP, Y=0.7437X, R2=0.9926) 
AND SV010 FORMULATION SERIES (BOTTOM, Y=0.7478X, R2=0.9952). THE DATA REPRESENTS MEAN ± 
STANDARD DEVIATION, N=3 FOR EMITTED DOSE AND N=10 FOR FLUTICASONE PROPIONATE 
CONCENTRATION. 
 
The total mass of fluticasone propionate recovered from the impactor during NGI testing 
and the mass of drug recovered from the impactor stages, impactor stage mass (ISM, 
mass of particles smaller than 6.48 µm at 90 l/min) (Marple et al. 2003b) together with the 
performance of the formulations in terms of fine particle fraction of the emitted and 
recovered dose are summarised in Table 3.5. A measurement of the drug 
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deagglomeration efficiency from the formulations as characterised by mean mass 
aerodynamic diameter is also presented in Table 3.5. 
In the previous studies investigating the impact of the loaded drug dose on DPI 
performance, it was reported that the fine particle mass exhibited an initial increase upon 
an increase in the drug dose after which a plateau level was achieved (El-Sabawi et al. 
2006; Young et al. 2005). However, after a critical concentration, an asymptotic increase 
in the fine particle mass was achieved at higher drug loadings. These studies claimed that 
the concentration where the change from the plateau level to the asymptotic increase took 
place was indicative of the filling of the active sites on the coarse carrier. In these studies, 
the drug concentrations where this transition took place were different for carriers 
exhibiting different surface roughness.  
 
The mass of the drug delivered to the impactor stages in the current study is plotted as a 
function of the drug concentration in Figure 3.8. For SV010, there was no evidence of a 
plateau level in the impactor stage mass. In the case of LH100, the formulations exhibited 
similar impactor stage mass at 0.08 and 0.1 wt-% concentrations and 0.15 and 0.20 wt-% 
concentrations.   
 
The results of Young et al. (2005) and El-Sabawi et al. (2006) also demonstrated an initial 
decrease in the fine particle fraction of the drug as the drug concentration was increased 
until a minima was reached. After the minimum, the performance increased. Different 
carriers exhibited a minimum fine particle fraction at different concentrations with a 
smoother carrier lactose exhibiting the minimum at a lower concentration of active 
pharmaceutical ingredient (API). This finding was attributed to a lower critical 
concentration requirement to occupy and saturate the active sites. The fine particle 
fractions of emitted and recovered doses in the current study are plotted as a function of 
the drug concentration for LH100 and SV010 formulations in Figure 3.9 and in Figure 
3.10, respectively. For both carriers, there was no initial dip in the fine particle fraction of 
the FP formulations. At lower drug concentrations, the fine particle fraction remained 
somewhat unaltered for both carriers. However, the experimental errors were relatively 
large. In terms of fine particle fraction performance of emitted and recovered dose, an 
increasing trend for LH100 formulations was seen from 0.4 wt-% drug loading onwards. 
For SV010, the increase started earlier with an increasing trend in the fine particle 
fractions from 0.2 wt-% drug concentration upwards.  
 
As discussed, the surface roughness of SV010 is greater than that of LH100. Thus, one 
would expect that the critical concentration for active site filling for SV010 would be higher 
than for LH100. However, the data from the current study indicate the opposite. Also, the 
performance of SV010, as measured by the impactor stage mass and fine particle 
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fractions of both the emitted and recovered dose, was superior to LH100. Furthermore, 
the proportion of fine particles detaching from SV010 during the particle sizing 
experiments as illustrated in Figure 3.3 was much higher than for LH100. Unlike the 
previous reported studies, this study questions the validity of the active site theory with the 
increasing addition of FP to the SV010 and LH100. 
 
TABLE 3.5 SUMMARY OF NGI TESTING OF THE FORMULATIONS IN TERMS OF TOTAL RECOVERED DOSE 
(RD) OF FLUTICASONE PROPIONATE,  MASS OF DRUG DELIVERED TO THE IMPACTOR STAGES (ISM),  THE 
FINE PARTICLE FRACTIONS OF EMITTED (FPFED) AND RECOVERED DOSE (FPFRD) AND THE MEAN MASS 
AERODYNAMIC DIAMETER (MMAD) OF THE DRUG FOR THE DIFFERENT FORMULATIONS. THE DATA 
REPRESENTS AVERAGE FROM 3 DETERMINATIONS ± STANDARD DEVIATION. 
 
Blend 
(wt-%) 
RD ± S.D. 
(µg) 
ISM ± S.D. 
(µg) 
FPFED ± S.D. 
(%) 
FPFRD ± S.D. 
(%) 
MMAD±S.D. 
(µm) 
LH
10
0 
0.02 5.45 ± 0.20 0.32 ± 0.06 6.21 ± 1.40 5.92 ± 1.30 4.26 ±  0.49 
0.05 12.50 ± 0.15 0.92 ± 0.06 7.82 ± 0.52 7.36 ± 0.49 3.73 ± 0.06 
0.08 18.72 ± 0.20 1.56 ± 0.22 8.92 ± 1.18 8.33 ± 1.11 3.47 ± 0.22 
0.10 22.95 ± 0.97 1.58 ± 0.00 7.66 ± 0.37 6.87 ± 0.30 3.71 ± 0.01 
0.15 36.54 ± 0.21 3.00 ± 0.12 9.24 ± 0.35 8.21 ± 0.33 3.17 ± 0.05 
0.20 48.02 ± 0.35 3.24 ± 0.14 7.54 ± 0.34 6.75 ± 0.33 2.94 ± 0.05 
0.40 96.76 ± 0.98 6.20 ± 0.12 7.23 ± 0.07 6.41 ± 0.09 3.04 ± 0.01 
1 238.13 ± 2.44 19.13 ± 0.75 9.52 ± 0.46 8.04 ± 0.36 2.70 ± 0.07 
2 467.38 ± 9.87 43.88 ± 1.41 12.06 ± 0.21 9.39 ± 0.11 2.94 ± 0.03 
SV
01
0 
0.02 5.83 ± 0.48 0.42 ± 0.05 8.59 ± 0.70 7.12 ± 0.25 3.21 ± 0.22 
0.05 12.39 ± 0.13 0.97 ± 0.04 8.88 ± 0.24 7.80 ± 0.24 3.13 ± 0.04 
0.08 19.72 ± 0.07 1.65 ± 0.09 9.28 ± 0.48 8.36 ± 0.41 3.03 ± 0.07 
0.10 24.25 ± 0.13 2.08 ± 0.08 9.50 ± 0.32 8.58 ± 0.27 2.92 ± 0.04 
0.20 52.75 ± 0.53 4.08 ± 0.49 8.67 ± 0.81 7.74 ± 0.76 2.74 ± 0.12 
0.30 72.13 ± 1.71 5.83 ± 0.12 9.06 ± 0.15 8.09 ± 0.28 2.80 ± 0.03 
0.40 98.13 ± 0.49 8.07 ± 0.51 9.57 ± 0.50 8.22 ± 0.51 2.62 ± 0.02 
1 233.42 ± 2.97 25.39 ± 0.32 13.21 ± 0.20 10.88 ± 0.15 2.44 ± 0.01 
2 454.7 ± 11.33 58.15 ± 1.60 16.17 ± 0.38 12.79 ± 0.40 2.45 ± 0.02 
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FIGURE 3.8 THE MASS OF DRUG DELIVERED TO THE IMPACTOR STAGES AS A FUNCTION OF THE 
FLUTICASONE PROPIONATE CONTENT (LOADED DOSE) OF THE FORMULATIONS. THE DATA REPRESENTS 
MEAN ± STANDARD DEVIATION, N=10 FOR THE FLUTICASONE PROPIONATE CONTENT AND N=3 FOR 
IMPACTOR STAGE MASS. 
 
FIGURE 3.9 THE FINE PARTICLE FRACTION OF EMITTED DOSE (FPFED) AS A FUNCTION OF THE 
FLUTICASONE PROPIONATE CONTENT (LOADED DOSE) FOR THE FORMULATIONS INVESTIGATED. THE DATA 
REPRESENTS MEAN ± STANDARD DEVIATION, N=10 FOR THE FLUTICASONE PROPIONATE CONTENT OF THE 
FORMULATIONS AND N=3 FOR FINE PARTICLE FRACTION OF EMITTED DOSE. 
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FIGURE 3.10 THE FINE PARTICLE FRACTION OF RECOVERED DOSE (FPFRD) AS A FUNCTION OF THE 
FLUTICASONE PROPIONATE CONTENT (LOADED DOSE) OF THE FORMULATIONS INVESTIGATED. THE DATA 
REPRESENTS MEAN ± STANDARD DEVIATION, N=10 FOR FLUTICASONE PROPIONATE CONTENT OF THE 
FORMULATIONS AND N=3 FOR FINE PARTICLE FRACTION OF RECOVERED DOSE. 
 
Calculations of the mean mass aerodynamic diameter (MMAD) of the drug delivered on 
the impactor stages of the respective formulations, raises further questions regarding the 
validity of the active sites theory. The values of MMAD are listed in Table 3.5 and are 
plotted as a function of the loaded drug dose in Figure 3.11. Across the entire 
concentration range investigated, the MMAD of the LH100 formulations was greater than 
for the SV010 formulations. These data indicate different drug deagglomeration behaviour 
for the formulations prepared with different carriers, with SV010 producing a higher 
degree of drug deagglomeration. 
 
A previous study has reported a similar decrease in the MMAD as drug concentration was 
increased (Dickhoff et al. 2005). The authors attributed the higher MMAD at low drug 
loading to the lower magnitude of press on forces at low drug concentration. 
Consequentially, due to the weak press on forces at low drug loadings, the mixing was 
less efficient and thus the drug was distributed on the surface of the large lactose carriers 
as large agglomerates. These agglomerates were not efficiently dispersed upon inhalation 
thus resulting in a high MMAD at low drug concentrations. The same study also 
suggested that the larger the carrier particles, the larger the press on forces, and the more 
efficient the drug re-distribution during blending (Dickhoff et al. 2005).  As in the current 
study, the SV010 was seen to have slightly larger overall particle size than LH100 (See 
125 
 
Figure 3.1 and Table 3.1), this could explain why the MMAD for SV010 formulations was 
smaller than for LH100 formulations over the entire concentration range.  
 
However, the suggestion by Dickhoff et al. (2005), according to which the formation of 
agglomerated systems at low drug loadings resulted to an increased MMAD, can be 
questioned. This is because the drag force experienced by a particle or an agglomerate 
upon fluidisation is proportional to the square of its diameter (Begat et al. 2004a). 
Furthermore, the kinetic energy of a particle or an agglomerate is proportional to its 
diameter cubed (Begat et al. 2004a). Therefore, firstly, the detachment of a particle or an 
agglomerate from a surface of a coarse carrier becomes more likely as its size is 
increased. Secondly, the likelihood of deagglomeration increases upon increasing the 
kinetic energy of the entities detached from surfaces upon fluidisation. Therefore, 
agglomerated systems should produce better drug deagglomeration efficiency, and 
consequentially, smaller MMAD. In the current study the formulations prepared with 
SV010 were seen to produce both a higher delivered dose and smaller MMAD. These 
data indicate the detachment of the drug from the surface of SV010 was more complete 
and that the formulations prepared with SV010 also went through a more complete 
deagglomeration than the formulations prepared with LH100. Therefore, the current data 
indicate agglomerate formation may be able to explain the differences seen in the 
formulation performance of LH100 and SV010 formulations. 
 
FIGURE 3.11 MEAN MASS AERODYNAMIC DIAMETER (MMAD) OF FLUTICASONE PROPIONATE DELIVERED 
TO THE IMPACTOR STAGES AS A FUNCTION OF FLUTICASONE PROPIONATE CONTENT (LOADED DOSE) OF 
THE FORMULATIONS. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, N=10 FOR FLUTICASONE 
PROPIONATE CONTENT OF THE FORMULATIONS AND N=3 FOR MEAN MASS AERODYNAMIC DIAMETER 
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Pre-separator deposition is of particular interest if evidence for the active site theory is 
being sought. This is because the majority of the large lactose particles will deposit in the 
pre-separator, with any drug adhered to the surface of the large carriers also depositing in 
the pre-separator. Figure 3.12 illustrates the pre-separator deposition patterns in a 
hypothetical case where the DPI performance is determined by the active sites theory. At 
low drug loading, well below the critical concentration, a high proportion of drug should be 
deposited in the pre-separator with very little drug being delivered to the impactor stages. 
As the drug concentration increases, but remains below the critical concentration, an 
increased proportion of the drug should be recovered from the pre-separator. This is 
because the added drug is preferentially binding to the active sites and therefore does not 
detach upon inhalation. At the critical concentration, pre-separator deposition should 
exhibit a peak value, as all the active sites are filled. If the drug concentration is then 
further increased, there should be an increase in the proportion of detached drug and a 
decrease in the pre-separator deposition with increasing drug concentration. This is 
because all the active sites have been saturated. Consequentially, the excess drug should 
bind to the low energy binding sites and thus detach easily upon the dose delivery.   
 
 
FIGURE 3.12 SCHEMATIC PREDICTION OF THE PROPORTION OF DRUG DEPOSITED IN THE PRE-SEPARATOR 
IF THE ACTIVE SITES THEORY HOLDS TRUE 
 
 
The stage-by-stage deposition profiles of the delivery of FP from the prepared 
formulations as a proportion of total recovered drug dose are shown in Figure 3.13. As 
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shown by the pre-separator deposition profiles of the formulations in Figure 3.13, it 
appears that the active sites theory could govern the drug detachment and carrier 
retention for SV010 formulations. However, the pre-separator deposition pattern seen for 
the series of SV010 formulations may also be explained by the additional amount of drug 
retained in the capsule and device at low drug concentrations. If the drug retained within 
the capsule and the device would have been emitted, the pre-separator deposition profile 
may have been similar to that exhibited for the LH100 formulations. In general, these data 
suggest limited evidence for active sites theory. 
 
The proportion of drug retained in the capsule exhibited a generally increasing trend upon 
increasing the drug loading with both the carriers. The increase in capsule deposition was 
seen to be statistically significant for the 0.15 wt-%, 1 wt-% (p<0.05) and for the 2 wt-% 
formulations (p<0.01) prepared with LH100 compared to the 0.02 wt-% formulation 
prepared with the same carrier. The device deposition patterns showed that at low drug 
loading, a higher proportion of drug was deposited in the device from the SV010 
formulations than from the equivalent LH100 formulations. However, at higher drug 
loadings the formulation series were similar in terms of device deposition. The device 
deposition of the drug from all the LH100 formulations was significantly higher than from 
the 0.02% formulation (p<0.05). For SV010 formulations, a significant increase in the 
device deposition was seen at 0.4 wt% and higher drug concentrations. 
 
The proportion of drug deposited in the mouthpiece and throat was not significantly 
affected by loaded drug dose (p>0.05). A slightly lower proportion of drug was retained in 
the throat from SV010 formulations than for the LH100 formulations. 
 
When the proportion of drug delivered to the impactor stages in Figure 3.13 was 
inspected, it was show that the proportion of drug recovered from Stage 1 of the impactor 
significantly decreased as the concentration of FP was increased. This trend was 
observed for both the carriers. As discussed above, the drug may either become more 
efficiently redistributed on the surface of the large carrier at higher drug concentrations or 
form agglomerates which reside on the lactose. Some of the agglomerates that should on 
the basis of their size be deposited in the pre-separator are sometimes carried through 
and deposited on Stage 1 of the impactor. Therefore, the decrease in the amount of drug 
recovered from Stage 1 is likely to be a consequence of either better drug re-distribution 
during formulation blending or greater drug deagglomeration upon fluidisation as a result 
of agglomerate formation.  
 
For the LH100 formulations, the proportion of drug deposited on Stage 2 did not indicate a 
clear trend with increasing drug concentrations. A significantly higher proportion of drug 
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was collected on Stage 3 at drug concentrations above 0.08 wt%. Drug deposition on 
Stages 4 to 8 did not exhibit clear trends. For the SV010 formulations, increasing 
proportion of drug was recovered from Stage 2 to Stage 5 as the loaded drug dose was 
increased. The stage deposition patterns for the formulations reflected the overall 
performance of the formulations, with SV010 formulations outperforming the formulations 
prepared with LH100.  
 
The in vitro performance data obtained for the formulation series prepared with the two 
different carriers provided very limited evidence for the active sites theory. To investigate 
whether changes in the fluidisation mechanism from erosion to fracture could explain the 
trends seen in the in vitro performance of the formulations, high speed imaging of 
fluidisation of selected formulations was performed. The findings will be described in the 
following section. 
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LH100 series 
SV010 series 
FIGURE 3.13 STAGE-BY-STAGE DEPOSITION PROFILES OF FLUTICASONE PROPIONATE FROM THE 
FORMULATIONS PREPARED WITH LH100 (TOP) AND SV010 (BOTTOM) AS THE IN TERMS OF PROPORTION 
OF THE DOSE RECOVERED FROM DIFFERENT PARTS OF THE IMPACTOR. THE DATA REPRESENTS MEAN ± 
STANDARD DEVIATION, N=3.  ASTERISKS DENOTE STATISTICALLY SIGNIFICANT DIFFERENCE * p<0.05, ** 
p<0.01 (1 WAY ANOVA, FISHER PAIRWISE COMPARISON WITH 95% CONFIDENCE LIMIT). MP & T = 
MOUTHPIECE AND THROAT, PS=PRE-SEPARATOR, S=STAGE. 
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3.3.4 Characterisation of the fluidisation mechanisms of the formulations 
 
It has been shown that there are two different mechanisms for fluidisation of DPI 
formulations, namely erosion and fracture (Shur et al. 2008a; Tuley et al. 2008). These 
studies demonstrated that free flowing powders exhibit an erosion mechanism and more 
cohesive powders fluidise via the fracture mechanism. (Tuley et al. 2008). It has also been 
shown that powders exhibiting the fracture mechanism upon fluidisation produce a better 
DPI performance (Shur et al. 2008a). In the aforementioned study, the improved 
performance for formulations fluidising following the fracture mechanism was attributed to 
the higher amount of particle-particle and particle-device collisions taking place when the 
powder fractures due to the high density of particles entrained upon a fracture of the 
powder bed. One of the objectives of the current study was to investigate whether these 
two different mechanisms of fluidisation may have influenced the improved fine particle 
fraction behaviour observed by Young et al. (2005) and El-Sabawi et al. (2006) for 
increased drug concentration. 
 
To study the fluidisation mechanism of the formulations, high speed imaging of the 
fluidisation event was recorded for low, intermediate and high drug loadings with both the 
carriers. Snapshots of the fluidisation events for 0.02, 0.4 and 2 wt-% FP formulations with 
LH100 and SV010 as the carriers are presented in Figure 3.14. No evidence of a change 
in the fluidisation mechanism was seen. All the formulations fluidised following the erosion 
mechanism.  
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FIGURE 3.14 REPRESENTATIVE SNAPSHOTS OF HIGH SPEED IMAGING FOOTAGE OF THE FLUIDISATION 
EVENT OF 0.02% FLUTICASONE PROPIONATE IN A) LH100 AND B) SV010, 0.4% FLUTICASONE 
PROPIONATE IN C) LH100 AND D) SV010 AND 2% FLUTICASONE PROPIONATE IN E) LH100 AND F) 
SV010 
 
 
3.3.5 Characterising the fluidisation and defluidisation properties of the 
formulations 
3.3.5.1 Method development 
 
The theoretical foundations of characterising the powder cohesion by means of measuring 
the pressure drop across the powder bed as a function of the fluidising gas velocity was 
described in Chapter 2, section 3.4. To the author’s knowledge, this technique has not 
been previously applied as a tool for understanding DPI formulation structure and 
performance. Therefore, the following section describes the method development for 
measuring the pressure drop across the powder bed using the FT4 powder rheometer. 
 
It has been shown that the pressure drop of the air distributor may play a significant role in 
the quality of fluidisation and recommendations for the resistance of the air distributor 
plate are available in the literature (Geldart et al. 1985). The consensus is that the 
pressure drop of the gas distributor plate should be high enough so that the fluidising gas 
is evenly distributed throughout the powder bed. If the resistance is too low the fluidising 
gas will find the path through the powder with the lowest resistance. As a consequence, 
the gas flow will not be evenly distributed throughout the powder bed. This ultimately 
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affects the quality of fluidisation. The pressure drop curve for the air distributor plate of the 
FT4 as a function of the fluidising gas velocity is presented in Figure 3.15. The figure 
shows that the pressure drop of the air distributor plate is negligible. The distributor’s low 
resistance to air flow was expected to affect the quality of fluidisation because, as 
discussed above, the fluidising gas was unlikely to be distributed uniformly throughout the 
powder bed.  
 
The pressure drop profile of the gas distributor plate was re-engineered to a higher 
pressure drop by placing a filter paper underneath the frit. However, this resulted in too 
high a pressure drop across the distributor indicating that the air could not permeate 
through the distributor. As a result, the gas distributor without modifications was used for 
the fluidisation experiments.    
 
Another critical parameter to the quality of the fluidisation is the height to diameter (H/D) 
ratio of the powder bed (Alavi et al. 2005; Valverde et al. 1998). The recommendation 
regarding the optimum H/D ratio varies and ranges from a ratio of 4 to 1 (Alavi et al. 2005; 
Valverde et al. 1998). The H/D ratio of 4 was recommended because the quality of 
fluidisation was seen to improve upon increasing the H/D ratio of the fluidised bed. This 
was attributed to proportionally higher inertia at low H/D ratios that had to be overcome to 
initiate the fluidisation (Alavi et al. 2005). Meanwhile, the H/D ratio of 1 was recommended 
to avoid wall friction effects (Valverde et al. 1998). It is important to note that the former 
study concentrated on Geldart group A powders with added Geldart C powders, while the 
latter concentrated on Geldart group C powders with added flow enhancers. The 
recommendations from the study by Alavi et al. (2005) were likely to be more applicable 
for the purposes of the current study because of the similarity of the powder system under 
investigation in the current study.  
 
To study the effect of the H/D ratio on the fluidisation properties of the current system, 
fluidisation experiments with different amounts of powder were conducted. Pressure drop 
profiles from fluidisation experiments for different amounts of SV010 are shown in Figure 
3.15. It can be seen that the mass of powder has an impact on the Umf with the onset of 
fluidisation shifting towards lower air velocities at higher powder loading. This is also 
illustrated in Figure 3.16 where the Umf is plotted against the mass of the powder bed. It 
can be concluded that a constant and high powder loading is required for reliable 
measurements of Umf.   
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FIGURE 3.15 PRESSURE DROP CURVES FOR THE AIR DISTRIBUTOR PLATE AND POWDER BEDS OF 
DIFFERENT MASSES DURING FLUIDISATION EXPERIMENTS OF SV010 LACTOSE 
 
FIGURE 3.16 MINIMUM FLUIDISATION VELOCITY AS A FUNCTION OF THE MASS OF SV010 LACTOSE 
MEASURED (N=1) 
 
 
To examine whether the H/D ratio of the powder bed was affecting the extent of 
fluidisation, the measured pressure drop at 15 mm/s fluidising gas velocity, at which the 
powders under examination had reached a steady pressure drop, was normalised against 
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the theoretical pressure drop (∆PTheor), that is defined by Equation 3.2, where m is the 
mass of the powder bed (kg), g is the acceleration due to gravity (9.81 ms-2) and A is the 
cross sectional area of the powder bed (m2).  
  
∆ࡼࢀࢎࢋ࢕࢘ ൌ ࢓ࢍ࡭     EQUATION 3.2 
 
The normalised pressure drop curves that describe the fraction of powder that has been 
fluidised for different amounts of SV010 are shown in Figure 3.17. It can be seen that with 
the lowest mass of powder (2.5 g), the lowest extent of fluidisation was achieved. 
Increasing the mass of powder above this resulted in a marginally higher fluidised fraction, 
a finding in an agreement with the study by Alavi et al. (2005). Figure 3.17 also shows that 
the slope of the pressure drop measured across the powder bed below Umf as the 
fluidising gas velocity was increased became steeper when the mass of the powder was 
increased. These data indicate that as the powder loading was increased, the void fraction 
within the powder bed became smaller, as defined by the Carman-Kozeny law (Carman 
1956). It is likely therefore that the walls of the fluidising vessel were supporting the weight 
of the powder when the H/D ratio was too low. These findings indicate that the 
recommendations of the H/D ratio by Alavi et al. (2005) are indeed more suitable for the 
current system than the recommendations by Valverde et al. (1998).  
 
FIGURE 3.17 NORMALISED PRESSURE DROP CURVES FOR DIFFERENT AMOUNTS OF SV010 LACTOSE 
DURING THE FLUIDISATION EXPERIMENTS (N=1) 
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On the basis of the method development experiments discussed so far, all fluidisation 
measurements were performed with between 12 and 13 g of powder. This loading was 
shown to produce stable Umf and a high fluidised fraction. Moreover, this amount of 
powder provided a high enough H/D ratio to avoid wall friction effects.  
 
Another factor that may contribute towards the more compact powder packing for 
increasing H/D ratios observed in the current study is the consolidation stresses induced 
by the increasing gravitational force acting on the powder bed. It has been shown by 
Valverde et al. (1998) that these stresses may increase the cohesion of a powder over a 
period of few hours. In their study, this was attributed to the increasing number of particle-
particle contacts taking place as a result of consolidation as a function of time. However, 
the investigators addressed this issue by showing that consolidation history of a powder 
could be erased by fully fluidising the powder less than five minutes before the 
measurements and allowing the powder to settle under gravity before pressure drop 
measurements commenced. In the current study, to erase the memory of the powder, the 
powder under investigation was fully fluidised for one minute. The air supply was then 
switched off for one minute to allow the powder to settle under gravity. The fluidisation 
experiment was started immediately after this settling period. It is therefore unlikely that 
the impact of increasing H/D ratio on the packing and fluidisation properties of the powder 
in the current study was due to increasing consolidation.  
 
In addition to the fluidisation cycle, a defluidisation cycle was undertaken to investigate the 
defluidisation properties of the formulations. A typical fluidisation/defluidisation profile for 
SV010 is presented in Figure 3.18. The pressure drop hysteresis has been used for 
defining the powder cohesion (Valverde et al. 2000; Valverde et al. 1998). On the other 
hand, during the defluidisation cycle the interparticulate forces are non-existent because 
the particles have been suspended by the fluidising gas and settle under gravity as the 
fluidising gas velocity is decreased (Wang et al. 2004). Therefore, in the current study, the 
area enclosed by the fluidisation/defluidisation curve was used as one of the measures for 
the interparticulate contacts in the powders, in essence powder cohesion.  
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FIGURE 3.18 FLUIDISATION-DEFLUIDISATION CURVES FOR SV010 (m=12.9 g). THE DATA REPRESENTS 
MEAN ± STANDARD DEVIATION, N=3. 
 
 
3.3.5.2 Cohesive properties of the formulations 
 
The fluidisation curves for the series of LH100 and SV010 formulations are plotted in 
Figure 3.19 and Figure 3.20, respectively. In both figures it can be seen that the addition 
of drug fines clearly alters the fluidisation behaviour of the formulations compared to the 
coarse carriers. These changes are characterised by the changes in Umf, area enclosed 
by the fluidisation/defluidisation curve and the fluidised fraction, values of which are listed 
in Table 3.6. These data will be discussed in more detail in the following paragraphs. For 
the individual fluidisation/defluidisation curves for each of the formulations the reader is 
referred to Appendix I.     
 
As shown in Figures 3.19 and 3.20, the initial gradient of the fluidisation curve for both the 
coarse carriers are different to those of the respective formulations. According to the 
Carman-Kozeny law (Carman 1956), this indicates that the void fraction in the coarse 
carriers is larger than in the formulations. Therefore, the addition of the drug fines to the 
coarse carrier produces a more compact powder packing structure under no 
consolidation. This is as expected because the drug particles will fill the voids within the 
randomly packed large lactose carrier particles.  
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TABLE 3.6 THE FLUIDISATION AND FLOW PROPERTIES OF THE COARSE CARRIERS AND THE FORMULATIONS 
IN TERMS OF MINIMUM FLUIDISATION VELOCITY (Umf), AREA ENCLOSED BY THE FLUIDISATION-
DEFLUIDISATION CURVE (AUC, DIMENSIONLESS PARAMETER), FLUIDISED FRACTION AT AN AIR VELOCITY 
OF 15 mm/s (∆P/∆PTheor ) AND THE FLOW RATE INDEX (FRI). THE DATA REPRESENTS MEAN ± STANDARD 
DEVIATION, N=3.  
 
Umf± S.D. 
(mm/s) 
AUC ± S.D. 
(-) 
∆P/∆PTheor  
± S.D. FRI ± S.D. 
LH100 8.47 ± 0.23 2.39 ± 0.18 0.32 ± 0.00 1.02 ± 0.01 
+0.02% FP 5.53 ± 0.12 1.22 ± 0.09 0.36 ± 0.00 1.02 ± 0.01 
+0.05% FP 6.13 ± 0.23 1.32 ± 0.06 0.36 ± 0.00 1.05 ± 0.01 
+0.08% FP 5.20 ± 0.00 0.82 ± 0.05 0.38 ± 0.01 1.10 ± 0.01 
+0.1% FP 5.60 ± 0.00 0.77 ± 0.07 0.37 ± 0.00 1.12 ± 0.01 
+0.15% FP 5.07 ± 0.23 0.72 ± 0.33 0.37 ± 0.01 1.13 ± 0.01 
+0.2% FP 5.47 ± 0.23 0.67 ± 0.08 0.39 ± 0.01 1.13 ± 0.01 
+0.4% FP 4.80 ± 0.00 0.58 ± 0.14 0.37 ± 0.00 1.15 ± 0.01 
+1% FP 4.80 ± 0.00 0.75 ± 0.05 0.37 ± 0.00 1.12 ± 0.02 
+2% FP 4.80 ± 0.00 0.93 ± 0.15 0.34 ± 0.00 1.09 ± 0.02 
SV010 8.33 ± 0.50 2.03 ± 0.07 0.35 ± 0.00 1.11 ± 0.00 
+0.02% FP 5.60 ± 0.00 0.86 ± 0.05 0.37 ± 0.00 1.13 ± 0.01 
+0.05% FP 5.60 ± 0.00 0.91 ± 0.07 0.37 ± 0.00 1.14 ± 0.01 
+0.08% FP 5.60 ± 0.00 0.87 ± 0.06 0.37 ± 0.00 1.14 ± 0.02 
+0.1% FP 5.73 ± 0.23 0.94 ± 0.02 0.36 ± 0.00 1.14 ± 0.03 
+0.2% FP 5.60 ± 0.00 0.86 ± 0.06 0.37 ± 0.00 1.12 ± 0.01 
+0.3% FP 5.47 ± 0.23 0.90 ± 0.04 0.38 ± 0.00 1.16 ± 0.02 
+0.4% FP 5.60 ± 0.00 0.80 ± 0.13 0.38 ± 0.00 1.16 ± 0.02 
+1% FP 6.27 ± 0.23 1.00 ± 0.12 0.35 ± 0.00 1.15 ± 0.02 
+2% FP 6.00 ± 0.40 1.42 ± 0.20 0.34 ± 0.00 1.12 ± 0.02 
 
The Umf for the formulations are plotted as a function of the loaded drug dose in Figure 
3.21. The Umf for the carriers is higher than for the formulations. It can be seen that SV010 
and LH100 have a very similar Umf (~8.5 mm/s) indicating similar powder cohesion 
behaviour. However, when the drug is added to the carriers, a gradual decrease in the Umf 
is seen for LH100 formulations up to 0.4 wt-% drug concentration (Umf =4.8 mm/s), after 
which no change in the Umf  of the formulations takes place. For SV010, a sudden drop to 
~5.6 mm/s in the Umf is observed as a consequence of adding drug between 
concentrations of 0.02 and 0.4 wt-%, suggesting a decrease in powder cohesion as a 
result of the addition of low amounts of the API. However, the Umf for the formulations with 
1 and 2 wt-% drug concentrations increases up to ~6 mm/s indicating the formulations 
with higher drug concentration become more cohesive. Because of the smaller change 
between the Umf of the coarse carrier and the formulations, these data indicate that SV010 
is less sensitive to the addition of drug fines than LH100. In addition, SV010 formulations 
at higher drug loading (0.2 wt-% and above) are more cohesive than equivalent LH100 
formulations.  
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FIGURE 3.19 THE FLUIDISATION CURVES OF FLUTICASONE PROPIONATE (FP) FORMULATIONS PREPARED 
WITH LH100 AS THE CARRIER IN AN ORDER OF INCREASING DRUG CONCENTRATION WITH LH100 IN THE 
FRONT AND 2% FORMULATION AT THE BACK. THE CURVES REPRESENT AVERAGE FROM 3 
DETERMINATIONS.  
 
FIGURE 3.20 THE FLUIDISATION CURVES OF FLUTICASONE PROPIONATE (FP) FORMULATIONS PREPARED 
WITH SV010 AS THE CARRIER IN AN ORDER OF INCREASING DRUG CONCENTRATION WITH SV010 IN THE 
FRONT AND 2% FORMULATION AT THE BACK. THE CURVES REPRESENT AVERAGE FROM 3 
DETERMINATIONS. 
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Similar trends were also seen by quantification of the area enclosed by the 
fluidisation/defluidisation curves. Since the air velocity measurement interval for the 
fluidisation/defluidisation curves was the same for all the samples, the areas were 
calculated as dimensionless areas, with the air velocity normalised by the air velocity 
measurement interval. The values of AUC for the formulations are summarised in Table 
3.6 and presented in Figure 3.22. These data suggest that LH100 is marginally more 
cohesive than SV010. The addition of drug decreased the cohesion of LH100 formulations 
gradually from 2.4 for LH100 to minimum of 0.6 which was achieved with a 0.4 wt-% drug 
concentration. At higher drug concentrations, an increase in the area enclosed by the 
fluidisation/defluidisation curve is observed for LH100 formulations. For the SV010 
formulations, an instant drop from 2 to 0.8 is achieved upon the addition of drug fines at 
0.02 wt-%. The values remain constant up to 1 wt-% concentration, when an increase in 
the cohesion as quantified by the area enclosed by the fluidisation/defluidisation curves is 
seen. Again, the range of values for SV010 is smaller than for LH100 formulations. As 
with the Umf data, these data indicate that the fluidisation properties of SV010 are less 
sensitive to the addition of the fines than LH100, and the SV010 formulations are more 
cohesive than the LH100 formulations at higher drug loadings. 
 
The fluidised fraction of the formulations, as quantified by the ratio between the measured 
and theoretical pressure drop for the powder bed, are plotted against the loaded drug 
dose in Figure 3.23. The numerical values are presented in Table 3.6. These data show 
that LH100 is fluidised to a lesser (0.32) extent than SV010 (0.35). However, as soon as 
the drug is added to LH100, the fluidised fraction increases up to 0.36 and continues 
increasing until a peak of ~0.39 is reached at 0.2 wt-% drug concentration. For SV010, a 
similar increase is seen with the peak value of ~0.38 at 0.3 wt-% concentration. After the 
peak concentration, a decrease in the fluidised fraction is observed with both carriers. 
Once again, the range of values for SV010 (0.35 to 0.38) is smaller than for LH100 (0.32 
to 0.38).   
 
The flow rate index (FRI), which is a dimensionless descriptor of general flow properties of 
powders, is an independent measurement from the fluidisation experiments. As discussed 
in the general materials and methods chapter of the thesis (Chapter 2.3.3) powders that 
are insensitive to changes in the flow rate have an FRI value of 1. These powders are 
generally free-flowing. Cohesive powders react to a decrease in the flow rate and thus 
have an FRI higher than 1. The values of FRI for the formulations presented in Table 3.6 
are plotted against the loaded drug dose in Figure 3.24. According to these data, LH100 
flows more freely than SV010 as it exhibits the lower FRI of the two carriers. When drug 
fines are added to the carriers, LH100 gradually gets more cohesive, until a peak value of 
1.15 is reached at 0.4 wt-% concentration, after which the FRI gradually decreases. For 
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SV010, hardly any change is observed in the value of FRI up to the concentration of 0.2 
wt-%. After this, an increase in FRI is seen with a peak value of 1.16 at 0.4 wt-% drug 
concentration and decay at higher concentrations. Yet again, LH100 demonstrates higher 
sensitivity to the addition of drug fines because of the wider range of values between the 
LH100 and the formulations.  
 
  LH100 formulations 
SV010 formulations 
 
FIGURE 3.21 THE MINIMUM FLUIDISATION VELOCITY (Umf) OF THE LH100 (TOP) AND SV010 
FORMULATIONS (BOTTOM) AS A FUNCTION OF FLUTICASONE PROPIONATE CONCENTRATION (LOADED 
DOSE) . THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, N=3. 
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LH100 formulations 
SV010 formulations 
FIGURE 3.22 COHESION OF THE FORMULATIONS AS QUANTIFIED BY THE AREA ENCLOSED BY THE 
FLUIDISATION AND DEFLUIDISATION CURVES AS A FUNCTION OF FLUTICASONE PROPIONATE 
CONCENTRATION (LOADED DOSE) FOR LH100 (TOP) AND SV010 FORMULATIONS (BOTTOM). THE DATA 
REPRESENT MEAN ± STANDARD DEVIATION, N=3. 
 
 
 
 
 
 
142 
 
LH100 formulations 
SV010 formulations 
FIGURE 3.23 THE FLUIDISED FRACTION  (∆P/ ∆PTheor) OF THE MODEL FORMULATIONS  AS A FUNCTION OF 
FLUTICASONE PROPIONATE CONTENT (LOADED DOSE) WITH LH100 (TOP) AND SV010 (BOTTOM) AS THE 
CARRIERS. THE DATA REPRESENT MEAN ± STANDARD DEVIATION, N=3. 
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LH100 formulations 
SV010 formulations 
FIGURE 3.24 THE MEASURED VALUES OF FLOW RATE INDEX (FRI)  AS A FUNCTION OF FLUTICASONE 
PROPIONATE CONTENT (LOADED DOSE) OF THE FORMULATIONS PREPARED WITH LH100 (TOP) AND 
SV010 (BOTTOM) AS THE CARRIERS. THE DATA REPRESENT MEAN ± STANDARD DEVIATION, N=3. 
 
These results indicate that the fluidisation and flow properties of SV010 are affected by 
the addition of drug fines to a lesser extent than LH100. This may be due in part to the 
rougher surface of the SV010 accommodating some of the drug fines. The rheometric 
analysis of the two lactose batches suggested that SV010 formulations at high drug 
concentrations were more cohesive than the LH100 formulations at equivalent drug 
loadings. At these concentrations, SV010 formulations produced a significantly higher fine 
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particle mass and fraction than the LH100 formulations (p<0.05). Therefore, the increased 
cohesion of the formulations might be able to explain some of the trends seen in the 
formulation performance. These data agree with previous studies, where an increase in 
the cohesive properties of the bulk powder significantly increased the performance of 
carrier based DPI formulations (Shur et al. 2008a; Shur et al. 2008b). However, the 
fluidisation properties do not reflect all the changes in DPI performance over the full range 
of drug loadings studied here. 
 
3.4. CONCLUSIONS 
 
This study focussed on investigating the validity of active sites theory in governing DPI 
performance. The results of the study provided contradictory evidence for the active sites 
theory, particularly as the lactose carrier with the rougher surface outperformed the 
smoother carrier in terms of various in vitro performance measures and demonstrated a 
lower concentration where an improvement in the DPI formulation performance became 
obvious. 
 
No changes in the fluidisation mechanism of the formulations over the concentration 
range studied here were observed and all the formulations fluidised following the erosion 
mechanism. Therefore, changes in the fluidisation mechanism are not capable of 
explaining the trends seen in the in vitro performance of the formulations either. The role 
of increased cohesion in improving the DPI performance was also investigated, and a 
novel pressure drop measurement method for characterising DPI formulations was 
developed. The results indicated that at higher drug concentrations, increased cohesion 
might play a part in determining the DPI performance. However, the increased cohesion 
was not capable of explaining the trends in in vitro performance over the whole range of 
drug loadings studied here.  
   
The results of the current study indicated that the redistribution of the drug agglomerates 
during blending of the formulations and their detachment from the carrier surface and 
deagglomeration upon inhalation may play a crucial role in determining the DPI 
performance. This will be further investigated in Chapter 4 of the thesis. 
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CHAPTER 4 THE IMPACT OF ADDED LACTOSE FINES TO THE 
CARRIER FLOW AND FLUIDISATION PROPERTIES AND DRY 
POWDER INHALER PERFORMANCE 
4.1 INTRODUCTION 
 
The particle size distribution of the added fine lactose is an important factor in determining 
whether the DPI formulation performance increases as more lactose fines are added. 
Finer sub-cuts of the lactose fines have been shown to be more effective in improving DPI 
performance (Adi et al. 2006; Adi et al. 2009; Guenette et al. 2009; Zeng et al. 1999). In 
the study reported here, the impact of adding lactose fines with different process histories, 
and thus particle size distributions, to the performance of DPI formulations was 
investigated.   
 
One aim of the study reported in the current chapter was to assess the suitability of 
different parameters describing the properties of the lactose carriers for predicting the 
formulation performance. Traditionally, characterisation of the amount of fines associated 
with the lactose carrier has been the holy grail of DPI formulators’ toolbox in estimating 
the performance of the final product. However, during the last years, an increasing 
amount of research effort has been concentrated in further understanding the relationship 
between the powder bulk properties and DPI performance. Understanding the relationship 
between raw material properties and DPI performance would enable a quality-by-design 
approach for manufacturing DPI products. Some studies have been successful in relating 
the fluidisation characteristic of the carrier to the final performance of the formulation 
(Pitchayajittipong et al. 2010; Shur et al. 2008a). Recent research also include a study 
where the permeability of the DPI formulation was related to the performance of the final 
product (Le et al. 2010), although the methodology suggested in the study did not prove 
the applicability of the method for quality-by-design purposes as only the permeability of 
the final formulations were related to performance. However, due to these promising 
reports, it was anticipated that powder flow and fluidisation characteristics of the lactose 
carriers may be suitable to be used as a quality-by-design tools. 
 
The role of the active sites theory and increased cohesion in governing the dry powder 
inhaler performance was investigated in Chapter 3. It was shown that the active sites 
theory is an unlikely explanation behind the improved DPI performance upon the addition 
of lactose fines, and that increased cohesion may play only a minor part in explaining the 
improvement. Instead, preliminary evidence for the role of agglomerate formation in 
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improving the formulation performance was seen. Therefore, the study reported here 
aimed also to examine whether drug-fines agglomerate formation could play a role in 
governing DPI performance.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
 
The different inhalation grades of lactose used in the study were Lactohale (LH) products 
obtained from DFE Pharma (Borculo, Netherlands) and were as follows: a sieved grade 
coarse carrier LH100, micronised lactose fines LH300 and two different grades of milled 
lactose fines, LH230 and LH210. Micronised budesonide (Astra Zeneca) was used as 
received. The cohesive-adhesive balance (CAB) value (Begat et al. 2004b) for the 
budesonide was 0.75 meaning the drug preferred to adhere to the lactose rather than to 
itself and the particle size was within the respirable range with the value of d90 at 4.40 µm. 
Methanol and acetonitrile were of HPLC grade (Fisher Scientific, Loughborough, UK) and 
water was reverse osmosis purified. (Millipore, France). 
 
 
4.2.2 Preparation of lactose pre-blends 
 
Three different series of lactose pre-blends were prepared at fines concentrations of 2.5, 
5, 10 and 20 wt-% in quantities of 100 g by sandwiching each of the fines between LH100 
in three layers in an earthed 500 ml stainless steel vessel described in Section 2.1.1.3 and 
blended using a Turbula T2F mixer (Glen Creston Ltd., Middlesex, UK) at 46 rpm for 60 
minutes. The pre-blends were stored at 20 ± 2 °C and 44% relative humidity (RH) for at 
least 24 hours before any further work or characterisation was performed.  
 
 
4.2.3 Particle sizing of the raw materials and the pre-blends 
 
The particle size distributions of the lactose raw materials and the pre-blends were 
measured dispersed dry at a pressure of 2 bar using a Sympatec Helos laser diffraction 
system with an R4 lens in conjunction with a Rodos T4 disperser and a Vibri feeder 
controlled by WINDOX software (all from Sympatec Gmbh, Germany). The feed rate was 
adjusted such that an optical concentration between 0.5 and 5% was obtained. Five 
repeat measurements were taken for each of the samples and the high resolution 
Fraunhofer model was applied for calculating the particle size distribution from the 
scattering data. An aliquot of budesonide was dispersed in 0.1% lecithin in cyclohexane 
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and ultrasonicated for one minute in an ultrasonic bath. The resulting suspension was 
added to the Cuvette dispersing system (Sympatec Gmbh, Germany) until an optical 
concentration of between 5 and 10% was obtained. Five repeated measurements of 5 
seconds duration using an R3 lens configuration were then taken.   
 
 
4.2.4 Scanning electron microscopy 
 
The scanning electron microscopy (SEM) for the raw materials and the pre-blends was 
performed on a JEOL JSM-6480LV (JEOL, Tokyo, Japan). The samples were mounted on 
stainless steel sample holders using sticky carbon tabs and coated with an Edwards 
sputter coater S150B (BOC Edwards, UK) for 5.5 minutes prior to the analysis. An 
acceleration voltage of 10 kV was applied for imaging.  
 
 
4.2.5 Powder flow properties on the Schulze RST-XS 
 
The following procedure was followed for characterizing the samples on the RST-XS 
annular ring shear tester controlled by RST-Control 95 software (both from Dietmar 
Schulze, Germany). For each test, a 30 ml annular shear cell was filled with the material 
under investigation without applying force to the upper surface of the powder bed. The 
powder was pre-sheared with a normal stress of 1000 Pa (τpre) until steady-state flow was 
achieved. A yield locus was then constructed by measuring the shear stress required to 
cause the powder to fail under three normal stresses lower than τpre (250 Pa, 500 Pa and 
750 Pa) and the flowability calculated using the instrument software. Each powder was 
tested three times and the mean flowability ratio (ffc) at 1000 Pa pre-shear stress was 
calculated. The ffc is the ratio between the consolidation stress and the unconfined yield 
strength of the powder, both of which are parameters that can be determined from the 
yield locus, and is a dimensionless parameter, which increases as powder flowability 
improves. Hence, the more cohesive the powder system, the lower the value of ffc for the 
system. A detailed description of the theory of measuring powder flow properties based on 
the yield locus, and the measurement methodology, see Chapter 2, section 2.3.2. 
 
 
4.2.6 Powder flow and fluidisation properties on the FT4 
 
The flow and fluidization behaviour of the lactose pre-blends were also characterised 
using the FT4 Powder Rheometer (Freeman Technology, Tewkesbury, UK). Detailed 
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background information and measurement methodologies can be found in Chapter 2, 
Section 3.3. 
 
Briefly, a 25mm bore diameter, 20 ml glass split vessel is filled with the powder under 
investigation before a conditioning cycle is run using a 23.5mm blade that is moved 
downwards in a clockwise helical path with an angle of 5 degrees at 60 mm/s. The split 
vessel is then opened to achieve a constant powder mass in the vessel before a specific 
measurement program is run. During a measurement the blade is moved through the 
powder in an anti-clockwise motion at a tip speed of 100 mm/s and a helical angle of 5 
degrees unless otherwise stated. Normalised basic flow energy (BFENorm), flow rate index 
(FRI), normalised fluidisation energy (FENorm), dynamic flow index (DFI), bulk and tapped 
densities were characterised for the lactose pre-blends. All the measurements were 
performed in triplicate: 
 
The Hausner ratio and Carr’s index for the lactose pre-blends were calculated from the 
bulk and tapped densities as per Equations 2.1 and 2.2, respectively. 
 
 
4.2.7 Preparation of model formulations with budesonide 
 
The lactose pre-blends were formulated with budesonide at 0.8 wt-% concentration to 
produce an array of model DPI formulations for in vitro testing. The formulations were 
prepared in quantities of 40 g by using the same stainless steel vessel as for blending the 
lactose pre-blends. The lactose pre-blends were sieved at 850 µm before the formulations 
were prepared in order to break any large agglomerates present in the pre-blends. 0.32 g 
of the drug was weighed and sandwiched between half of the lactose, which was blended 
for 10 minutes with a Turbula at 46 rpm, after which the remaining the lactose was added 
and blending was continued for a further 45 minutes. The formulations were sieved at 250 
µm in order to break any large agglomerates and stored at 20 ± 2 °C and 44% RH for at 
least 24 hours before any further work. The drug content uniformity of the blends was 
measured by taking ten random samples of 12.5 mg and determining the amount of drug 
in the samples by high performance liquid chromatography (HPLC). Dose variation of less 
than 6% was achieved for all blends.  
 
 
4.2.8 Drug content assay by HPLC 
 
The drug content was determined by high performance liquid chromatography (HPLC) 
following the method described in Chapter 2, Section 4.2.  
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4.2.9 In vitro testing of the formulations 
 
The in vitro performance of the formulations was tested using a Next Generation Impactor 
(NGI) equipped with a pre-separator (Copley Scientific, Nottingham, UK). Two 
hydroxypropylmethylcellulose (HPMC) capsules, containing 12.5 mg of the formulation 
each, were aerosolised through the system with Rotahaler (GlaxoSmithKline, UK) and 
Handihaler (Boehringer Ingelheim, Germany). The flow rates were adjusted using the TPK 
critical flow control unit (Copley Scientific, Nottingham, UK) such that 90L/min was used 
for Rotahaler and 52 L/min for Handihaler. A 4kPa pressure drop for Rotahaler was 
measured at a flow rate of 160 L/min. However, the NGI is only calibrated to flow rates up 
to 100 L/min, and therefore 90 L/min was used for the Rotahaler. For Handihaler, 52 L/min 
was measured as the flow rate producing a pressure drop of 4kPa without a capsule. The 
duration of aerosolisation was adjusted so that 4L of air was withdrawn through the 
system. Each determination was performed in triplicate. The NGI stages have different 
cut-off values at different airflow rates (See section 2.6.1.2.6). To compare the 
performance of the formulations on different devices, results were normalised by 
calculating the mean mass aerodynamic diameters (MMAD) and the fine particle fraction 
of particles less than 5 µm calculated by extrapolation. The fine particle fraction was 
normalised to the emitted dose (FPFED). 
 
 
4.2.10 Analysis of statistical significance 
 
Statistical analysis of the results was performed using Minitab v15 software (Minitab Inc., 
Pennsylvania, USA). Comparisons were performed using one-way analysis of variance 
(ANOVA) with Fisher comparison confidence level set to 95% or 99% depending on the 
outputs evaluated.  
 
4.3 RESULTS AND DISCUSSION 
 Physical properties of the raw materials 4.3.1
Representative SEM photomicrographs of the coarse lactose carrier and lactose fines 
used in the study are shown in Figure 4.1. The coarse lactose carrier LH100 (Figure 4.1A) 
exhibited a typical tomahawk morphology of alpha lactose monohydrate (Graham et al. 
1997), with a few intrinsic fine lactose particles adhering to the surfaces. Micronised 
lactose LH300 (Figure 4.1B) had a uniform, fine particle size. All the micronised particles 
imaged were smaller than 20 µm. The milled fines LH230 and LH210 (Figure 4.1C and 
Figure 4.1D respectively) were composed of particles with wider particle size distributions. 
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In both these milled materials, only a small proportion of the particles were less than 5 µm. 
The coarser particles made up the bulk of the milled lactose materials and it is worth 
noting that the very fine lactose particles were adhering to the surfaces of these larger 
particles.  
The particle size distributions of the lactose fines, as measured by laser diffraction, are 
summarised in Table 4.1 and shown in Figure 4.2 together with the particle size 
distribution of LH100, whose data is summarised in Table 4.2. These results support the 
general observations of the SEM images. For the coarse carrier lactose (LH100), the 
mode of the particle size distribution was approximately 100 µm with a tail of finer material 
and a very small proportion (1.3%) of fine lactose particles present below 4.5 µm. For the 
micronised lactose (LH300), the median particle size was 2.41 µm, with 90% of the 
particles finer than 7.76 µm. Of the two milled fines used in the study, LH230 particles 
exhibited the smaller particle size distribution, with a d50 of 8.05 µm compared to a d50 of 
14.30 µm for LH210 particles. 
 
 
FIGURE 4.1 900X MAGNIFICATION SCANNING ELECTRON MICROGRAPHS OF A) LH100 B) LH300 C) 
LH230 AND D) LH210 
 
 
A B
C D
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TABLE 4.1 PARTICLE SIZE DISTRIBUTIONS OF THE LACTOSE FINES USED IN THE STUDY IN TERMS OF d10, 
d50 AND d90. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION (S.D.), n=5. 
 d10 ± S.D. (µm) d50 ± S.D. (µm) d90 ± S.D. (µm)
LH300 0.84 ± 0.01 2.41 ± 0.07 7.76 ± 0.27 
LH230 1.31 ± 0.01 8.05 ± 0.06 21.97 ± 0.09 
LH210 1.64 ± 0.01 14.3 ± 0.22 39.45 ± 0.54 
 
 
FIGURE 4.2 PARTICLE SIZE DISTRIBUTIONS OF THE RAW MATERIALS USED IN THE STUDY. THE 
DISTRIBUTIONS SHOWN ARE AVERAGES OF FIVE REPEATED MEASUREMENTS. 
 
 
 Physical properties of the lactose pre-blends 4.3.2
The proportion of fine lactose particles in the carrier has been reported to be a key 
attribute in increasing the performance of DPI products in several studies (Adi et al. 2009; 
Guenette et al. 2009; Louey et al. 2003). The particle size distributions of the lactose pre-
blends prepared with micronised (LH300) and milled lactose fines (LH230 and LH210) 
with LH100 as the coarse carrier are summarised in Table 4.2. The particle size 
distributions of the series of LH300 pre-blends at 2.5, 5, 10 and 20 wt-% concentrations 
are shown in Figure 4.3 (top). The proportion of intrinsic lactose fines less than 4.5 µm 
associated with the batch of LH100 was 1.3%. Upon the initial addition of 2.5 wt-% of 
micronised (LH300) fines to the coarse carrier (LH100), the proportion of particles <4.5 
µm increased to 4.9%. Upon increasing the concentration of the micronised component 
(LH300) to 5, 10 and 20 wt-%, the cumulative percentage of fines below 4.5 µm present in 
the carrier blends increased to approximately 9, 17 and 23%, respectively (Table 4.2).    
152 
 
The particle size distributions of the pre-blends prepared with the finer of the two milled 
lactose fines (LH230) are also shown in Figure 4.3 (middle).  These data indicate that the 
addition of fines up to a concentration of 10 wt-% altered the particle size distribution of 
the lactose pre-blends mainly in the size range between 5 and 50 µm. Meanwhile, Table 
4.2 shows that the addition of the LH230 fines at 2.5, 5 and 10 wt-% concentrations 
resulted in 2.8, 4.3 and 7.2% proportion of particles below 4.5 µm, respectively. A 
concentration of 20 wt-% was required to initiate a more pronounced contribution towards 
the fine end of the particle size distribution, whereby the percentage of particles <4.5 µm 
increased to approximately 12.5%. The particle size distributions of the pre-blends 
prepared with the coarser grade of the milled lactose fines (LH210) are also shown in 
Figure 4.3 (bottom). The addition of the LH210 fines contributed mainly to the particle size 
distribution between 10 and 50 µm. Table 4.2 shows that even at a concentration of 20 wt-
%, the proportion of fine lactose particles <4.5 µm was only 6%.  
Representative scanning electron micrographs of the LH300 pre-blends are shown in 
Figure 4.4. Up to 10 wt-% concentration, the lactose fines were distributed on the surfaces 
of the large carrier particles mainly as agglomerates. At 20 wt-% concentration, the fines 
appeared to form a more uniform surface coverage rather than distributing themselves on 
the surface of the large carrier particles as smaller agglomerates.  
Scanning electron micrographs of the LH230 pre-blends are presented in Figure 4.5. The 
larger fines have been distributed between the large carrier particles. Up to 10 wt-% 
concentration (Figure 4.5A to C), mainly single fine particles (<10 µm) were seen adhered 
on the surfaces of the large carrier crystals. At 20 wt-% concentration (Figure 4.5D), 
agglomerates of fines were also observed on the surfaces of the large carrier particles.  
 
Representative scanning electron micrographs of the LH210 pre-blends are shown in 
Figure 4.6. The micrographs indicate that at all fines concentrations of LH210, some 
primary fine particles (<10 µm) and also some larger fine particles (~20 µm) were 
adhering to the surfaces of the large carrier particles. The surfaces of the large carrier 
particles remained relatively free of agglomerated fine particle lactose across the range of 
concentrations.   
Recently, it was suggested that there are five different regimens governing DPI 
performance (Young et al. 2011). According to the suggestions, the initial regimen was the 
filling of active sites followed by the filling of low energy binding sites. After this, the third 
regimen is where monolayer coverage of the carriers was approached. The fourth 
regimen was agglomerate formation just before a monolayer coverage is reached. The 
final regimen suggested was formulation segregation due to too high a fines content.  
However, SEM images from the current study showed no evidence of monolayer 
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formation. The size range of lactose fines (<10 µm) that have been previously 
demonstrated to be efficient in improving DPI performance (Guenette et al. 2009), 
appeared, on the basis of the SEM, to form agglomerated systems on the surface of the 
larger carrier particles when present at concentrations favourable for agglomerate 
formation. For the LH300 based formulations, the concentration where agglomerate 
formation began to appear was 5 wt-% (Figure 4.4B). For the LH230 formulation the 
critical concentration was 20 wt-% (Figure 4.5D). With the LH210 formulations, a high 
enough fines content was not reached to achieve agglomerate formation (Figure 4.6.). 
 
TABLE 4.2 PARTICLE SIZE DISTRIBUTIONS OF THE LACTOSE CARRIERS USED IN THE STUDY IN TERMS OF 
d10, d50 AND d90. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION (S.D.), n=5. IN ADDITION, THE 
MEAN VALUES (n=5) OF PROPORTION OF PARTICLES FINER THAN 4.5 AND 30 µm PRESENT IN THE 
CARRIERS ARE TABULATED.  
 d10 ±  S.D. (µm) 
d50 ± S.D. 
(µm) 
d90 ±  S.D. 
(µm) 
<4.5 µm 
(%) 
<30 µm 
(%) 
LH100 44.30 ± 1.58 103.37 ± 1.01 159.62 ± 0.56 1.29 6.24 
+2.5% LH300 23.44 ± 1.01 99.66 ± 0.35 161.02 ± 2.15 4.88 11.48 
+5% LH300 5.22 ± 0.32 95.19 ± 0.79 157.27 ± 3.31 9.34 17.03 
+10% LH300 2.08 ± 0.02 87.30 ± 0.85 154.55 ± 3.77 17.43 26.97 
+20% LH300 1.73 ± 0.06 60.76 ± 2.11 139.93 ± 3.40 23.04 42.75 
+2.5% LH230 26.41 ± 0.84 99.78 ± 0.37 160.88 ± 0.31 2.76 10.95 
+5% LH230 14.70 ± 0.29 96.58 ± 0.64 159.82 ± 3.02 4.32 15.13 
+10% LH230 7.33 ± 0.14 89.55 ± 0.38 156.65 ± 1.02 7.23 23.23 
+20% LH230 3.26 ± 0.21 67.18 ± 1.55 134.32 ± 2.77 12.47 38.15 
+2.5% LH210 31.53 ± 1.05 100.23 ± 0.64 158.57 ± 2.12 1.98 9.56 
+5% LH210 23.63 ± 0.61 97.72 ± 0.62 159.85 ± 1.74 2.62 12.27 
+10% LH210 14.25 ± 0.27 91.51 ± 0.70 156.18 ± 3.04 4.08 17.89 
+20% LH210 8.72 ± 0.12 79.30 ± 1.53 151.45 ± 6.27 6.02 26.79 
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LH300 pre-blends 
 
LH230 pre-blends 
 
LH210 pre-blends 
 
FIGURE 4.3 PARTICLE SIZE DISTRIBUTIONS OF THE LACTOSE PRE-BLENDS PREPARED WITH LH300 (TOP), 
LH230 (MIDDLE) AND LH210 (BOTTOM). THE DISTRIBUTIONS ARE AVERAGES FROM FIVE REPEATED 
MEASUREMENTS. 
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FIGURE 4.4 SCANNING ELECTRON MICROGRAPHS OF A) 2.5 B) 5 C) 10 AND D) 20 WT-% LH300 PRE-
BLENDS AT 900X MAGNIFICATION. THE LENGTH OF THE SCALE BAR IN ALL THE IMAGES IS 20 µm 
 
 
FIGURE 4.5 SCANNING ELECTRON MICROGRAPHS OF A) 2.5 B) 5 C) 10 AND D) 20 WT-% LH230 PRE-
BLENDS AT 900X MAGNIFICATION. THE LENGTH OF THE SCALE BAR IN ALL THE IMAGES IS 20 µm 
A B
C D
A B
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FIGURE 4.6 SCANNING ELECTRON MICROGRAPHS OF A) 2.5 B) 5 C) 10 AND D) 20 WT-% LH210 PRE-
BLENDS AT 900X MAGNIFICATION. THE LENGTH OF THE SCALE BAR IN ALL THE IMAGES IS 20 µm 
 
 
 Powder flow and fluidisation properties of the lactose pre-blends 4.3.3
Measuring the powder flow properties using a shear cell tester is an established and 
widely accepted technique (Schwedes et al. 1990). The dynamic approach used for 
example by the Freeman Technology FT4 powder rheometer is more empirical and based 
on characterising differences amongst a group of powders based on their resistance to 
flow under a bulldozing action of an impeller blade and relating the measurement results 
to the observed powder bulk behaviour during processing (Freeman 2007). However, 
recent theoretical work has been carried out to gain greater understanding of the powder 
properties affecting the results obtained on the dynamic FT4 system (Bharadwaj et al. 
2010). A factor that has possibly limited the popularity of the FT4 for characterising 
powder flow properties is that the results obtained with the system are sometimes not 
intuitive. For example, during a basic flow energy test, non-cohesive powders exhibit high 
flow energies and the more cohesive the powder, the lower is the basic flow energy. 
However, it has been described in the literature (Freeman 2007) that the results obtained 
on the FT4 can be explained by the powder transmission zone ahead of the blade. The 
extent of the zone is dependent on the particle-particle interactions taking place as the 
impeller blade moves through the powder bed. In the case of free flowing material, the 
A B
C D
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powder transmission zone in front of the blade is larger because less air is entrapped 
between the particles. Due to the close packing of the particles, the bulldozing action of 
the blade is transmitted further ahead of the blade within the powder. Consequentially, 
more energy is required to keep the blade moving at a constant speed through a bed of 
free flowing powder than a bed of cohesive powder.  
To validate the rheometry results obtained on the FT4 in this study, measurements of the 
lactose pre-blends were performed alongside Schulze RST-XS ring shear testing. The 
results of the powder flow and fluidisation properties as characterised on the two different 
instruments are summarised in Table 4.3. Additionally, traditional indicators of powder 
flowability used in the pharmaceutical industry, the Hausner ratio and Carr’s Index, of the 
lactose carriers were measured. 
The normalised basic flow energies (BFENorm) of the lactose pre-blends are plotted against 
the powder flowability number (ffc) measured on the Schulze ring shear tester in Figure 
4.7. The figure shows a linear relationship (R2= 0.9403) existed between the ffc and the 
BFENorm of the powder for the series of lactose pre-blends used in this study. These data 
suggest that the normalised basic flow energy of the lactose samples in this study can be 
used as a descriptor for the general powder flow properties. However, it has to be noted 
that the correlation between results obtained using static and dynamic measurements, as 
observed here for the series of lactose pre-blends, does not necessarily exist if a series of 
chemically different materials are characterised with static and dynamic measurement 
methods (Freeman 2007; Krantz et al. 2009).  
TABLE 4.3 SUMMARY OF THE POWDER FLOW AND FLUIDISATION PROPERTIES OF THE CARRIERS AS 
CHARACTERISED BY FLOWABILITY NUMBER (ffc), NORMALISED BASIC FLOW ENERGY (BFENorm), FLOW 
RATE INDEX (FRI), NORMALISED FLUIDISATION ENERGY (FENorm), DYNAMIC FLOW INDEX (DFI), CARR’S 
INDEX AND HAUSNER RATIO. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION (S.D.), n=3. 
 
ffc 
 ± 
 S.D. 
BFENorm
± S.D.  
(mJg-1) 
FRI 
± 
 S.D. 
FENorm     
± S.D.  
(mJg-1) 
DFI  
± 
 S.D. 
Carr’s  
Index ± 
S.D. 
Hausner 
Ratio ± 
S.D. 
LH100 5.55±0.23 25.12±0.40 1.02±0.01 0.70±0.08 37.37±4.01 13.8±0.2 1.16±0.00 
+2.5% LH300 4.35±0.25 22.06±0.31 1.10±0.01 0.84±0.09 27.90±3.14 18.3±0.5 1.22±0.01 
+5% LH300 3.43±0.10 20.34±0.49 1.19±0.02 1.23±0.07 16.61±1.33 20.0±1.0 1.25±0.01 
+10% LH300 2.25±0.06 15.68±0.54 1.52±0.02 1.44±0.07 10.87±0.57 27.5±0.5 1.38±0.01 
+20% LH300 1.63±0.02 9.93±0.14 2.41±0.15 1.75±0.01 5.69±0.35 31.7±2.0 1.46±0.04 
+2.5% LH230 4.28±0.26 21.65±0.11 1.06±0.00 0.95±0.10 24.07±0.35 17.7±0.3 1.22±0.00 
+5% LH230 3.45±0.37 19.37±0.17 1.09±0.00 1.12±0.13 18.49±2.63 20.1±0.7 1.25±0.01 
+10% LH230 2.59±0.04 16.07±0.15 1.29±0.01 1.54±0.10 10.74±1.46 26.4±0.6 1.36±0.01 
+20% LH230 1.74±0.03 10.52±0.33 1.81±0.06 1.93±0.17 6.15±0.44 32.1±1.5 1.47±0.03 
+2.5% LH210 4.97±0.13 23.48±0.42 1.03±0.01 0.78±0.02 31.39±0.73 15.5±0.7 1.18±0.01 
+5% LH210 4.14±0.19 21.11±0.59 1.06±0.05 1.00±0.14 21.14±0.44 18.1±0.1 1.22±0.00 
+10% LH210 3.51±0.14 19.54±0.31 1.14±0.01 1.04±0.09 19.56±0.56 20.9±0.3 1.26±0.01 
+20% LH210 2.28±0.02 13.24±0.10 1.41±0.02 1.60±0.03 9.21±0.67 27.0±0.2 1.37±0.00 
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FIGURE 4.7 THE RELATIONSHIP BETWEEN THE ffc NUMBER MEASURED ON THE SCHULZE RST-XS RING 
SHEAR TESTER AND THE NORMALISED BASIC FLOW ENERGY (BFENorm) MEASURED ON THE FT4 POWDER 
RHEOMETER FOR THE LACTOSE PRE-BLENDS INVESTIGATED IN THE STUDY. THE DATA REPRESENTS MEAN 
± STANDARD DEVIATION, n=3.  
Powder cohesion can be classified according to the ffc number measured on the Schulze 
RST-XS system, as shown in Table 4.4. Powders with ffc values between 2 and 4 are 
classified as cohesive and powders with values from 4 to 10 as free flowing (Schulze 
2010). Figure 4.7 indicates that, for the lactose pre-blends used in this study, a BFENorm < 
20 mJg-1 was associated with cohesive powders. 5, 10 and 20 wt-% blends of LH300 and 
LH230 were classified as cohesive according to their ffc numbers. In the case of LH210, 
an addition of at least 10 wt-% of the fines was required for the pre-blends to be classified 
as cohesive.  
The Hausner ratio and Carr’s index are widely used as descriptors of powder flow for 
pharmaceutical applications (Emery et al. 2009; Shah et al. 2008; Thalberg et al. 2004) 
and can also be used for classifying powder cohesion (Shah et al. 2008). The values of 
Carr’s Index and the Hausner ratio for the pre-blends are summarised together with the 
other flow descriptors in Table 4.3. The classification of the powder flow properties of the 
pre-blends according to ffc, Hausner ratio and Carr’s Index is presented in Table 4.4. The 
classification of the flowability of the pre-blends by the Hausner ratio and Carr’s index are 
in good agreement with the classification by ffc. These data show that the parameters are 
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well suited for qualitatively describing the flow properties of lactose and the influence of 
the addition of fine lactose to the carriers.  
Flow rate index (FRI) measures the sensitivity of a powder to a change in the tip speed of 
a blade (Freeman 2007). The parameter is a descriptor of powder cohesion. In general, 
free-flowing powders are not sensitive to changes in the flow rate due to the consistency 
of the powder transmission zone ahead of the blade at different flow rates. Therefore, 
free-flowing powders often have values of FRI close to one (Freeman 2007). The flow rate 
index of the lactose carriers investigated in the current study are plotted against the 
flowability number ffc in Figure 4.8. The plot demonstrates that for free-flowing lactose 
carriers, the flow rate index was insensitive in distinguishing between powders with 
different cohesive properties. However, once the powder blends were classified as 
cohesive, the flow rate index became sensitive to the changes in the powder flow 
properties. Therefore, flow rate index measurements could be used as a parameter for 
differentiating between cohesive powders when the ffc is below 3. 
The universal FT4 powder tester also enables the study of powder properties under 
aeration, which may allow characterization of the rheological properties of aeratable 
powders over a range of fluidization conditions (Shur et al. 2008a; Shur et al. 2008b) The 
dynamic flow index (DFI) and normalised fluidization energy (FENorm) measurements of the 
lactose pre-blends under aeration are summarised in Table 4.3. These parameters, which 
are descriptors of change in flow and cohesive properties of the powders under 
fluidisation, are plotted in Figure 4.9. The DFI describes the reactivity of the powder to 
aeration. A high value of DFI indicates the air permeates easily through the powder bed 
and the material will flow readily. On the other hand, a low value of FENorm indicates that 
the powder can be easily and homogeneously suspended in air as single particles or 
small agglomerates. This is because the torque and the force required to keep the blade 
moving through a fully fluidised powder bed at a constant speed are low due to the lack of 
particle-particle contacts. Thus, the extent of the powder transmission zone in front of the 
blade is small. In contrast, if the powder is cohesive, more work is required to move the 
blade through the agglomerated, poorly aerated powder leading to a higher torque and 
consequentially higher values of FENorm. The relationship between the change in the 
aeratability of a powder (DFI) and its fluidization behaviour (FENorm) are illustrated by the 
polynomial relationship in Figure 4.9. These data indicate that powders that are more 
reactive to an airflow are also more readily suspended in the air when fluidising gas is 
permeated through the powder bed.  
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TABLE 4.4 CLASSIFICATION OF POWDER FLOW PROPERTIES OF THE LACTOSE PRE-BLENDS ACCORDING TO 
FLOWABILITY NUMBER (ffc), CARR’S INDEX AND HAUSNER RATIO THAT ARE PARAMETERS DESCRIBING 
POWDER FLOW 
 ffc Carr’s Index Hausner Ratio 
LH100 Easy flowing Good Free flowing 
 +2.5% LH300 Easy flowing Intermediate Free flowing 
 +5% LH300 Cohesive Intermediate Poor 
 +10% LH300 Cohesive Poor Poor 
 +20% LH300 Cohesive Poor Poor 
 +2.5% LH230 Easy flowing Intermediate Free flowing 
 +5% LH230 Cohesive Intermediate Poor 
 +10% LH230 Cohesive Poor Poor 
 +20% LH230 Cohesive Poor Poor 
 +2.5% LH210 Easy flowing Intermediate Free flowing 
 +5% LH210 Easy flowing Intermediate Free flowing 
 +10% LH210 Cohesive Intermediate Poor 
 +20% LH210 Cohesive Poor Poor 
 
 
 
FIGURE 4.8 THE RELATIONSHIP BETWEEN FLOW RATE INDEX (FRI) AND FLOWABILITY NUMBER ffc FOR THE 
LACTOSE CARRIERS INVESTIGATED IN THE STUDY. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, 
n=3. 
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FIGURE 4.9 THE RELATIONSHIP BETWEEN THE NORMALISED FLUIDISATION ENERGY (FENorm) AND THE 
DYNAMIC FLOW INDEX (DFI) FOR THE LACTOSE CARRIER BLENDS INVESTIGATED IN THE CURRENT STUDY. 
THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, n=3. 
 
 
 The relationship between the fines content and the flow properties of 4.3.4
the lactose pre-blends 
According to the recent hypothesis of Shur et al., the addition of lactose fines may 
improve DPI performance by increasing the cohesive strength of the formulations (Shur et 
al. 2008a). This section of the chapter aims to investigate whether a relationship between 
the types of fines, increasing fines concentration and the cohesive strength of the pre-
blends can be established. 
When ffc values of the lactose carriers are plotted against the proportion of particles finer 
than 4.5 µm present in the pre-blends, the micronised fines (LH300) data follow a very 
different trend to both the milled fines grades (LH230 and LH210), as shown in Figure 
4.10. However, if the ffc is plotted against the proportion of particles below 30 µm as per 
Figure 4.11, all data points follow a single gradient, independent of the type of fines 
added. These data may be explained by the fact that if only the proportion of fines below 
4.5 µm is taken into account, the impact of only a small proportion of the added fines to 
the powder flow properties is inspected. However, if fines below 30 µm are inspected, a 
more complete description of the situation with the added fines is achieved. These data 
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are in an agreement with a study by Guenette et al. (2009), where it was shown that the 
fines below 10 µm had the largest negative effect on the flow properties of lactose carriers 
for inhalation, but that also the fines fraction between 10 and 40 µm decreased the 
powder flowability. In their study, it was shown that particles larger than 40 µm had no 
impact on the powder flow properties.  
A plot of the FENorm of the lactose pre-blends as a function of the percentage of particles 
<4.5 µm is shown in Figure 4.12. This figure demonstrates that the presence of 
micronised (LH300) fines also had a different impact on the fluidisation properties of the 
pre-blends than the milled fines (LH230 and LH210). For example, 10 wt-% addition of 
micronised fines (LH300) finer than 4.5 µm resulted in an FENorm of approximately 1.2 
mJ/g, whereas a similar proportion of milled fines (LH230 and LH210) produced FENorm of 
approximately 1.6 mJ/g. The relationship between FENorm and the proportion of fines 
below 30 µm present in the carriers is illustrated in Figure 4.13. The data points in this 
graph are scattered to a greater extent than those shown in Figure 4.11, where the ffc was 
plotted against the proportion of fines below 30 µm. These data indicate that flow and 
fluidisation characteristics of the lactose pre-blends are governed by different 
mechanisms. Therefore, measuring the fluidisation properties of the pre-blends in addition 
to the flow properties may add value to the characterisation of lactose carriers for DPI 
formulations. 
 
FIGURE 4.10 THE RELATIONSHIP BETWEEN ffc AND THE PROPORTION OF FINES <4.5µm IN THE LACTOSE 
PRE-BLENDS. THE DATA FOR ffc REPRESENTS MEAN ± STANDARD DEVIATION, n=3. THE DATA FOR 
PROPORTION OF PARTICLES FINER THAN 4.5 µm REPRESENTS MEAN OF 5 DETERMINATIONS. 
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FIGURE 4.11 THE RELATIONSHIP BETWEEN ffc AND THE PROPORTION OF FINES <30µm IN THE LACTOSE 
PRE-BLENDS. THE DATA FOR ffc REPRESENTS MEAN ± STANDARD DEVIATION, n=3. THE DATA FOR 
PROPORTION OF PARTICLES FINER THAN 30 µm REPRESENTS MEAN OF 5 DETERMINATIONS. 
 
 
FIGURE 4.12 THE RELATIONSHIP BETWEEN THE PROPORTION OF FINES BELOW 4.5 µm PRESENT IN THE 
CARRIER AND THE NORMALISED FLUIDISATION ENERGY (FENorm ) OF THE LACTOSE PRE-BLENDS. THE DATA 
FOR FENorm REPRESENTS MEAN ± STANDARD DEVIATION, n=3. THE DATA FOR PROPORTION OF PARTICLES 
FINER THAN 4.5 µm REPRESENTS MEAN OF 5 DETERMINATIONS. 
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FIGURE 4.13 THE RELATIONSHIP BETWEEN THE PROPORTION OF FINES BELOW 30 µm PRESENT IN THE 
CARRIER AND THE NORMALISED FLUIDISATION ENERGY (FENorm ) OF THE LACTOSE PRE-BLENDS. THE DATA 
FOR FENorm REPRESENTS MEAN ± STANDARD DEVIATION, n=3. THE DATA FOR PROPORTION OF PARTICLES 
FINER THAN 30 µm REPRESENTS MEAN OF 5 DETERMINATIONS. 
 
To summarise, this section of the chapter has addressed that the addition of lactose fines 
to the carrier pre-blends increases the cohesion of the powder bulk both in terms of flow 
and fluidisation properties. The increase in the cohesive strength is defined by the 
presence of lactose fines below approximately 30 µm, as suggested by the Geldart 
powder classification system (Geldart 1973).   
 
 In vitro performance of DPI formulations prepared with the lactose pre-4.3.5
blends as carriers 
 
The in vitro performance of budesonide formulations prepared using the lactose blends 
were tested with the Rotahaler™ and the Handihaler™ DPI devices, and are summarised 
in Table 4.5 in terms of their fine particle fraction (FPFED) and mean mass aerodynamic 
diameter (MMAD) values.  
Rotahaler is a low resistance device (0.040 cmH200.5/(l/min)(Clark et al. 1993), while 
Handihaler is a high resistance device (0.158 cmH2O0.5/(l/min)(Al-Showair et al. 2007). 
Thus, aerolisation performance of the formulations from these two devices could be 
165 
 
expected to be different. However, as shown in Table 4.5 and illustrated in Figure 4.14, 
the FPFED for all of the formulations were nearly identical when aerosolised from the two 
different devices. These data indicate that the de-agglomeration process of the 
formulations may be governed by the powder properties rather than the device properties.  
Figure 4.14 highlights that an addition of 5 wt-% or more of LH300 was required to 
significantly (p<0.01) increase the DPI performance compared to the formulation prepared 
with LH100. For LH230, a 20 wt-% addition was required to significantly improve 
aerolisation performance compared to LH100. Across the range of concentrations 
investigated, the addition of LH210 did not significantly increase performance compared to 
LH100 (p>0.05). These data show that the addition of milled lactose fines to a carrier-
based lactose formulation which is aerosolised from a capsule-based device does not 
necessarily improve the dry powder inhaler formulation performance. 
Figure 4.14 indicates that only a low wt-% concentration of micronised LH300 fines is 
required to significantly improve DPI performance. These data suggest that the addition of 
micronised fines can significantly alter the fine particle delivery performance of micronised 
budesonide in capsule based DPI devices. These findings are in agreement with previous 
studies by Zeng et al. (1999) and Adi et al. (2006; 2009) who observed that micronised 
lactose fines were more efficient in improving DPI performance than coarser sized lactose 
fines. The former study attributed the observation to the active site theory with larger 
lactose fines being less effective in occupying the high energy binding sites on the surface 
of the large lactose. The latter two studies concluded that the larger lactose fines were 
acting as secondary carriers, therefore being less efficient in improving the performance of 
DPI products.  
The mean mass aerodynamic diameter of the drug aerosolised from the different 
formulations on the two different devices are summarised in Table 4.5 and illustrated in 
Figure 4.15. Although the devices appeared to be identical in delivering the drug from the 
formulations as characterised by FPFED, the values of MMAD indicate that Handihaler was 
capable of de-agglomerating the formulations to a greater extent than Rotahaler resulting 
in smaller MMAD values 
In a previous study, changes in the values of MMAD were reported as lactose fines were 
added to DPI formulations and these changes were attributed the formation of drug-fines 
agglomerates that were distributed within the impactor (Podczeck 1999). When the trends 
in the MMAD for the different formulations are inspected (Figure 4.15), it is shown that the 
MMAD for the formulations containing LH300 remain somewhat unchanged over the 
range of fines concentrations for both devices. These data indicate that the extent of de-
agglomeration did not significantly change for the formulations containing micronised fines 
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despite the increasing fines content. For the formulations prepared with the milled fines, 
LH230 and LH210, an increasing trend in the MMAD was seen as the fines content of the 
formulations was increased. For the Rotahaler, the MMAD was significantly higher for 5 
and 10 wt-% LH230 formulations and the 10 and 20 wt-% LH210 formulations than for the 
LH100 formulation. For the Handihaler, all additions of LH230 or LH210 increased the 
MMAD of the drug significantly compared to the formulation prepared with LH100 only.  
However, Figure 4.15 demonstrates that the addition of 20 wt-% LH230 formulation was 
an outlier from the increasing trend in the MMAD with increasing concentration of milled 
fines for both devices. The MMAD for this formulation decreased compared to the 10 wt-% 
LH230 formulation. It was also shown earlier that when 20 wt-% of LH230 fines were 
added to the formulation, a significant improvement in the DPI performance in terms of 
FPFED was achieved. The increase in the FPFED and the simultaneous decrease in MMAD 
suggest that the powder properties of the lactose pre-blends prepared with LH230 
changed drastically at high enough wt-% concentrations so that deagglomeration of the 
formulation became a more favourable process.  
TABLE 4.5 IN VITRO PERFORMANCE OF THE FORMULATIONS PREPARED WITH THE LACTOSE PRE-BLENDS 
AS THE CARRIERS IN TERMS OF FINE PARTICLE FRACTION OF EMITTED DOSE (FPFED) AND MEAN MASS 
AERODYNAMIC DIAMETER (MMAD). THE DATA FOR FPFED REPRESENTS MEAN ± STANDARD DEVIATION, 
n=3. THE DATA FOR MMAD REPRESENTS MEAN ± GEOMETRIC STANDARD DEVIATION (GSD), n=3. 
 
Rotahaler Handihaler 
FPFED ± S.D. 
(%) 
MMAD ± 
GSD (µm) 
FPFED ± S.D. 
(%) 
MMAD ± 
GSD (µm) 
LH100 15.68 ± 0.42 3.28 ± 1.92 15.21 ± 1.55 3.00 ± 1.81 
 +2.5% LH300 20.18 ± 1.56 3.73 ± 1.79 22.72 ± 2.42 3.16 ± 1.74 
 +5% LH300 28.37 ± 2.26 3.71 ± 1.77 33.94 ± 1.78 3.01 ± 1.73 
 +10% LH300 40.02 ± 4.03 3.41 ± 1.82 43.07 ± 0.62 2.95 ± 1.77 
 +20% LH300 37.80 ± 3.43 3.48 ± 1.96 37.00 ± 4.39 3.22 ± 1.87 
 +2.5% LH230 17.31 ± 3.02 3.50 ± 2.02 17.63 ± 1.11 3.26 ± 1.90 
 +5% LH230 16.13 ± 1.95 4.31 ± 1.86 20.84 ± 3.39 3.31 ± 1.97 
 +10% LH230 20.92 ± 2.55 4.40 ± 1.87 22.50 ± 2.10 3.62 ± 1.98 
 +20% LH230 32.07 ± 2.85 3.74 ± 2.12 31.51 ± 0.31 3.45 ± 2.08 
 +2.5% LH210 14.52 ± 1.34 3.60 ± 1.88 16.18 ± 0.70 3.26 ± 1.80 
 +5% LH210 15.39 ± 2.57 3.66 ± 1.89 18.27 ± 0.21 3.34 ± 1.87 
 +10% LH210 18.11 ± 3.33 4.13 ± 1.83 19.36 ± 3.67 3.41 ± 1.85 
 +20% LH210 17.95 ± 0.94 4.04 ± 2.05 18.82 ± 1.08 3.56 ± 2.04 
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Rotahaler 
Handihaler 
FIGURE 4.14 THE FINE PARTICLE FRACTION OF EMITTED DOSE FROM THE DIFFERENT FORMULATIONS WITH
ROTAHALER (TOP) AND HANDIHALER (BOTTOM). THE DATA REPRESENTS MEAN ± STANDARD DEVIATION,
n=3. AN ASTERISK DENOTES STATISTICALLY SIGNIFICANT DIFFERENCE (p<0.01) COMPARED TO THE
FORMULATION PREPARED WITH LH100 ONLY. 
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Rotahaler 
Handihaler 
 
FIGURE 4.15 THE MEAN MASS AERODYNAMIC DIAMETER OF THE DRUG AEROSOLISED FROM THE DIFFERENT 
FORMULATIONS WITH ROTAHALER (TOP) AND HANDIHALER (BOTTOM). THE DATA REPRESENTS MEAN ± 
STANDARD DEVIATION, n=3. AN ASTERISK DENOTES A STATISTICALLY SIGNIFICANT DIFFERENCE (p<0.01) 
IN MMAD COMPARED TO THE FORMULATIONS PREPARED WITH LH100 ONLY 
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Figure 4.16A, B and C show the stage-by-stage deposition of budesonide from a 
Rotahaler device for a series of formulations prepared with LH300, LH230 and LH210, 
respectively. Figure 4.17A, B and C show the equivalent data for the Handihaler device. It 
can be seen that when the concentration of the fines is increased, the capsule deposition 
from Rotahaler remained constant over all the fines concentrations with all the fines. With 
the Handihaler, the addition of all the fines at 2.5 wt-% concentration decreased the 
capsule deposition very slightly compared to the LH100 formulation. However, increasing 
the concentration of fines did not further decrease dose retention within the capsule. 
Figure 4.16 suggests that for all fines, the proportion of drug recovered from the Rotahaler 
increased with the addition of lactose fines. The increase in the device deposition was 
more pronounced for the micronised fines (LH300) with the amount of drug recovered 
from the device doubling as the fines concentration was increased from 0 to 20 wt-%. The 
increase in the proportion of drug deposited in the Rotahaler was statistically significantly 
greater (p<0.01) for LH300 formulations at 5 wt-% or higher fines content than for the 
LH100 only formulation. For the LH230 milled fines, an addition of 20 wt-% of fines was 
required to cause a significant increase in the proportion of drug recovered from the 
Rotahaler device. The increasing addition of LH210 fines only affected device deposition 
very little with no statistically significant increase in the proportion of drug recovered from 
the device over the range of fines concentrations added.  
Increased device deposition upon an increasing fines concentration has been previously 
reported by Podczeck (1998; 1999), who used a Monohaler device in their study. In 
contrast, Figure 4.17 shows that device retention for the Handihaler device was very low, 
with approximately 5% retained, and remained unchanged with all the different fines and 
at all the fines concentrations. The difference in the proportion of the drug retained in the 
different devices is likely to be due to the larger volume of the chamber of 11.58 ml of 
Rotahaler  (Behara et al. 2011a) compared to a volume of 0.76 ml of Handihaler (Behara 
et al. 2011a). Because of the larger volume chamber of the Rotahaler, a larger surface 
area is available for the drug to adhere on. Also, in Handihaler the powder is retained in 
the capsule until it is fluidised. Therefore, the movement of the capsule and the emptying 
of the powder from the device appear to be highly efficient and insensitive to the cohesive 
properties of the formulations. 
Figure 4.16A, B and C show that an increase in the proportion of the drug deposited in the 
mouthpiece and throat compared to the formulation prepared with LH100 only was 
observed for all the different fines with the Rotahaler device. Compared with the LH100, 
the increase in mouthpiece and throat deposition was statistically significant for 5, 10 and 
20% LH230 formulations and 20% LH210 formulation (p<0.05). However, the proportion 
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of drug aerosolised on Rotahaler recovered from the mouthpiece and throat was relatively 
low, approximately 10% of the recovered dose. 
Figures 17A, B and C show that, for all fines, the proportion of drug deposited in the 
mouthpiece and throat from the Handihaler device increased when the fines concentration 
was increased. For the LH100 formulation, approximately 18% of budesonide was 
recovered from the mouthpiece and throat. With 20 wt-% LH300, the proportion of drug 
deposited in the mouthpiece and throat was roughly 30%, with 20 wt-% LH230 
approximately 32% and with 20 wt-% LH210 approximately 35%. It has been shown that 
the throat deposition from DPI formulations is governed both by particle impaction due to 
the high velocity jet exiting the device and the kinetic energy of the particles following 
turbulence created by the device (DeHaan et al. 2004). The same study addressed that 
the kinetic energy is dependent on the diameter of the device outlet with smaller outlets 
producing higher turbulence, and thus higher kinetic energies. Handihaler has a smaller 
outlet diameter than Rotahaler. Therefore, the conclusions by DeHaan et al. (2004) may 
explain the results of the current study with more drug depositing in the throat from 
Handihaler than from Rotahaler.  
Figure 4.16 demonstrates that the proportion of drug depositing in the pre-separator when 
aerosolised on Rotahaler was greatly affected by the addition of lactose fines. The 
addition of micronised fines LH300 was shown to have the largest impact with the pre-
separator deposition reducing from 50% to less than 40% for 2.5 wt-% fines blend, to less 
than 30% for the 5 wt-% blend and, furthermore, to less than 20% for the 10 wt-% blend. 
Interestingly, a plateau was then reached and further addition of the micronised fines did 
not further decrease the proportion of drug deposited in the pre-separator. In the case of 
the finer of the two milled fines, LH230, a decrease in the pre-separator deposition was 
also observed, with fines concentrations up to 10 wt-% showing a significant decrease 
from 50% deposition down to 30%. The addition of 20 wt-% LH230 decreased the amount 
of drug recovered from the pre-separator to a similar level of less than 20% as the 10 and 
20 wt-% LH300 blends. As discussed, the 20 wt-% LH230 formulation performed 
significantly better than any other formulations prepared with milled fines investigated 
during the current study. These data indicate that once a critical concentration of LH230 
milled fines in the formulation was achieved, the drug detachment from the particles 
depositing in the pre-separator, i.e. the large carrier crystals and the larger fraction of the 
fine particle lactose itself, became favourable. With the addition of 20 wt-% LH210, pre-
separator deposition decreased, from 50% in the absence of added fines, to 35%. The 
trends observed in the pre-separator deposition with Handihaler (Figure 4.17) were very 
similar to those observed for the Rotahaler.  
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These data showing a decrease in the amount of drug recovered from the pre-separator 
as more lactose fines were added to the formulations are in an agreement with studies 
carried out by Podczeck (1998; 1999), Srichana et al. (1998b), Guchardi et al.(2008) and 
Shur et al. (2008a). Podczeck (1998; 1999) attributed the observation to the smaller 
proportion of large lactose carrier particles present in the formulations as the fines 
concentration was increased. Therefore, less surface area of the large lactose carrier 
crystals was available for the drug particles to adhere on, and simultaneously, the drug 
was possibly carried to the impactor stages as agglomerates with the lactose fines. This 
theory is significant for the current study especially in terms of the pre-separator 
deposition saturation for 10 and 20 wt-% LH300 formulations. In number terms, the 20 wt-
% LH300 pre-blend contains a much lower number of large carrier crystals than the 10 wt-
% blend. Therefore, less drug should be expected to be recovered from the pre-separator 
from the 20 wt-% formulation. However, this was not the case. Therefore, it is likely that 
the drug was deposited in the pre-separator as large agglomerates with the lactose fines 
from this formulation.  
Figure 4.16 shows that the stage-by-stage deposition of budesonide was significantly 
improved on all stages by adding LH300 at 10 or 20 wt-% concentrations or LH230 at 20 
wt-% concentration compared to LH100. Figure 4.17 shows that for the Handihaler device, 
the stage deposition of budesonide significantly increased for 5, 10 and 20 wt-% blends of 
LH300 on stage 2 and below (p<0.05). In the case of LH230, the stage deposition 
significantly increased for 10 and 20 wt-% formulations on stage 2 and below (p<0.05). 
For the LH210 series of formulations, a significant increase in the amount deposited on 
the stages were only seen up to stage 3 with 5, 10 and 20 wt-% fines added. 
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FIGURE 4.16 THE STAGE-BY-STAGE DEPOSITION PROFILES OF BUDESONIDE FROM THE MODEL 
FORMULATIONS AEROSOLISED ON ROTAHALER WITH A) LH300 B) LH230 AND C) LH210 AS THE FINES IN 
THE CARRIER. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, n=3. 
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A 
B 
C 
FIGURE 4.17 THE STAGE-BY-STAGE DEPOSITION PROFILES OF BUDESONIDE FROM THE MODEL
FORMULATIONS AEROSOLISED ON HANDIHALER WITH A) LH300 B) LH230 AND C) LH210 AS THE FINES IN
THE CARRIER. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, n=3. 
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 The relationship between the physical properties of the carrier pre-4.3.6
blends and the in vitro performance of the formulations 
 
The fine particle fraction of emitted dose of the formulations investigated in the current 
study on Rotahaler and Handihaler are plotted against the percentage of particles finer 
than 4.5 µm present in the carrier in Figure 4.18. It can be observed that with both the 
devices a weak correlation between the proportion of fines and the FPFED existed when 
the proportion of the fines was below ~17%. The data at lower fines concentrations were 
more scattered for Handihaler than for Rotahaler. Various previous studies have reported 
a correlation between the proportion of fines present in the carrier and the DPI 
performance. Some of these studies were conducted using Rotahaler (Adi et al. 2009; 
Louey et al. 2003). However, linear correlations between the FPF and fines content of the 
carriers have also been observed with other devices, such as Monohaler (Guenette et al. 
2009). 
 
Figure 4.18 shows that, with both devices, the fine particle delivery performance of 
budesonide from the formulations reached a maximum with the addition of 10 wt-% LH300 
fines, with 17.4% of the particles in the carrier less than 4.5 μm. Using the 20 wt-% LH300 
pre-blend containing 23% of particles finer than 4.5 μm led to a decrease in the FPFED 
with both devices. These data are in agreement with a previous study, where the addition 
of 10 wt-% was reported as the optimum concentration of micronised fines, and where 
higher lactose fines concentrations decreased performance (Louey et al. 2003). In their 
study, the observed behaviour was attributed to the dilution of the drug in the 
agglomerates formed between the lactose fines and the drug when the lactose fines 
concentrations were higher. Similar observations were also made by Young et al.(2011), 
who attributed the decrease to the segregation of the formulation in the presence of 
excess fines. 
It is also important to note from Figure 4.18 that the relationship between the proportion of 
fine particles present in the carrier and  DPI performance was not affected by the process 
history (micronised vs. milled) of the added fine component. 
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Rotahaler 
Handihaler 
FIGURE 4.18 THE RELATIONSHIP BETWEEN THE PROPORTION OF FINE PARTICLE LACTOSE (<4.5 µm) AND 
THE DPI PERFORMANCE IN TERMS OF FINE PARTICLE FRACTION OF EMITTED DOSE (FPFED) FOR 
ROTAHALER (TOP) AND HANDIHALER (BOTTOM). THE DATA FOR FPFED REPRESENTS MEAN ± STANDARD 
DEVIATION (N=3) AND THE DATA FOR PROPORTION OF PARTICLES FINER THAN 4.5 µm THE MEAN FROM 
FIVE REPEATED MEASUREMENTS. 
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Fluidisation of the DPI formulation is a key step in delivering the API to the patient’s lungs. 
Therefore, the fluidisation properties of the carrier pre-blend, which forms the bulk of the 
DPI formulations, are anticipated to give information on the aerosolisation efficiency of the 
DPI formulations. It has already been shown by Shur et al. (2008a) and Pitchayajittipong 
et al. (2010) that in some cases the fluidisation energy of the carrier lactose correlates 
with the performance of DPI model formulations.  
The FPFED of the formulations used in the current study were plotted against the 
fluidization energy of the carrier blend for each of the formulations and shown in Figure 
4.19. In the case of the addition of micronised fines (LH300), there was a linear 
relationship between the energy required to fluidise the formulation and the fine particle 
fraction delivered up to 10 wt-% fines concentration with both the Rotahaler and the 
Handihaler. However, at 20 wt-% concentration, despite the increase in the fluidisation 
energy, the fine particle fraction decreased. Figure 4.19 also shows that with the milled 
fines (LH230 and LH210) the response between the FPFED and the fluidisation energy 
was linear with both the Rotahaler and the Handihaler. Figure 4.19 shows that for the 
milled fines an increase in the fluidisation energy only corresponded to a very slight 
improvement in the performance.  
The process of delivering the medication to the patient’s lungs from a DPI formulation 
involves fluidisation, entrainment and deagglomeration of the formulation. Gac et al. 
(2008) showed that the energy required to achieve de-agglomeration of the DPI 
formulation is higher than the energy required to fluidise the formulation. Therefore, it is 
not surprising that the fluidisation energy fails to predict the DPI performance of the 
formulations over a wide range of different fines concentrations and types of fines. 
However, the current study has shown that although a universal correlation between the 
fluidisation energy and DPI performance is not possible correlations do exist over certain 
ranges. Therefore, fluidisation properties may be suitable for predicting the DPI 
performance for a less variable set of carriers, such as for investigation of batch to batch 
variability of processed lactose. 
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Rotahaler – LH300 Rotahaler – LH230 and LH210 
Handihaler – LH300 Handihaler- LH230 and LH210 
FIGURE 4.19 THE RELATIONSHIP BETWEEN THE NORMALISED FLUIDISATION ENERGY (FENORM) OF THE 
CARRIER PRE-BLENDS AND THE DPI PERFORMANCE IN TERMS OF FINE PARTICLE FRACTION OF EMITTED 
DOSE (FPFED) FROM FORMULATIONS PREPARED WITH DIFFERENT FINES AND AEROSOLISED WITH 
DIFFERENT DEVICES. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, n=3. 
 
 
 Microstructure of the formulations prepared with the different fines 4.3.7
 
Due to the different components of dry powder inhaler formulations (drug + fines + coarse 
carrier), the resulting powders are complex. An added complication is the device used for 
delivering the dose. Therefore, achieving a complete understanding of the detachment 
and deagglomeration of the drug from DPI products has proved to be difficult. Recent 
research has concentrated on understanding the powder microstructure and the resulting 
deagglomeration mechanisms (Behara et al. 2011b). This study showed that blending 
different concentrations of micronised lactose with micronised drug altered the structure 
and the deagglomeration mechanism of the resulting blends. However, the model 
formulations in this study did not contain the coarse lactose carrier component. Thus, the 
applicability of these findings to the current research problem is questionable, because 
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both the fluidisation properties and the microstructure of the formulations will be 
significantly different due to the presence of the large carrier component.  
A schematic of the microstructure of the formulations in the current study is presented in  
Figure 4.20. The in vitro data suggests that improved performance can be easily obtained 
by the addition of micronised fines. However, improved performance was also achieved 
when the finer of the milled fines was present in a large concentration, so that the 
proportion of the fine particle lactose was sufficient to achieve agglomerate formation. 
SEM images (Figures 4.4, 4.5 and 4.6) of these formulation blends with budesonide 
support the theory of agglomerate formation.  
From findings presented in this chapter, the following hypothesis on the action of the 
different fines is presented. With micronised fines, agglomerates between the drug and 
the lactose fines are formed readily due to the large number of lactose fines present 
already at low concentrations. With milled fines at low concentrations, not a high enough 
proportion of the fine particle lactose is present in the formulation. Therefore, agglomerate 
formation cannot take place. Instead, the drug particles are distributed on the surfaces of 
the medium sized fines (>15um) and the coarse carrier particles. The deagglomeration 
efficiency of the drug from these particles is thought to be low. Therefore, low DPI 
performance is obtained from these formulations, with a large proportion of the drug 
deposited in the pre-separator. However, if the concentration of the milled component is 
increased, the proportion of the finest lactose in the carrier may become sufficient to 
achieve agglomerate formation with the finer sized particles which are co-delivered as an 
agglomerate within the in vitro apparatus. Consequentially, increased DPI performance 
can be achieved from formulations prepared with milled fines.   
FIGURE 4.20 SCHEMATIC OF THE MICROSTRUCTURE OF THE FORMULATIONS CONTAINING MICRONISED
FINES (TOP) AND MILLED FINES AT LOW (MIDDLE) AND HIGH (BOTTOM) CONCENTRATIONS, AND THE IMPACT
OF THE MICROSTRUCTURE ON THE DPI PERFORMANCE. BLUE SHADES REPRESENT DIFFERENT SIZE
LACTOSE (LARGE, INTERMEDIATE AND FINES) AND PINK REPRESENTS DRUG PARTICLES 
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4.4 CONCLUSIONS 
This chapter investigated the role of drug-fines agglomerate formation and increased 
cohesion in improving the DPI performance. The data showed that the addition of lactose 
fines increased the cohesion of the bulk powder. The increase in cohesion was 
determined by the presence of lactose fines <30 µm. However, despite previous studies 
showing promising preliminary results for using the flow properties of the carrier for 
predicting the performance of DPI formulations for simple series of lactose carriers 
(Pitchayajittipong et al. 2010; Shur et al. 2008a), no direct correlation between any of the 
parameters describing powder flow and fluidisation properties and the final DPI 
performance could be established in this study for a more diverse set of carriers. 
Therefore, increasing powder cohesion upon the addition fines in improving the DPI 
performance is unlikely to explain the phenomenon.  However, that said, various linear 
sub-correlations were seen within the current dataset between the fluidisation properties 
and the formulation performance. Therefore, the flow and fluidisation properties are still 
likely to be able to differentiate between carriers that are similar in terms of particle size 
but would produce a slightly different performance. Thus, the characterisation of 
fluidisation and flow properties of the lactose carriers used in routine DPI manufacturing is 
recommended.  
The results of this chapter indicated that drug-fines agglomerate formation is likely to play 
a major role in determining DPI performance. The SEM images of the carrier blends 
indicated that agglomerate formation took place once a high enough fines concentration 
was available. Unfortunately the bulk powder characterisation techniques available are not 
able to investigate the micro-structure of agglomerate formation. However, significant 
improvements in the DPI performance for the different formulation series coincided with 
the concentration where agglomerate formation was visible in the SEM images. The 
agglomerate formation theory is further supported by the fact that for LH210, for which no 
agglomerate formation was seen in the SEM images, the DPI performance did not 
significantly improve over a range of concentrations of the milled fines.  
One of the objectives of the current study was to find parameters that would enable 
quality-by-design approach for DPI manufacturing. Various different parameters 
describing properties of the lactose pre-blends were characterised with the aim of finding 
a parameter that could be used as a tool for accepting or rejecting excipient batches for 
DPI product manufacturing. However, none of the parameters characterised during the 
current study were able to predict the performance of DPI formulations uniformly, when 
such a large and variable set of carriers was used. In the next chapter, multivariate 
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statistical analysis tools and artificial neural networks are used for establishing a more 
complete understanding of the lactose characteristics that govern the DPI performance. 
181 
 
CHAPTER 5 STATISTICAL METHODS AND ARTIFICIAL NEURAL 
NETWORKS AS TOOLS FOR UNDERSTANDING THE MECHANISMS 
GOVERNING DRY POWDER INHALER PERFORMANCE 
5.1 INTRODUCTION 
 
Establishing a structure-function relationship that would allow predicting the formulation 
performance for DPI formulations on the basis of the properties of the formulation 
components has proved to be a challenging task. This is most likely due to the batch 
process nature of the manufacturing operations of the drug, the excipients and the 
formulations themselves (de Boer et al. 2012). A small change in one of the raw materials 
or the process parameters during the manufacturing process of the materials or the 
formulation can dramatically change the performance attributes of the final product (de 
Boer et al. 2012). However, despite the incomplete understanding of the mechanisms 
governing the DPI performance, the physical and physicochemical properties of the drug 
and the excipient are extensively characterised prior to the formulation process to pinpoint 
raw materials that may possibly lead to a rejected final product.   
 
There are a number of different lactose characteristics that have been shown to 
correspond to the final DPI product performance. These properties include, for example, 
surface energy of the lactose measured by inverse gas chromatography (Tong et al. 
2006), the specific surface area of the carrier (Kawashima et al. 1998), the fine particle 
content of the carrier (Islam et al. 2004; Louey et al. 2003) and the energy required to 
fluidise the carrier (Pitchayajittipong et al. 2010). These studies proposed, based on 
relatively small datasets, that there exists a relationship between a single parameter 
describing the lactose properties and the DPI performance. However, the data presented 
in Chapter 4 of the current thesis indicated that the relationships between the lactose 
properties and the DPI performance do not necessarily follow simple linear correlations 
when a diverse range of lactose carriers and fines are used in the formulations.  
 
Another potential reason for the lack of a structure-function relationship describing the DPI 
performance is the limited understanding of the mechanisms governing the drug 
detachment, deagglomeration and fine particle delivery from these formulations. The 
current study aims to address the gap in this knowledge from the point of view of the 
lactose carrier. To illustrate the fundamental problem formulators are facing when trying to 
link the lactose carrier properties to the formulation performance, the manufacturing 
process of the lactose carrier blends should be considered. When the lactose grades for 
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DPI formulations are manufactured by the means of air classification, blending, milling or 
sieving (Guenette et al. 2009), the control over the physical and physicochemical 
properties of the resulting carrier blend is very limited. Other physical and 
physicochemical properties of the lactose blends also change upon the increasing lactose 
fines concentration (Guenette et al. 2009). Due to the covariant nature of the different 
parameters, finding a single parameter describing the lactose carrier that could be used 
for predicting the DPI performance by using linear correlations is very unlikely. Instead, 
efforts need to be concentrated on understanding more complex relationships relating to 
the lactose carrier that govern the DPI performance.  
Podczeck (1998) was an early researcher who recognised the need for more complex 
statistical analysis methods for understanding the structure-function relationship in DPI 
formulations. This was followed by the studies of Zeng et al. (2000a), who established a 
two parameter model for the fine particle delivery from DPI formulations based on 
parameters describing shape of the carrier particles. In both these studies, multiple linear 
regression (MLR) was used for establishing the relationship between the lactose 
properties and the DPI formulation performance. MLR is an extension of linear correlation, 
where the relationship between the response and various factors is determined 
simultaneously (Rajalahti et al. 2011). The method is based on the assumptions that the 
underlying relationships are linear and that the input parameters are not co-linear. 
However, as pointed out by Rajalahti et al. (2011), controlling the input variables so that 
co-linearity would be avoided is difficult unless experimental design is applied. Therefore, 
due to the lack of control in the resulting physical properties upon the preparation of the 
carriers for inhalation as discussed above, the method is unlikely to be suitable for 
analysing structure-function relationships in DPI formulations. 
Partial least squares (PLS) regression analysis was developed for analysing biased data 
and therefore the method is applicable for cases where the factors are highly correlated 
(Rajalahti et al. 2011). As discussed above, this is the case for the parameters describing 
the carriers used in DPI formulations. The PLS method is based on reducing the input 
parameters to a set of uncorrelated components. These components describe the 
underlying structure of the dataset (Rajalahti et al. 2011). PLS analysis reports the 
importance of the different parameters within the components in the form of standardised 
coefficients (Rantanen et al. 2004). These coefficients give information on the relative 
importance of the different variables within the model, and have been used, for example, 
to gain an understanding of the mechanisms governing granulation processes (Rantanen 
et al. 2004).  
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Computers are superior to the human brain in numerical computation and symbol 
manipulation. However, the human brains’ capability of learning, adapting and tolerating 
faulty or noisy data is not incorporated in a modern computer (Jain et al. 1996). Artificial 
neural networks (ANNs) are computational tools that aim to combine the superior 
properties of both computers and the human brain (Jain et al. 1996). The concept of 
artificial neural networks is loosely based on what is known of the operation of biological 
nerve cells and how they connect to form the nervous system (Basheer et al. 2000). A 
schematic presentation of a biological neuron is shown in Figure 5.1. According to 
Basheer et al. (2000), the information is mediated in a nerve cell by electrical impulses 
that are brought to the cell body by the dendrites. The nucleus located in the cell body 
determines whether the signal received from the dendrites is strong enough to be 
forwarded along the axon. When the signal reaches the synapse in the end of an all axon, 
neurotransmitters are emitted. These substances diffuse across the synaptic gap and are 
received by the dendrites in the adjacent neurons, causing a synaptic response. The 
response is not linear as a function of the neurotransmitter concentration, but all or 
nothing response based on exceeding a threshold concentration of neurotransmitters. The 
response can also either be inhibitory or exhibitory (Basheer et al. 2000). The simplest 
neural network, called the perceptron, is analogous to a biological neuron (Jain et al. 
1996). The structure of a perceptron is illustrated in the schematic shown in Figure 5.2. In 
a perceptron, the nodes represent the dendrites and axons. The connection weights (w) 
are the synapses. The activation function (Σ) corresponds to the cell body by adding up 
the connection weights. The threshold function f(Σ) mimics the nucleus by determining 
whether the intensity of the signal received is strong enough to initiate output (Agatonovic-
Kustrin et al. 2000; Basheer et al. 2000; Jain et al. 1996). These basic units of artificial 
intelligence can be combined to form extensive networks. Feed forward networks are the 
most commonly used ANNs (Svozil et al. 1997). A schematic of a three layer feed forward 
network is shown in Figure 5.3. Any feed forward ANN consists of an input layer, at least 
one hidden layer and an output layer. In a feed forward network, each neuron in a certain 
layer is connected with all the neurons in the adjacent layers. No connections between 
neurons within a layer are allowed (Svozil et al. 1997).  
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FIGURE 5.1 SCHEMATIC PRESENTATION OF A BIOLOGICAL NEURON 
 
 
FIGURE 5.2 SCHEMATIC PRESENTATION OF A PERCEPTRON WITH INPUTS (1, 2, ..n) AND THE CONNECTIONS 
(W1, W2, Wn) FROM THE INPUTS TO THE NEURON IN THE HIDDEN LAYER WHERE THE SUM OF THE 
CONNECTION WEIGHTS (Σ) IS CALCULATED AND PASSED TO THE THRESHOLD FUNCTION f(Σ) TO DETERMINE 
WHETHER OUTPUT IS CALCULATED 
 
 
FIGURE 5.3 SCHEMATIC PRESENTATION OF A FEED FORWARD NETWORK CONSISTING OF INPUT, HIDDEN 
AND OUTPUT LAYERS 
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Modelling data using ANNs is based on presenting the data to the network and training 
the network to recognise the underlying trends in the dataset (Jain et al. 1996). The 
training can either be supervised or unsupervised (Jain et al. 1996; Svozil et al. 1997). In 
unsupervised learning, data patterns, instead of the output data, are presented to the 
network. The network is expected to learn data based on data patterns presented to it 
(Svozil et al. 1997). In supervised learning, output data is presented to the network and 
the weights between the connections are adjusted so that the desired output is reached 
(Svozil et al. 1997). Various network training algorithms are available for learning the 
underlying data (Jain et al. 1996). A brief introduction to supervised learning using feed 
forward networks and backpropagation learning algorithms is discussed below. 
 
Before data is presented to the network, input and output values are normalised so that all 
the inputs have equal ranges. This is done to avoid any parameters with larger values 
from dominating the input and output values and consequentially saturating the hidden 
nodes (Basheer et al. 2000). To train the network, the dataset is divided into training, 
validation and test subsets (Basheer et al. 2000). In backpropagation training, the 
connection weights are adjusted and the signal is sent towards the output layer of the 
network. The errors between the actual and predicted output are then computed and the 
connection weights are adjusted based on the backward feedback on the network error 
(Basheer et al. 2000). The process of network training using the backpropagation training 
algorithm is illustrated in detail in the schematic shown in Figure 5.4. At first, the 
connection weights are randomly initialised and the sum of the connection weights (Σ) 
then computed. If the sum of the connection weights does not exceed the transfer function 
f(Σ), the weights are re-adjusted and the cycle is restarted (Agatonovic-Kustrin et al. 
2000). However, if the sum of the connection weights is larger than the transfer function, 
the data is passed onward to compute the error between the target and the computed 
output (Agatonovic-Kustrin et al. 2000). Computing the network error is often done by the 
sum of squares method (Basheer et al. 2000). The decrease in the network error for 
training and test sets during the training cycles is monitored as illustrated in Figure 5.5. 
The network error initially decreases rapidly for both the sets as training cycles are 
performed. This is because the network is learning the underlying patterns in the dataset. 
However, the decrease in the error slows down for the training set as the number of 
training cycles is increased. This is because the network may start memorising or over-
fitting the data when the number of training cycles is high enough (Basheer et al. 2000). 
The optimum network is achieved when the error for the test set reaches a minimum 
(Basheer et al. 2000), as illustrated in Figure 5.5. The connection weights are adjusted by 
an amount defined by the learning rate (η) until the optimum network is identified and then 
retrieved (Basheer et al. 2000). Another critical parameter for network training is the 
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momentum (µ), which prevents the network error from getting stuck in a local minimum 
during the training cycles (Basheer et al. 2000).  
Once the network has been trained, the generalisation capacity of the network can be 
verified by inspecting the measured output against the output predicted by the network as 
illustrated in Figure 5.6. A network that is capable of generalising data does not exhibit 
fluctuations over the range of measured output values in a way that an over trained 
network would (Basheer et al. 2000). The likelihood of network overtraining can be 
reduced by reducing the number of hidden nodes in the network (Basheer et al. 2000). As 
the number of hidden nodes in a neural network is often based on trial and error, these 
data are useful in determining whether the optimum number of hidden nodes is applied in 
the network design (Basheer et al. 2000). 
FIGURE 5.4 THE PROCESS OF TRAINING A FEED FORWARD BACKPROPAGATION NEURAL NETWORK 
FIGURE 5.5 THE REDUCTION OF ERROR DURING NETWORK TRAINING FOR THE TRAINING SET (SOLID CURVE)
AND FOR THE TEST SET (DOTTED CURVE).  THE OPTIMUM NETWORK HAS BEEN REACHED WHEN THE ERROR
FOR THE TEST SET STARTS INCREASING 
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FIGURE 5.6 NETWORK THAT IS ABLE TO GENERALISE THE DATA (SOLID CURVE) AND AN OVER TRAINED 
NETWORK THAT HAS OVER LEARNED THE DATA (DOTTED CURVE) 
 
ANNs are a popular data analysis tool in pharmaceutical applications. Studies where 
ANNs have been used include, for example, relating the flow properties of excipients to 
the micromeritic properties of the materials (Kachrimanis et al. 2003), modelling drug 
dissolution (Mendyk et al. 2005), optimising formulations for controlled release tablets 
(Barmpalexis et al. 2011) and transdermal drug delivery products (Takayama et al. 1999) 
However, to date, the application of neural network analysis in inhalation-related research 
problems has been limited. To the author’s best knowledge, the only investigators who 
have applied ANNs for inhalation research is De Matas et al., who used ANNs for 
modelling in vivo - in vitro correlations for inhalation formulations (2008), and the clinical 
effect of inhaled bronchodilators (2010).  
 
The aim of the current study was to establish functional relationships between different 
lactose properties and DPI performance. This was done by using different statistical 
methods and artificial neural network analysis in parallel for determining the most 
important lactose characteristics in governing the DPI performance. The functional 
relationships were not only established between the lactose properties and the 
performance in terms of fine particle delivery, but also in terms of drug de-agglomeration 
and detachment from the large carrier crystals. In addition to establishing a universal 
correlation between lactose properties and the formulation performance, the results of the 
current study were used for building an understanding of the mechanisms for how lactose 
fines govern the DPI performance.  
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5.2 MATERIALS AND METHODS 
 
Three different coarse lactose carriers and four different fine particle lactose products 
were used in the study. Two of the coarse carriers were Lactohale (LH) products, namely 
LH100 (Sieved coarse grade) and LH206 (Lightly milled coarse grade). The third coarse 
carrier was SV010 (Sieved coarse grade). Three of the fine particle lactose fractions were 
also Lactohale grades, namely LH300 (micronised fines), LH230 (finer milled fines) and 
LH210 (coarser milled fines). All the Lactohale products were donated by DFE Pharma 
(Borculo, Netherlands). The fourth fine particle lactose grade used was Sorbolac 400 from 
Meggle (Germany).   
 
Carrier lactose pre-blends were prepared by blending the different fine fractions of lactose 
with the coarse carriers at 2.5, 5, 10 and 20 wt-% concentrations according to Table 5.1. 
The mixing procedure was as described in Chapter 4 of the thesis. Similarly, the particle 
size distributions and flow and fluidisation properties of the prepared lactose pre-blends 
were characterised as described in Chapter 4. The only parameter describing powder flow 
that was not introduced in Chapter 4 and is used in the current study is the specific energy 
(SE). This parameter is based on the force and torque measured on the Freeman 
Technology FT4 powder rheometer during upward blade motion. The specific energy (SE) 
value describes the flow properties of the powders in a stress free state at near zero 
consolidation due to the lack of the downward pressing force of the blade (Freeman 
2007). 
 
The preparation of the budesonide DPI formulations and assessment of in vitro 
performance were performed as described in Chapter 4. However, the DPI device used 
for aerosolising the formulations was Cyclohaler (Teva Pharmaceuticals, Netherlands). 
The flow rate used for aerosolising the formulation was 90 l/min with a duration of 2.7 
seconds. 
 
Linear correlations between the physical properties of the lactose carriers and the DPI 
performance of the formulations were established using the Minitab version 15 statistical 
analysis package (Minitab Ltd, Coventry, UK). Partial least squares (PLS) analysis was 
also performed using the Minitab version 15 statistical analysis package (Minitab Ltd, 
Coventry, UK). No cross validation was used and the number of components was 
specified at 10.  
 
The artificial neural network analysis of the data was performed using Alyuda 
Neurointelligence software (Alyuda Neurointelligence, California, USA). The input data 
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were pre-processed using the pre-processing function of the software so that the range of 
input values were within the range of [-1…1] and output values within the range of [0…1]. 
The dataset was partitioned into training, test and validation sets so that 27 records (70%) 
were in the training set and 6 in the validation and test sets each (15% each). A batch 
back-propagation training algorithm was used for the network training. The network 
architecture was selected manually as 12-4-1 for fine particle fraction of emitted dose and 
12-5-1 for mean mass aerodynamic diameter and pre-separator deposition. The selection 
of the network architecture was made based on achieving a network with the optimum 
generalisation capacity (see Figure 5.6). The logistic transfer function (Benitez et al. 1997) 
and sum of squares error function (Aitkin et al. 2003) were used for determining the firing 
intensity of a neuron and the error between the actual and predicted output, respectively. 
For all the networks, a momentum of 0.9 was used. The learning rate was set to 0.1 for 
the ANN modelling of the fine particle fraction of the emitted dose and pre-separator 
deposition, and 0.25 for the ANN modelling of the mean mass aerodynamic diameter. In 
all cases, network training was stopped by error change when the mean square error of 
the network or the dataset error over 10 training cycles changed by less than 0.0000001.  
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TABLE 5.1 SUMMARY OF THE COARSE AND FINE LACTOSE COMPONENTS USED FOR PREPARING THE 
CARRIER PRE-BLENDS USED IN THE CURRENT STUDY AND THE PROCESS HISTORY AND THE 
CONCENTRATIONS OF THE FINES PRESENT IN THE DIFFERENT PRE-BLENDS 
Carrier ID Coarse fraction 
Type of 
Fines Fines 
Wt-% 
fines 
1 LH100 - - 0 
2 LH100 Micronised LH300 2.5 
3 LH100 Micronised LH300 5 
4 LH100 Micronised LH300 10 
5 LH100 Micronised LH300 20 
6 LH100 Milled LH230 2.5 
7 LH100 Milled LH230 5 
8 LH100 Milled LH230 10 
9 LH100 Milled LH230 20 
10 LH100 Milled LH210 2.5 
11 LH100 Milled LH210 5 
12 LH100 Milled LH210 10 
13 LH100 Milled LH210 20 
14 LH100 Milled Sorbolac 400 2.5 
15 LH100 Milled Sorbolac 400 5 
16 LH100 Milled Sorbolac 400 10 
17 LH100 Milled Sorbolac 400 20 
18 LH206 - - 0 
19 LH206 Micronised LH300 2.5 
20 LH206 Micronised LH300 5 
21 LH206 Micronised LH300 10 
22 LH206 Micronised LH300 20 
23 LH206 Milled LH230 2.5 
24 LH206 Milled LH230 5 
25 LH206 Milled LH230 10 
26 LH206 Milled LH230 20 
27 LH206 Milled LH210 2.5 
28 LH206 Milled LH210 5 
29 LH206 Milled LH210 10 
30 LH206 Milled LH210 20 
31 SV010 - - 0 
32 SV010 Micronised LH300 2.5 
33 SV010 Micronised LH300 5 
34 SV010 Micronised LH300 10 
35 SV010 Micronised LH300 20 
36 SV010 Milled LH210 2.5 
37 SV010 Milled LH210 5 
38 SV010 Milled LH210 10 
39 SV010 Milled LH210 20 
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5.3 RESULTS AND DISCUSSION 
5.3.1 Characterisation of the physical properties of the carriers 
 
The particle size distributions of the pre-blends are summarised in Table 5.2. The table 
demonstrates that the proportion of fines below 4.5 µm ranged from 1.3% for blend #1 to 
approximately 23% for blend #5. The three blends with the highest proportion of fines 
below 4.5 µm were the blends #5, #22 and #35. The proportion of fines below 4.5 µm for 
these carriers was between 22 and 23%. All these carriers were prepared with 20 wt-% of 
the micronised fines LH300. Table 5.2 also shows that the range of values measured for 
the proportion of particles finer than 15 µm ranged approximately from 2.5 to 40% and 
approximately from 3.8 to 43% for the proportion of particles finer than 30 µm. The 
similarity of the ranges for these two parameters indicated that the majority of the particles 
added to the carriers upon the addition of fines were finer than 15 µm. The values of d10 
of the carrier blends varied between 1.7 and 50 µm. 
 
The bulk, flow and fluidisation properties of the carrier blends are summarised in Table 
5.3. The bulk densities of the pre-blends spanned from 0.560 (Blend #9) to 0.747 g/ml 
(Blend #1) and tapped densities from 0.845 (Blend #31) to 0.893 g/ml (Blend #17). The 
values of Hausner ratio for the pre-blends varied between 1.135 (Blend #18) and 1.537 
(Blend #26). The factor linking these observations was that the carriers with the highest 
bulk density and lowest tapped density and Hausner ratio did not contain any added fines. 
On the other hand, the blends with the lowest bulk density and highest tapped density and 
Hausner ratio were prepared with 20 wt-% LH230 or Sorbolac 400.  
 
Table 5.3 shows that the values of BFENorm for the carrier blends varied between 9.55 
(Blend #34) and 26.03 mJ/g (Blend #31). The DFI for blend #31 was the largest at 51 
whereas the lowest DFI of 4.96 was recorded for blend #22. The values of FRI ranged 
between 1.02 for blend #1 and 2.41 for blend #35. Blend #1 also had the lowest FENorm of 
0.7 mJ/g. Blends #9 and #21 had the highest FENorm of 1.93. Blends #1 and 31, which 
were the least cohesive according to the parameters discussed above, contained no 
added fines. Blends #34, #22, #35, #9 and #21 on the other hand were characterised as 
the most cohesive according to these parameters. All of these blends contained at least 
10 wt-% of added fines. Specific energy (SE) was included in the study due to a clear 
increasing trend upon the addition of fines when SV010 was used as the coarse fraction 
(Blends #31 to #39). The values of SE for the carriers in the current study ranged from 
5.58 mJ/g for Blend #18 to 6.59 mJ/g for Blend #24.  
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TABLE 5.2 SUMMARY OF PARTICLE SIZE OF THE CARRIER PRE-BLENDS IN TERMS  PROPORTION OF FINES 
BELOW 4.5, 15 AND 30 µM AND THE 10TH PERCENTILE OF DENSITY DISTRIBUTION (d10). THE VALUES 
SHOWN ARE AVERAGES FROM FIVE REPEATED MEASUREMENTS. 
Carrier  
ID 
<4.5 µm 
(%) 
<15 µm 
(%) 
<30 µm 
(%) 
d10 
(µm) 
1 1.29 3.02 6.24 44.30 
2 4.88 8.25 11.48 23.44 
3 9.34 13.94 17.03 5.22 
4 17.43 24.52 26.97 2.08 
5 23.04 40.24 42.75 1.73 
6 2.76 6.70 10.95 26.41 
7 4.32 10.15 15.13 14.70 
8 7.23 16.78 23.23 7.33 
9 12.47 28.93 38.15 3.26 
10 1.98 5.14 9.56 31.53 
11 2.62 6.78 12.27 23.63 
12 4.08 10.44 17.89 14.25 
13 6.02 15.91 26.79 8.72 
14 2.37 6.23 10.05 29.77 
15 3.32 9.20 13.81 17.01 
16 5.88 15.60 21.72 8.68 
17 10.20 27.62 36.70 4.39 
18 2.44 2.54 3.81 49.78 
19 6.13 8.11 9.27 34.3 
20 10.42 13.76 14.80 4.11 
21 18.16 24.42 25.24 1.95 
22 22.43 39.53 40.60 1.8 
23 3.69 6.49 8.69 36.76 
24 5.29 9.99 13.01 15.08 
25 8.04 16.30 20.79 6.74 
26 12.40 27.77 35.18 3.28 
27 3.45 5.50 7.91 38.48 
28 3.66 6.74 10.21 29.09 
29 5.05 10.51 16.23 13.97 
30 7.01 16.79 26.57 7.67 
31 1.55 3.03 5.19 49.61 
32 3.17 6.23 8.07 40.48 
33 6.51 11.75 13.57 9.18 
34 12.08 21.08 22.61 3.49 
35 22.47 38.05 39.33 1.74 
36 2.01 4.41 7.46 40.97 
37 2.57 6.03 10.16 29.42 
38 3.63 9.29 15.53 16.54 
39 6.53 16.38 26.27 8.13 
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TABLE 5.3 FLOW AND FLUIDISATION PROPERTIES OF THE CARRIER PRE-BLENDS IN TERMS OF BULK AND 
TAPPED DENSITIES, HAUSNER RATIO, BASIC FLOW ENERGY (BFENorm), DYNAMIC FLOW INDEX (DFI), FLOW 
RATE INDEX (FRI), NORMALISED FLUIDISATION ENERGY (FENorm) AND SPECIFIC ENERGY (SE). THE VALUES 
SHOWN ARE AVERAGES FROM THREE REPEATED MEASUREMENTS  
 
Carrier 
ID 
Bulk 
density 
(g/ml) 
Tapped 
density 
(g/ml) 
Hausner 
ratio 
BFENorm 
(mJ/g) DFI FRI 
FENorm 
(mJ/g) 
SE 
(mJ/g) 
1 0.747 0.855 1.159 25.12 37.37 1.02 0.70 6.02 
2 0.727 0.854 1.224 22.06 27.90 1.10 0.84 5.84 
3 0.699 0.847 1.250 20.34 16.61 1.19 1.23 6.06 
4 0.667 0.860 1.380 15.68 10.87 1.52 1.44 6.25 
5 0.681 0.869 1.464 9.93 5.69 2.41 1.75 6.27 
6 0.709 0.865 1.216 21.65 24.07 1.06 0.95 6.14 
7 0.676 0.866 1.252 19.37 18.49 1.09 1.12 6.12 
8 0.645 0.880 1.358 16.07 10.74 1.29 1.54 6.10 
9 0.560 0.867 1.474 10.52 6.15 1.81 1.93 5.66 
10 0.731 0.863 1.183 23.48 31.39 1.03 0.78 5.96 
11 0.711 0.872 1.221 21.11 21.14 1.06 1.00 6.00 
12 0.699 0.881 1.264 19.54 19.56 1.14 1.04 6.08 
13 0.621 0.882 1.369 13.24 9.21 1.41 1.60 5.85 
14 0.703 0.859 1.223 21.26 24.92 1.08 1.01 5.87 
15 0.695 0.871 1.254 20.23 18.91 1.13 1.17 6.13 
16 0.669 0.883 1.319 16.95 13.68 1.25 1.33 6.26 
17 0.625 0.893 1.428 11.81 8.52 1.88 1.44 6.26 
18 0.744 0.861 1.135 22.67 30.23 1.08 0.82 5.58 
19 0.708 0.854 1.206 19.85 17.55 1.10 1.14 5.94 
20 0.668 0.857 1.284 17.60 11.74 1.16 1.53 6.09 
21 0.613 0.856 1.396 15.65 8.02 1.42 1.93 6.29 
22 0.604 0.875 1.449 9.96 4.96 2.27 1.88 6.21 
23 0.725 0.881 1.214 21.00 23.78 1.08 0.93 6.20 
24 0.692 0.874 1.264 19.71 15.90 1.09 1.41 6.59 
25 0.663 0.877 1.324 15.75 10.55 1.27 1.56 6.29 
26 0.575 0.883 1.537 11.48 6.06 1.66 1.89 5.96 
27 0.733 0.869 1.186 21.47 28.66 1.05 0.81 5.68 
28 0.720 0.873 1.212 19.68 21.50 1.09 1.00 5.70 
29 0.683 0.879 1.288 17.36 15.27 1.15 1.22 5.99 
30 0.635 0.885 1.395 13.34 9.70 1.39 1.49 6.01 
31 0.729 0.845 1.158 26.03 51.02 1.11 0.57 5.74 
32 0.729 0.858 1.177 23.60 41.61 1.10 0.57 5.72 
33 0.703 0.849 1.209 20.74 17.52 1.15 1.14 5.99 
34 0.636 0.855 1.344 9.55 9.55 1.32 1.91 6.17 
35 0.599 0.861 1.438 10.18 6.39 2.45 1.57 6.19 
36 0.741 0.858 1.158 25.79 34.31 1.09 0.80 5.80 
37 0.725 0.865 1.193 22.83 31.65 1.10 0.78 5.76 
38 0.687 0.862 1.255 18.95 24.34 1.15 1.03 5.90 
39 0.645 0.887 1.375 15.35 10.63 1.43 1.52 6.21 
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5.3.2 In vitro testing of the formulations 
 
The in vitro performance of the formulations is summarised in Table 5.4 in terms of fine 
particle fraction of emitted dose (FPFED), mean mass aerodynamic diameter (MMAD) and 
the proportion of drug recovered from the pre-separator (PS of RD). The formulation 
performance ranged between an FPFED of 20.8% (Blend #31) and 46.9% (Blend #4). The 
MMAD of the drug collected from the stages was between 2.58 (Blend #1) and 3.51 µm 
(Blend #17). The proportion of drug recovered from the pre-separator varied between 
12.7% for Blend#5 and 42.9% for Blend #14. Blends #1and #31 contained no added fines. 
Blend #14 contained 2.5% of Sorbolac 400 resulting in a low proportion of fines (%<4.5 
µm = 2.37) within the carrier blend as indicated by Table 5.2. These blends produced the 
lowest FPFED, smallest MMAD and the highest proportion of drug deposited in the pre-
separator. Blends #4, #5 and #17 were at the other end of the spectrum. Blends #4 and 
#5 had high fine particle content with the proportion of particles finer than 4.5 µm 17.4 and 
23%, respectively.  
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TABLE 5.4 SUMMARY OF IN VITRO PERFORMANCE OF THE FORMULATIONS PREPARED WITH THE LACTOSE 
PRE-BLENDS AS THE CARRIER IN TERMS OF FINE PARTICLE FRACTION OF EMITTED DOSE (FPFED), MEAN 
MASS AERODYNAMIC DIAMETER (MMAD) AND THE PROPORTION OF TOTAL RECOVERED BUDESONIDE THAT 
WAS DEPOSITED IN THE PRE-SEPARATOR (PS OF RD). THE RESULTS SHOWN ARE AVERAGES FROM THREE 
REPEATED IN VITRO ASSESSMENTS. 
Carrier 
ID FPFED (%) 
MMAD 
(µm) 
PS of RD 
(%) 
1 24.10 2.58 38.23 
2 26.56 2.94 31.00 
3 35.78 3.04 21.17 
4 46.94 3.09 13.37 
5 39.74 3.36 12.74 
6 23.85 2.78 35.15 
7 25.32 3.00 31.68 
8 28.21 3.26 21.63 
9 35.95 3.25 15.42 
10 23.13 2.75 37.09 
11 24.14 2.85 33.94 
12 27.38 3.00 25.87 
13 26.63 3.14 23.97 
14 21.03 2.86 42.90 
15 22.08 2.92 37.80 
16 27.19 3.04 28.27 
17 26.90 3.51 20.47 
18 24.56 2.62 39.31 
19 32.49 2.81 27.04 
20 36.09 2.92 21.73 
21 44.71 3.19 13.63 
22 36.73 3.48 14.53 
23 25.50 2.78 32.30 
24 26.75 2.89 28.46 
25 28.69 3.15 23.31 
26 32.89 3.34 18.56 
27 23.28 2.70 38.94 
28 25.11 2.79 34.34 
29 24.33 2.88 30.23 
30 30.41 3.01 22.93 
31 20.82 2.65 44.25 
32 23.28 2.96 34.95 
33 30.63 3.04 27.09 
34 39.65 3.12 17.12 
35 35.15 3.40 13.84 
36 22.26 2.77 41.25 
37 23.05 2.91 40.17 
38 24.42 3.02 36.12 
39 25.52 3.01 23.49 
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5.3.3 Statistical analysis of the dataset 
5.3.3.1 Linear correlations between the physical properties of the carrier and 
the in vitro performance of the formulations 
 
Linear correlations have been previously observed between different parameters 
describing the lactose properties and the DPI performance with smaller datasets (Islam et 
al. 2004; Louey et al. 2003; Tong et al. 2006). Therefore, the first step in the pursuit of 
developing a universal model for predicting DPI performance based on the carrier 
properties and for understanding the mechanisms governing the DPI performance was to 
conduct statistical analysis for linear correlations. If a good linear correlation could be 
obtained between the fine particle delivery, deagglomeration and detachment 
characteristics of the formulations and the properties of the carriers, the prediction and 
understanding of the DPI formulation performance would be straightforward. In addition, 
having a single parameter describing the structure-function relationship between the 
carrier properties and the formulation performance would provide a simple quality-by-
design tool for excipient suppliers and pharmaceutical companies manufacturing 
inhalation products. 
 
The results of the analysis are summarised in Table 5.5. These data indicate that for 
predicting the fine particle fraction of emitted dose, the percentage of fine particle lactose 
<4.5 µm in the carrier produced the best linear correlation with a value 0.861. These data 
are in good agreement with studies published by various investigators where the 
proportion of lactose fines within the carrier was shown to correlate with the DPI 
performance (Guenette et al. 2009; Islam et al. 2004; Louey et al. 2003). It is also notable 
that in the current study the R2 value for the correlation between the particle size 
parameters decreased from 0.861 to 0.740 and 0.638 when the fine fractions were 
defined as %<4.5, %<15 and %<30 µm, respectively. These data are in agreement with a 
previous study where the finer fractions of lactose were seen to produce better 
correlations with the DPI performance than the larger size fractions (Adi et al. 2009).   
 
One of the theories explaining the improved DPI performance upon the addition of lactose 
fines is based on the increased cohesive strength of the bulk powder (Shur et al. 2008a). 
In Chapter 4 of the thesis, the increased cohesion of the carrier blend or the formulation 
itself was shown to correspond to an increased DPI performance in some cases. 
Increasing FENorm and FRI and decreasing BFENorm are measured for powders as they 
become more cohesive (Freeman 2007). The Hausner ratio on the other hand increases 
upon increasing cohesive strength of the powder (Shah et al. 2008). Table 5.5 shows that 
the FPFED had positive correlations of 0.748, 0.649 and 0.578 against FENorm, Hausner 
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ratio and FRI, in that order. The relationship between the BFENorm and FPFED was 
characterised by a negative correlation of -0.664. These results for the linear relationship 
between the different powder flow parameters and FPFED demonstrate that the more 
cohesive the carrier blend, the higher the performance. However, because the R2 values 
are relatively low, the linear models based on the flow and fluidisation properties are not 
capable of explaining the variation in the FPFED as well as the particle size parameters. 
Therefore, the correlation results between the FPFED and the different parameters 
describing the lactose carriers demonstrated that the presence of fine particle lactose was 
more essential for determining the DPI performance than the increase in the powder bulk 
cohesion induced by the addition of the fines.  
 
Table 5.5 demonstrates that the linear correlation between the MMAD and the proportion 
of fines below 30 µm was the highest with an R2 value of 0.924. A high R2 value of 0.907 
was also produced with the correlation between MMAD and the proportion of particles 
finer than 15 µm. These data indicate that the interaction of the drug with the larger fines 
is also an important factor to be taken into account in addition to the proportion of the 
finest particles when designing a powder formulation for inhalation. In fact, it has been 
previously suggested that the larger fines may act as secondary carriers (Adi et al. 2009). 
The results of the current data analysis support the hypothesis of the larger lactose fines 
acting as secondary carriers.   
 
The strongest correlation between the physical properties of the lactose blends and the 
pre-separator deposition was achieved for FENorm with a R2 value of -0.891. The 
parameters correlating the next best were %<15 µm and %<4.5 µm with values of -0.885 
and -0.882, correspondingly. These data may indicate that the drug detachment from the 
surface of the larger carrier crystals is possibly regulated by the fluidisation properties of 
the carrier. However, also the proportion of fine particles within the carrier is an important 
parameter in determining the drug detachment from the surface of the large carrier. 
However, as shown in Chapter 4 of the thesis, the fluidisation energy of a carrier was 
somewhat related to the fine particle content below 30 µm. Therefore, it is impossible to 
conclude by means of linear regression whether the proportion of fines or the fluidisation 
properties is the most important factor in governing the pre-separator deposition. 
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TABLE 5.5 COEFFICIENT OF CORRELATION FOR LINEAR RELATIONSHIPS BETWEEN THE DIFFERENT DPI 
PERFORMANCE MEASURES AND THE PROPERTIES OF THE LACTOSE PRE-BLENDS USED AS THE CARRIERS IN 
THE FORMULATIONS. THE CORRELATIONS ARE BASED ON THE AVERAGE VALUES REPORTED IN TABLES 
5.2, 5.3 AND 5.4. 
 Correlation coefficient 
 FPF of ED MMAD  PS of RD 
<4.5 µm 0.861 0.793 -0.882 
<15 µm 0.740 0.907 -0.885 
<30 µm 0.638 0.924 -0.862 
d10 -0.687 -0.839 0.867 
Bulk density  -0.589 -0.839 0.805 
Tapped density  -0.147 0.368 -0.226 
Hausner ratio 0.649 0.889 -0.866 
BFENorm -0.664 -0.864 0.872 
DFI -0.673 -0.784 0.870 
FRI 0.578 0.825 -0.741 
FENorm  0.748 0.800 -0.891 
SE  0.413 0.431 -0.533 
 
 
5.3.3.2 Partial least squares analysis of the dataset 
 
Partial least squares analysis was developed for statistical analysis of biased data 
(Rajalahti et al. 2011). The bias can for example be highly correlated input parameters 
(Rajalahti et al. 2011). This is often the case for the carriers used in DPI formulations, 
because the only controlled parameter during the manufacturing process is the proportion 
of fines. However, the other properties of the carriers, such as flow and fluidisation 
characteristics, are known to change upon the addition of fines (Chapter 4). Therefore, 
partial least squares analysis should be well suited for analysing the current dataset. 
 
The x-variance and R2 values describing the PLS models for the different DPI 
performance measures are summarised in Table 5.7. The x-variance parameter describes 
the extent to which the components of the PLS model fit the underlying variation in the 
input parameter values. It can be seen that the PLS models established have x-variance 
values higher than 0.99. This means that the components capture the variance in the 
input data well. The R2 value in PLS models describes the linearity between the 
components and the response. The R2 values for all the models are also listed in Table 
5.7. The linearity of the models is high with R2 values between 0.92 and 0.96.  
 
The coefficients reported by the PLS analysis describe the importance and the sign of the 
different input parameters in defining the components of the model (Rantanen et al. 2004).  
If the factors in the model have different units, as is the case in the current study, the 
standardised coefficient should be used instead. The standardised coefficients describe 
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how many standard deviations an output variable will change when per standard deviation 
increase in a predictor variable. The standardised coefficients for the different parameters 
describing the lactose carriers from the PLS analysis of the DPI formulation performance 
are summarised in Table 5.7. The standardised coefficients for the PLS analysis of FPFED 
are plotted in Figure 5.4. The most important parameters in the model are FRI, %<30 µm 
and %<4.5 µm. The standardised coefficients for these parameters were -1.88, 1.85 and 
1.57 respectively. These data indicate that the fine particle delivery from a DPI formulation 
is governed by a combination of the proportion of fines, the presence of larger fines and 
the cohesive properties of the carrier.   
 
For MMAD, the PLS model highlighted the %<15 µm as the most important parameter by 
far, as illustrated in Figure 5.8. The value of the standardised coefficient for this parameter 
was 2.75 as shown in Table 5.6. These data are in good agreement with the results of the 
linear regression analysis, as discussed above, and supports the theory of the larger fines 
acting as secondary carriers (Adi et al. 2009). 
 
Figure 5.8 shows that for the pre-separator deposition, the most important parameters in 
the PLS model were %<30 µm, FRI and %<4.5 µm.  Table 5.7 lists the values of PLS 
standardised coefficient for these parameters as -1.54, 1.15 and -0.93. Interestingly, the 
standardised coefficients for these parameters are roughly of equal magnitude but of 
opposite sign compared to the PLS coefficients for FPFED (Table 5.7 and Figure 5.6). This 
is a reassuring result, because the drug attached to the surface of the large carrier 
crystals will be deposited in the pre-separator and therefore will not contribute to the fine 
particle fraction. In contrast, the drug that has detached from the surface of the large 
carrier will contribute to the FPFED. Therefore, the lactose properties regulating the pre-
separator deposition and the FPFED should be the same, but of opposite direction.    
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TABLE 5.6 THE STANDARDISED COEFFICIENTS FOR THE DIFFERENT PHYSICAL PARAMETERS DESCRIBING 
THE LACTOSE CARRIERS IN THE PARTIAL LEAST SQUARES MODEL DEFINING DPI PERFORMANCE. THE 
PARAMETERS DESCRIBING HOW WELL THE DATA IS FITTED WITHIN THE MODEL ARE ALSO TABULATED (X-
VARIANCE AND R2).  THE CORRELATIONS WERE ESTABLISHED USING THE AVERAGE VALUES REPORTED IN 
TABLES 5.2, 5.3 AND 5.4. 
 Input FPFED MMAD PS of RD 
PLS 
Standardised 
coefficients 
%<4.5 1.57 -0.73 -0.93 
%<15 -0.21 2.75 0.17 
%<30 1.85 -0.25 -1.54 
d10 0.62 -0.34 -0.29 
Bulk density 0.21 -0.35 0.04 
Tapped density -0.34 0.12 0.11 
Hausner ratio -0.13 -0.47 0.32 
BFENorm -0.22 0.15 0.23 
DFI -0.35 0.03 0.31 
FRI -1.88 -0.62 1.15 
FENorm -0.20 -0.33 0.22 
SE 0.04 -0.07 -0.10 
Model  
parameters 
X-variance 0.9974 0.9962 0.9973 
R2 0.9632 0.9254 0.9366 
 
 
 
FIGURE 5.7 STANDARDISED COEFFICIENTS FOR THE DIFFERENT PARAMETERS FROM PARTIAL LEAST 
SQUARES ANALYSIS FOR FINE PARTICLE FRACTION OF EMITTED DOSE FOR BUDESONIDE 
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FIGURE 5.8 STANDARDISED COEFFICIENTS FOR THE DIFFERENT PARAMETERS FROM PARTIAL LEAST 
SQUARES ANALYSIS FOR MEAN MASS AERODYNAMIC DIAMETER OF BUDESONIDE 
 
FIGURE 5.9 STANDARDISED COEFFICIENTS FOR THE DIFFERENT PARAMETERS FROM PARTIAL LEAST 
SQUARES ANALYSIS FOR PRE-SEPARATOR DEPOSITION OF BUDESONIDE 
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5.3.4 Artificial neural network analysis of the dataset 
The training of the artificial neural network is of critical importance if a network with good 
generalisation capability is to be obtained (Basheer et al. 2000). Attention has to be paid 
so that the training data covers the range of outputs. This is because training the network 
is based on learning the underlying trends in data. Therefore, the network cannot perform 
well if it has to extrapolate data (Basheer et al. 2000). The measured output for the DPI 
performance indicators is plotted against the output predicted by the ANN in Figure 5.7. 
The figure shows that for all the output parameters studied here, the training set (black 
dots) was selected so that there is no need for extrapolating the outputs within the test 
(grey dots) or validation sets (circles). The graphs in Figure 5.7 also demonstrate that the 
networks were good at generalising data. This is because these data points are not 
scattered to a great extent, as discussed in the introduction of the Chapter.  
Once trained, neural networks can be used for different purposes, such as forecasting, 
pattern classification and optimisation (Jain et al. 1996). In the current study, the networks 
were applied as a tool for understanding the mechanisms for how lactose fines govern the 
DPI performance. This was done by inspecting the relative importance of the different 
input parameters in the trained network. The importance of each of the parameters 
measured for the lactose carriers, in essence the weight of the connections for the 
parameter in the trained network, for predicting the different DPI performance attributes 
are summarised in Table 5.8. The relative importance of the different input parameters in 
the network modelling FPFED is illustrated in Figure 5.10. The proportion of fines below 4.5 
µm was the most important parameter with approximately 57% connection weights 
deriving from this parameter. This is in an agreement with the results obtained by the 
statistical methods as discussed earlier in the Chapter. The proportion of fines is followed 
by FRI with considerably lower importance of approximately 13.6%. This result is different 
from the PLS model, that indicated that the proportion of fines and the FRI were equally 
important in determining the FPFED. As discussed in Chapter 4, FRI was not a sensitive 
measure for free flowing powders but was able to distinguish between cohesive powders. 
If the values of FRI (Table 5.3) are plotted against the %<30 µm (Table 5.2), these data 
points follow a single curve (graph not shown). Therefore, the possible reason for the 
lower significance of the FRI in the ANN model than in the PLS model is that the ANN is 
able to mimic the non-linearity in the data, whereas the PLS model tries to fit a linear 
model to data, thus resulting in a biased result (Rajalahti et al. 2011). 
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FIGURE 5.10  MEASURED VS. PREDICTED OUTPUT FOR A) FINE PARTICLE FRACTION OF EMITTED DOSE B) 
MEAN MASS AERODYNAMIC DIAMETER AND C) PRE-SEPARATOR DEPOSITION FOR THE DATA POINTS USED 
IN TRAINING (BLACK DOTS), VALIDATION (CIRCLES) AND TEST SETS (GREY DOTS) 
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In the network modelling the MMAD of the drug aerosolised from different formulations, 
the proportion of fines below 15 µm was by far the most important parameter with 76% of 
the connection weights in the network deriving from this parameter. This is shown in Table 
5.8 and illustrated in Figure 5.11. These data indicate that although the proportion of fines 
<4.5 µm was the most important parameter in determining the DPI performance as 
defined by FPFED, the larger fines play a role in determining the extent of deagglomeration 
of the drug. Once again, this result is in agreement with the statistical analysis methods as 
discussed earlier in the Chapter. 
 
Table 5.8 and Figure 5.12 demonstrate that in the network describing the drug deposition 
in the pre-separator, the proportion of particles finer than 4.5 µm was the most important 
parameter at 46% connection weight. The second most important parameter was the d10 
with an importance of 19%. These data indicate it is not only the proportion of fine particle 
lactose that defines the pre-separator deposition, but also the size of the fines. This 
finding is in an agreement with the theory according to which the larger fines act as 
secondary carriers within DPI formulations (Adi et al. 2009)  
 
Looking at the importance of the different parameters characterised for the lactose 
carriers as listed in Table 5.8, specific energy has a very low connection weights of less 
than 1% in all the models. Similarly, tapped density and Hausner ratio have low 
importance of less than 5% in all the networks relating to DPI performance attributes. 
Therefore, these properties of the lactose carriers may not have significant relevance in 
determining DPI performance. 
 
TABLE 5.7 THE CONNECTION WEIGHTS FOR THE DIFFERENT INPUTS PARAMETERS IN THE NEURAL 
NETWORKS DESCRIBING DPI PERFORMANCE. THE NETWORKS WERE BASED ON THE AVERAGE VALUES 
REPORTED IN TABLES 5.2, 5.3 AND 5.4.  
 Connection weights (%) 
 FPFED MMAD PS of RD 
%<4.5 56.94 2.50 45.76 
%<15 0.09 75.56 1.05 
%<30 1.24 0.45 5.27 
d10 3.64 4.82 19.17 
BFENorm 0.57 0.08 9.05 
Bulk density 6.78 1.99 7.78 
Tapped density 3.75 1.56 3.45 
Hausner ratio 4.91 4.45 0.43 
DFI 7.90 0.37 4.21 
FENorm 0.13 7.15 2.88 
FRI 13.65 0.18 0.03 
SE 0.41 0.88 0.92 
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FIGURE 5.11 THE RELATIVE IMPORTANCE OF THE DIFFERENT INPUT PARAMETERS IN THE NEURAL 
NETWORK MODELLING FINE PARTICLE FRACTION OF EMITTED DOSE OF BUDESONIDE 
 
FIGURE 5.12 THE RELATIVE IMPORTANCE OF THE DIFFERENT INPUT PARAMETERS IN THE NEURAL 
NETWORK MODELLING MEAN MASS AERODYNAMIC DIAMETER OF BUDESONIDE 
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FIGURE 5.13 THE RELATIVE IMPORTANCE OF THE DIFFERENT INPUT PARAMETERS IN THE NEURAL 
NETWORK MODELLING DEPOSITION OF BUDESONIDE IN THE PRE-SEPARATOR 
 
 
5.3.5 Mechanistic considerations for how the lactose fines govern the DPI 
performance 
 
The drug that is detached from the surface of the large and intermediate carrier particles 
and deagglomerated will be deposited in the lower stages of the impactor and reflected in 
the FPFED measurements. With all the three different data analysis methods, the 
proportion of particles finer than 4.5 µm was one the most dominant lactose parameters in 
determining FPFED. These data indicate that the fine particle delivery as defined by the 
fine particle fraction is governed by the presence of fine particle lactose. The statistical 
analysis methods that are based on the assumption that the underlying data is linear and 
not covariant also highlighted some of the lactose flow and fluidisation properties as 
important in determining the FPFED. However, on the basis of data in this chapter, the only 
conclusion that can be made is that the presence of the fine particle lactose is essential in 
improving the DPI performance. No further conclusions can be drawn on the mechanisms 
for how these fines might improve the DPI performance.  
 
Also the drug detachment from the carrier as defined by the pre-separator deposition was 
affected by the proportion of lactose fines according to all the models developed in the 
current study. However, some of the models also highlight the proportion of large fines 
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and the flow and fluidisation properties of the lactose carrier as relatively important 
parameters in determining the pre-separator deposition.   
 
The drug de-agglomeration efficiency as measured by the MMAD on the other hand was 
mostly affected by the presence of the larger fine particle lactose, as the proportion of 
fines <30 µm produced the best R2 value for linear correlations and the proportion of fines 
below 15 µm was highlighted as the single most important parameter in the PLS and ANN 
models for MMAD. To relate the important parameters to the drug deposition in the 
impactor, it has to be noted that the fine particle fraction of emitted dose used in the 
current study was based on fine particle mass below 5 µm collected on the impactor 
stages, as described in Chapter 2 of the thesis. At 90 l/min, the flow rate used in the 
current study, this cut-off is between NGI stages 1 and 2 (Marple et al. 2003b). Therefore, 
the drug collected on Stage 1 of the impactor will not be reflected in the FPFED. However, 
the material collected on Stage 1 was included in the MMAD calculation. Consequentially, 
it was reasoned that the MMAD described the Stage 1 deposition at least to some extent. 
The reason for the importance of the larger fine particle lactose in determining the MMAD 
is likely to be related to the fact that some of these particles with drug particles remaining 
attached to the surfaces of these particles may be deposited on the upper stages of the 
impactor. Therefore, the hypothesis of Adi et al. (2009) according to which the 
intermediate lactose fines act as secondary carriers is a viable explanation for the 
relationship between the presence of larger fines and the increasing MMAD. 
 
 
5.4 CONCLUSIONS 
 
The DPI performance is governed by multiple properties of the lactose carriers that often 
cannot be changed in a controlled way independently from each other. In this chapter, 
PLS and ANN analysis of the structure-function data were used in addition to linear 
regression to obtain more complete understanding of the lactose characteristics that 
govern the DPI performance. The PLS and ANN analysis of the current dataset showed 
that although proportion of fines is the most important parameter in determining the DPI 
performance, the parameter does not explain all of the variation. Therefore, simple linear 
correlations are not reliable for predicting the formulation performance and more 
comprehensive models, such as the ones applied in the current study, should be used 
instead.    
 
When it comes to understanding the relationship between the lactose properties and the 
DPI performance, some advancements with respect to the behaviour of larger fines were 
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made in this chapter. The drug detachment from the large carrier particles and the 
deagglomeration as measured by pre-separator deposition and MMAD were seen to be 
regulated by the presence of the larger lactose fines. The results of the current study 
further confirms the role of the larger fine particle lactose acting as a secondary carrier as 
was suggested by Adi et al. (2009).  
 
However, the role of the fine particle lactose in determining the DPI performance could not 
be resolved by the means of the data analysis methods used in the current study. 
Nevertheless, the significance of the fine particle lactose in regulating the performance 
was proved once again. The study represented in the following Chapter of the thesis will 
concentrate on understanding the significance of the fine particle lactose in regulating the 
in vitro drug deposition. 
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CHAPTER 6 LACTOSE CHARACTERISTICS GOVERNING THE 
REGIONAL DEPOSITION OF THE DRUG IN THE NEXT GENERATION 
IMPACTOR 
6.1 INTRODUCTION 
 
Previous studies have addressed that the fine particle lactose added to DPI formulation 
has to be fine enough if an improvement in the formulation performance is to be achieved 
(Adi et al. 2006; Guenette et al. 2009; Louey et al. 2003). Chapter 5 of the thesis showed 
that from a wide set of physical parameters describing the lactose carriers, the proportion 
of particles below 4.5 µm was the most important one in determining the DPI 
performance. Once again, this study confirmed the crucial role of the finest lactose 
particles in governing the DPI performance. However, the mechanism for how these fine 
particles of lactose alter the formulation performance has remained unclear, with a 
number of theories trying to explain the behaviour. It was shown in Chapter 3 of the thesis 
that the active sites theory (El-Sabawi et al. 2006; Young et al. 2005) is an unlikely 
explanation for the improved performance upon the addition of lactose fines. Similarly, 
Chapters 3 and 4 of the thesis showed that the increased cohesion theory (Shur et al. 
2008a) may play a minor role in improving the DPI performance. However, this theory was 
not capable of universally explaining improved performance when a wide range of 
different carriers were investigated. The agglomerate formation theory (Lucas et al. 1998) 
has gained the strongest evidence during the investigations carried out in this thesis. 
Chapter 4 indicated that improved DPI performance in the presence of lactose fines was 
indeed related to agglomerate formation with the fine lactose particles.  
 
As advised by the inhalation monographs of the European and US Pharmacopoeias, 
pharmaceutical impactors are routinely used for determining the respirable dose of the 
inhaled drug from different formulations. The assays often rely on dissolving the drug 
collected in the different parts of the impactor. The concentration of the solute is then 
chemically determined by means of either HPLC or UV-VIS spectrophotometry. However, 
these impactor data are often used solely as a performance indicator. The objective of this 
study is to gain a more rounded understanding of the mechanisms governing the drug 
deposition in the impactor in the presence of lactose fines. The goal was pursued by using 
complementary analytical methods alongside the in vitro performance analysis of DPI 
formulations. 
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The amount of drug deposited in the throat from a formulation aerosolised with different 
devices has previously been investigated (DeHaan et al. 2001). This study showed that 
different amounts of drug were deposited in the throat from the same formulations 
aerosolised using different devices. This study concluded that the drug deposition in the 
throat was governed by the inertia and kinetic energy of the particles exiting the device. 
Other studies have compared the drug deposition in the USP throat and throat casts that 
mimic the human oropharyngeal cavity in greater detail (Niven et al. 1994; Zhang et al. 
2007). The former study showed that the amount of drug deposited in the USP throat was 
an overestimation of the amount of drug deposited in an induction port mimicking the 
human mouth and throat region (Niven et al. 1994). The latter study however showed that, 
for DPI formulations, the USP throat was as accurate an estimate of the amount of drug 
deposited in vivo in the throat as any anatomically relevant oropharyngeal cast (Zhang et 
al. 2007). Nevertheless, despite the research efforts concentrated on understanding the 
impact of throat geometry on the drug deposition, the impact of formulation characteristics 
on the drug deposition in the throat has been largely neglected in discussion of data in 
most studies that investigated the effect of carrier properties on the DPI performance. The 
only study where an attempt was made in relating the carrier properties to the throat 
deposition was performed by Podczeck (1998). In this study, the drug losses in the throat 
were attributed mainly to the aspect ratio of the large carrier particles. The study showed 
that less drug deposited in the throat from carriers composed of more elongated particles. 
It was suggested that these elongated lactose particles exhibited better aerodynamic 
properties. Consequentially, these particles were more likely to be carried through the 
USP induction port in the air stream without impacting on the walls. As a result, fewer 
large carrier particles with drug adhering to the surfaces were deposited in the throat thus 
contributing to lower drug loss in the throat.   
 
Laser diffraction particle sizing of the aerosol emitted from the DPI device has been 
previously used for studying powder fluidisation and entrainment (Watling et al. 2010), 
powder de-agglomeration (Adi et al. 2006; Behara et al. 2011b; Behara et al. 2011c; Le et 
al 2012a. ; Zhou et al. 2010) and the kinetics of device emptying (Behara et al. 2011a). 
Aerosol particle sizing using laser diffraction has also been suggested as a rapid 
alternative for quality assurance purposes for inhalation formulations (de Boer et al. 2002; 
Marriott et al. 2006; Pilcer et al. 2008). In the study reported here, laser diffraction particle 
sizing of the aerosol was utilised for measuring the particle size of the plume entering and 
exiting the USP induction port of the Next Generation Impactor (NGI). The motivation for 
this was two-fold. Firstly, these experiments were expected to give information on 
differences in the de-agglomeration efficiency possibly related to fines content of the 
formulations. Secondly, the gap in the knowledge base relating drug losses in the USP 
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throat to the properties of the carriers containing different amounts of lactose fines could 
be investigated. 
 
Pre-separator deposition is an important feature of carrier based DPI formulations and is 
critically important in understanding the mechanism for how the lactose fines increase 
performance. This is because coarse carrier particles, and any drug that remain attached 
to these particles upon aerosolisation of the dose, will deposit in the pre-separator. 
Previous studies by Guchardi et al. (2008) and Podczeck (1998) have demonstrated a 
decrease in the drug deposition in the pre-separator upon increasing fines concentration. 
The former of these studies concluded that the decreasing trend in the pre-separator 
deposition fitted with both the active site and agglomerate formation theories (Guchardi et 
al. 2008). The latter of the two studies concluded that the decrease in the proportion of 
drug deposited in the pre-separator was due to a smaller proportion of large carrier 
particles being available for the drug to adhere to (Podczeck 1998). Consequentially, 
agglomerates were formed between the lactose fines and the drug particles and carried 
through the pre-separator to the stages of the impactor. The study reported here aims to 
further address drug losses in the pre-separator and in understanding the relationship 
between carrier properties and in vitro drug deposition in the pre-separator. 
 
Several studies have been made in an attempt to understand the mechanisms governing 
DPI performance by determining the deposition of lactose in the different parts of the 
impactor alongside drug determination (Guchardi et al. 2008; Karhu et al. 2000; Srichana 
et al. 1998b). These studies proved that in addition to the drug, fine lactose is deposited 
on the impactor stages. However, due to the limitations of traditional, solution-based 
analytical chemistry techniques, these studies only provided speculative evidence of 
agglomerate formation between lactose fines and the drug. Therefore, to study the 
possible co-deposition of the drug and lactose fines, there remains a need to develop a 
greater understanding of the fate of both fine lactose and drug and their association at the 
lower stages of an inertial impactor and to develop novel characterisation methods.  
 
Early attempts in finding alternative analysis methods for materials deposited in an 
impactor from a DPI formulation were made by Srichana et al. (1998c), who used 
scanning electron microscopy in conjunction with X-ray microanalysis to study interactions 
between lactose and salbutamol sulphate particles. More recent studies have shown that 
Raman spectroscopy is a promising technique for studying particulate interactions in 
inhaled formulations. These have been mainly investigating the interactions between the 
different drug particles within combination pressurised metered dose (pMDI) formulations 
(Rogueda et al. 2011; Steele et al. 2004; Theophilus et al. 2006). Studies with DPI 
products have also been conducted using Raman spectroscopy (Kinnunen et al. 2009; 
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Šašić et al. 2010). Kinnunen et al. (2009) used Raman spectroscopy for studying the co-
deposition of lactose and FP on the impactor stages from a commercial DPI formulation. 
Šašić et al. (2010) used Raman spectroscopy for investigating the particulate interactions 
between lactose carrier particles and two different APIs within a combination DPI. Both 
these studies concluded that Raman spectroscopy was a promising technique for studying 
the microstructure, the interaction between particles, within DPI formulations. In the 
current study, further developments in gaining statistically significant data were taken due 
to significant developments in the combination of Raman spectroscopy with microscopy 
imaging instrumentation. Morphologically directed Raman spectroscopy was used for 
characterising the physical properties and chemical composition of the material delivered 
to the impactor stages. This was done to obtain any evidence on drug-lactose fines 
agglomerate formation and co-deposition on impactor stages.  
 
Raman spectroscopy is based on the inelastic scattering of monochromatic light upon 
interaction with the vibrational energy states of molecules, a phenomenon discovered by 
Raman and Krishnan (1928). This scattering can be divided into three different cases, as 
illustrated in Figure 6.1. Rayleigh scattering is the most prevalent phenomena with more 
than 99.999% of the incident light not interacting with the vibrational states of the molecule 
(Vankeirsbilck et al. 2002). Thus, the scattered photons have an identical frequency to the 
light source and produce no Raman scattering. However, some of the photons interact 
with the vibrational states of the molecules. The light can either excite a molecule to a 
higher vibrational energy state or relax the molecule to a lower vibrational energy state. As 
a result of these interactions, the scattered photon has either lower (Stokes scattering) or 
higher (anti-Stokes scattering) frequency than the light source, respectively. Due to the 
rarity of Stokes and anti-Stokes scattering compared to Rayleigh scattering, the Raman 
signal is relatively weak. However, recent advances in instrumentation have improved the 
sensitivity of the technique (Wartewig et al. 2005). Due to its non-invasive nature, Raman 
spectroscopy has a wide range of pharmaceutical applications. These include for example 
polymorph (Findlay et al. 1998; Gamberini et al. 2006), impurities (Widjaja et al. 2008) and 
counterfeit product detection (Roggo et al. 2010). Recently, Raman spectroscopical 
techniques have also been used for on-line monitoring of pharmaceutical processes thus 
enabling quality-by-design approaches for pharmaceutical manufacturing (De Beer et al. 
2011).  
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FIGURE 6.1 DIFFERENT SCATTERING PHENOMENA TAKING PLACE UPON EXCITATION OF A MOLECULE  
 
In summary, the aim of the current study is to investigate the drug deposition in the 
impactor from formulations containing different amounts of lactose fines in greater detail 
using complementary techniques, namely aerosol particle sizing, morphological analysis 
and Raman spectroscopy, in parallel with in vitro performance assessment of the 
formulations. This major objective is to enhance our understanding of the mechanisms 
governing drug delivery from DPI formulations containing fine particle lactose. In 
particular, the study aims to further support that agglomerate formation between the drug 
and the lactose fines is the predominant mechanism for governing the DPI performance. 
  
6.2 MATERIALS AND METHODS 
 
The lactose pre-blends were prepared as described in Chapter 4 of the thesis. The same 
applies to the formulation and in vitro work, with the exception that a Cyclohaler device 
was used at a flow rate of 90l/min. The proportion of fines in the carrier blends was also 
characterised as described in Chapter 4.  
 
The particle size measurements of the material exiting the device and throat were 
performed using the Spraytec (Malvern Instruments, Worcestershire, UK) laser diffraction 
instrument equipped with a 300 mm lens. The inhalation cell held in a horizontal 
configuration was used for sizing the material entering the throat and in a vertical 
configuration was used for measuring the material exiting the throat. Prior to 
measurements, the background scattering was recorded for a duration of 10 seconds. To 
ensure high enough particulate concentration at the measurement zone, the 
measurements were triggered once scattering of 50 units was measured at detector 
number 9. The particle size distributions were retrieved for a 100ms period before the 
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trigger condition was exceeded. Initially, measurements were performed for 5 seconds 
after the trigger condition had been met. However, it was observed that no powder passed 
through the measurement zone after approximately 1.5 seconds. Therefore, the particle 
size was measured for 2 seconds at a frequency of 2.5 kHz. Mie theory was applied for 
calculating the particle size distributions from the raw scattering data with refractive index 
of 1.52, imaginary refractive index of 0.01 and density of 1 applied for lactose. The 
refractive index of the dispersant (air) was 1. The multiple scattering correction was 
enabled for the analysis. The trends in particle size parameters (d10, d50, d90 and 
transmission) were inspected and averaged particle size distributions were created 
between time points where the plume had passed through the measurement zone.  
 
Samples of material deposited in the pre-separator and the Stage 2 of the NGI when 
aerosolised at 90 l/min using the Cyclohaler were collected by placing a mirror surfaced 
microscope slide on the inlet of the pre-separator and underneath the nozzles on Stage 2 
of the NGI.  
 
The particles collected in the pre-separator were characterised using the Morphologi G3 
automated image analysis system (Malvern Instruments, Worcestershire, UK). Episcopic 
bright field illumination was used for the microscopic visualisation of the particles with the 
light intensity calibrated at 80.0 ± 0.2 %. The 5x objective (size range 6.5 to 420 µm for 
shape information) lens was used for scanning the samples with the focus fixed at 0 µm 
and the plate tilt compensation enabled. The scan area size was set to 13 mm by 13 mm, 
the overlap between any two adjacent frames to 30%, the binary threshold to a grayscale 
value of 123 and the trash size to 10 pixels. Post analysis, any touching particles were 
removed by filtering out particles with values of solidities below 0.9. Before the shape 
analysis, particles consisting of less than 100 pixels were filtered out to remove noise from 
the shape distributions.  
 
The particles deposited on Stage 2 were characterised on the Morphologi G3-ID 
morphologically directed Raman spectroscopy system (Malvern Instruments, 
Worcestershire, UK). The settings for the morphological scan were as above for the pre-
separator with the following exceptions. The 50x objective lens (size range 0.5 to 40 µm 
for shape information) was used for the morphological analysis of the particles. The scan 
area was set to 4.5 mm by 4.5 mm, the overlap between adjacent frames to 40% and the 
binary threshold to a grayscale value of 130. Post analysis, any touching particles were 
removed by filtering particles with values of solidities below 0.92.  
 
After the morphological analysis of particles deposited on Stage 2, the particles were 
sorted according to their size using circular equivalent (CE) diameter. All the particles 
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larger than 3 µm were highlighted for the Raman analysis that was performed using the 
Kaiser Optical Systems MK II Probe head integrated in the Morphologi G3-ID system. The 
XY coordinates of the particles recorded during the morphological analysis were used for 
locating the centre of the particles, where the Raman spectrum was acquired. The 
spectrum for each particle was collected using 10 seconds exposure time with excitation 
at a wavelength of 785 nm over the spectral range of 100 to 1825 cm-1 at a resolution of 4 
cm-1. The signal was detected using a charge coupled device (CCD) camera. The Raman 
spot size with the 50x objective was approximately 3 µm in diameter. 
 
Reference spectra were recorded for lactose and budesonide. These reference spectra 
were used for identifying the chemical composition of the material collected on Stage 2. 
The identification was performed by comparing the entire spectrum for the analysed 
particles to the library spectra of lactose and budesonide using the Morphologi G3-ID 
software. The Morphologi G3-ID software was also used for allocating matching scores for 
lactose and budesonide for the particles analysed by comparing the similarity of the 
spectra of the particle to the library spectra of lactose and budesonide. A matching score 
of 1 indicates identical spectra and a score of 0 indicates the spectrum bears no 
resemblance to the library spectra at all. On the basis of the scores, the particles could be 
identified as pure lactose (Lactose ≥ 0.75 and budesonide < 0.450), pure budesonide 
(Budesonide ≥ 0.75 and lactose < 0.45) or an agglomerate of lactose and budesonide (All 
the remaining particles). When allocating the classification parameters for the pure 
substances, visual comparison of the library spectra and the spectra of the particles was 
used for confirming that no obvious signals of the other component was seen in the 
spectra. Similarly, for the particles classified as agglomerates, it was visually inspected 
that the characteristic signals for both the pure substances were present in the spectra. 
 
6.3 RESULTS AND DISCUSSION 
6.3.1 In vitro performance of the formulations 
 
It was shown in Chapter 4 and Chapter 5 of the thesis as well as in previous studies 
(Guenette et al. 2009; Louey et al. 2003) that the proportion of fine lactose particles 
present in the carrier is an important parameter in defining the DPI performance. The 
fines content (%<4.5 µm) of the carriers and the in vitro performance of the 
formulations prepared with the carriers investigated in the current study are 
summarised in Table 6.1. Table 6.1 demonstrates that the proportion of fine particle 
lactose in the carriers increased from 1.3% for the LH100 to 6% for the 20 wt-% 
LH210 and to 23% for the 20 wt-% LH300 added to the coarse LH100 carrier. 
Meanwhile, the fine particle fraction of emitted dose upon the addition of 20 wt-% 
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LH210 and LH300 fines to LH100 increased from approximately 24 to 26 to 40% 
respectively.  
 
Table 6.1 also shows that the mean mass aerodynamic diameter (MMAD) of the drug 
collected from the impactor stages increased simultaneously with the proportion of 
lactose fines and the fine particle fraction of emitted dose. The increase in the MMAD 
indicated that the drug was delivered to the impactor stages in larger entities upon the 
increase in the lactose fines content. These could either be agglomerated drug 
particles or agglomerates of the fine lactose and the drug particles. An increase in the 
value of MMAD of the drug upon the addition of lactose fines has also been 
previously reported by Podczeck (1998). In that study, the dependency of the MMAD 
on the fines content was attributed to changes in the preferred adhesion site of the 
drug particles (lactose fines vs. coarse lactose particles) in the presence of lactose 
fines.   
 
TABLE 6.1 PROPORTION OF FINE PARTICLES IN THE CARRIER BLEND AS MEASURED BY LASER 
DIFFRACTION AND THE IN VITRO PERFORMANCE OF THE FORMULATIONS IN TERMS OF FINE PARTICLE 
FRACTION OF EMITTED DOSE (FPFED) AND THE MEAN MASS AERODYNAMIC DIAMETER (MMAD) OF THE 
DRUG AEROSOLISED FROM THE FORMULATIONS. THE DATA FOR % < 4.5 µM REPRESENTS AN AVERAGE OF 
FIVE REPEATED MEASUREMENTS. THE DATA FOR FPFED AND MMAD REPRESENTS MEAN ± STANDARD 
DEVIATION, N=3. 
% < 4.5 µm FPFED ± S.D. (%) 
MMAD ± S.D. 
(µm) 
LH100 1.29 24.10 ± 0.24 2.58 ± 0.02 
+20% LH210 6.02 26.63 ± 0.13 3.14 ± 0.01  
+20% LH300 23.04 39.74 ± 1.34 3.36 ± 0.03 
 
 
The stage-by-stage deposition profiles of the drug aerosolised from the different 
formulations are shown in Figure 6.2 and summarised in Table 6.2. The deposition 
profiles show that the addition of 20 wt-% LH300 to the formulation significantly decreased 
the amount of drug deposited in the capsule compared to LH100 and the 20 wt-% LH210 
formulations. The decrease was statistically significant (p<0.05) compared to the 
formulation prepared with LH100 only. Increasing trends in the device and in the 
mouthpiece and throat deposition were apparent upon increasing concentration of fines. 
Compared to the formulation prepared with LH100 only, the increase was not statistically 
significant for device deposition (p>0.05) but was significant for the mouthpiece and throat 
deposition. A decreasing trend in the pre-separator deposition was observed upon an 
increase in the fines content. The decrease was statistically significant (p<0.05) for both 
the formulations containing added fines compared to the formulation prepared with LH100 
only (p<0.05). The amount of drug recovered from the pre-separator decreased from 35 to 
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20 and further to 10 µg upon the addition of 20 wt-% LH210 and 20 wt-% LH300, 
respectively. The amount of drug delivered to the impactor stages in general increased 
with increasing fines concentration. The increase was significant (p<0.05) on all the 
stages for the LH300 formulations and on stages 1 and 2 for the LH210 formulation 
compared to the formulation containing no extrinsic lactose fines.  
   
TABLE 6.2 THE AMOUNT OF DRUG RECOVERED FROM THE DIFFERENT PARTS OF THE NEXT GENERATION 
IMPACTOR FROM THE DIFFERENT FORMULATIONS. MP & T REPRESENTS THE MOUTHPIECE AND THROAT 
AND PS THE PRE-SEPARATOR. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, N=3. 
  
Amount of drug recovered from stage ± S.D. 
(µg) 
LH100 +20% LH210 +20% LH300 
Capsules 21.40 ± 1.18 20.30 ± 1.09 12.78 ± 0.83 
Device 12.16 ± 0.74 14.23 ± 0.83 15.29 ± 0.88 
MP & T 6.39 ± 0.26 11.82 ± 0.53 15.59 ± 1.31 
PS 34.87 ± 1.00 20.58 ± 0.38 11.21 ± 1.25 
Stage 1 1.68 ± 0.06 3.38 ± 0.08 5.59 ± 0.07 
Stage 2 3.37 ± 0.10 4.78 ± 0.10 9.82 ± 0.14 
Stage 3 4.01 ± 0.11 4.19 ± 0.13 7.93 ± 0.20 
Stage 4 4.71 ± 0.11 3.96 ± 0.02 6.45 ± 0.25 
Stage 5 1.99 ± 0.05 1.86 ±  0.13 2.50 ± 0.09 
Stages 6-8 0.62 ± 0.02 0.75 ± 0.08 0.90 ± 0.03 
 
 
FIGURE 6.2 STAGE-BY-STAGE DEPOSITION PROFILES OF BUDESONIDE FROM THE FORMULATIONS 
INVESTIGATED IN THE STUDY. MP & T REPRESENTS THE MOUTHPIECE AND THROAT AND PS THE PRE-
SEPARATOR. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION, N=3. 
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6.3.2 Size of the material exiting the device 
 
The plume exiting the device after the aerosolisation of the different formulations was 
characterised using laser diffraction aerosol particle sizing. The average value of d10 
during device emptying and the variation in the value of d10 over this event, σd10, are 
summarised in Table 6.3. Additionally, the ratio between the σd10 and d10 for each 
formulation is tabulated. These data show that the values of d10 reflect the fines content 
of the formulations, with LH100 formulation producing the largest and the 20 wt-% LH300 
formulation the smallest d10.  
 
A decreasing trend in σd10 was observed upon increasing lactose fines concentration. To 
evaluate the significance of the decreasing trend for σd10, the ratio between and σd10 and 
d10 of the formulations was calculated. It was anticipated that the decrease in σd10 could 
be related to the measurement accuracy rather than to the formulation characteristics. If 
this was the case, the decrease in σd10 would simply be a consequence of the decreasing 
value of d10, and the ratio between the two parameters would remain constant for the 
different formulations. Conversely, if the ratios were different for the formulations, the 
parameter would describe the de-agglomeration characteristics of the formulations. Table 
6.3 demonstrates that the ratio between σd10 and d10 varied between the different 
formulations with the LH100 and the 20 wt-% LH210 formulations having higher values 
than the 20 wt-% LH300 formulation. These data indicate that the consistency of de-
agglomeration was higher for the 20 wt-% LH300 formulation than for the formulations 
prepared with LH100 only and with 20 wt-% LH210. These data may be indicative of the 
20 wt-% LH300 formulation having a microstructure more favourable for constant de-
agglomeration than the other two formulations investigated.  
 
 
TABLE 6.3 THE AVERAGE d10 AND THE VARIATION IN THE VALUE OF d10 (σd10) OVER THE DEVICE 
EMPTYING EVENT FOR THE MATERIAL EXITING THE CYCLOHALER AND THE RATIO BETWEEN THE TWO 
PARAMETERS FOR THE DIFFERENT FORMULATIONS. THE DATA REPRESENTS MEAN ± STANDARD DEVIATION 
(S.D), N=3. 
d10 ± S.D. (µm) σd10 ± S.D. (µm) σd10/ d10 
LH100 24.58 ± 1.85 7.41 ± 0.30 0.30 ± 0.01
+20% LH210 8.16 ± 1.03 2.32 ± 0.79 0.28 ± 0.06 
+20% LH300 3.00 ± 0.18 0.63 ± 0.12 0.21 ± 0.04 
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6.3.3 Throat deposition 
 
There are numerous studies in the literature where the particle size distribution of the 
plume exiting the device has been characterised using a horizontal configuration for the 
Spraytec inhalation cell (Adi et al. 2006; Behara et al. 2011a; Behara et al. 2011b; Behara 
et al. 2011c; Le et al. 2012a; Watling et al. 2010; Zhou et al. 2010). However, to the 
author’s knowledge, the vertical configuration of the inhalation cell has not been utilised 
for characterising the plume exiting the induction port of the impactor. In the current study, 
the particle size distributions of both the plume entering and exiting the USP throat were 
characterised. This was done to understand what formulation characteristics govern the 
drug deposition in the throat. The particle size distributions of the formulations upon 
entering and exiting the USP throat of the impactor are presented in Figure 6.3. For all the 
formulations, the particle size distributions measured after the USP throat had less fine 
material and more large material than the distributions measured before the throat. These 
data indicate qualitatively that fine material was lost in the throat.  
 
On the basis of the distributions shown in Figure 6.3 it appeared that large material was 
being created as the formulations passed through the throat. However, this was practically 
impossible because the measurements were performed in a closed system. In addition, 
despite the fact that the particle size distributions are volume based, the loss of fines was 
still reflected in them. Thus majority of the material lost in the throat had to be fine 
particles. To illustrate this, the following example should be considered; if one particle of a 
diameter of 100 µm is lost in the throat, to have an equal contribution in the volume based 
distribution, 1000 particles with a diameter of 10 µm have to be lost.  
 
To enable quantitative analysis of the amount of material deposited in throat, the particle 
size distributions of the formulations before the throat were normalised. To do this, an 
assumption that no large particles were lost in the throat had to be made. The assumption 
was justified due to the reasons related to the volume of particles of different sizes 
discussed in the preceding paragraph. Also, the results of the quantitative analysis were 
found to be insensitive to the assumption. To obtain a factor describing the difference in 
the modes of the particle size distributions, the ratios between the modes of the particle 
size distributions for each of the formulations before and after the throat were calculated. 
The size distributions of the formulations measured before throat were then multiplied by 
this factor. This way, particle size distributions with equal frequencies for the modes were 
obtained.  
 
The normalised particle size distributions of the formulations before the throat together 
with the size distributions measured after the throat are presented in Figure 6.4. The 
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figure demonstrates that for the formulation prepared with LH100, the majority of the 
particles deposited in the throat were finer than approximately 50 µm. With the 20 wt-% 
LH210 formulation, most of the particles deposited in the throat were between 5 and 50 
µm in size. However, also some particles between 50 and 100 µm were deposited in the 
throat from this formulation. With the 20 wt-% LH300 formulation, the particle size of 
material deposited in the throat was below 30 µm, although some material up to 100 µm in 
size was seen to deposit in the throat also from this formulation. Notably, the small 
population of agglomerates present in the distribution measured before the throat between 
600 and 900 µm were deposited in the USP throat.  
 
Further data analysis revealed that the amount of drug deposited in the USP throat 
correlated with the proportion of particles finer than 29 µm lost in the throat (R2=0.999), as 
illustrated in Figure 6.5. The figure shows that the smaller the proportion of fines below 29 
µm depositing in the throat, the less drug is lost in the throat. These data indicate that the 
drug deposition in the throat was governed by co-deposition with the lactose fines present 
in the formulation. This may be because of the formation of drug-fines agglomerates (20 
wt-% LH300 formulation) or due to the drug adhering to the surface of the larger lactose 
fines present in the formulation (20 wt-% LH210 formulation). The correlation may also be 
partly due to higher plume density for the formulations with added fines. Consequentially, 
the likelihood of particles impacting on the walls of the throat is higher from the 
formulations with added fines.  To the author’s knowledge, these data relating the fines 
content of the lactose carrier to the drug deposition in the induction port are novel.   
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LH100 
 
+20% LH210 
 
+20% LH300 
 
 
FIGURE 6.3 THE PARTICLE SIZE DISTRIBUTIONS OF MATERIAL ENTERING (SOLID LINES) AND EXITING THE 
THROAT (DASHED LINES) WITH LH100 (TOP), 20% LH210 (MIDDLE) AND 20% LH300 (BOTTOM) IN LH100 
AS THE CARRIER. THE DATA REPRESENTS THE AVERAGE PARTICLE SIZE DISTRIBUTION OF MATERIAL 
PASSING THROUGH THE MEASUREMENT ZONE DURING THE DURATION OF THE MEASUREMENTS (2S). 
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LH100 
 
+20% LH210 
 
+20% LH300 
 
FIGURE 6.4 NORMALISED PARTICLE SIZE DISTRIBUTIONS OF MATERIAL ENTERING THE THROAT (SOLID 
LINES) AND SIZE OF THE MATERIAL EXITING THE THROAT (DASHED LINES) FOR LH100 (TOP), 20% LH210 
(MIDDLE) AND 20% LH300 FORMULATIONS (BOTTOM). THE DATA REPRESENTS THE AVERAGE PARTICLE 
SIZE DISTRIBUTION OF MATERIAL PASSING THROUGH THE MEASUREMENT ZONE DURING THE DURATION OF 
THE MEASUREMENTS (2S). 
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FIGURE 6.5 THE RELATIONSHIP BETWEEN THE PROPORTION OF PARTICLES DEPOSITED IN THE THROAT AND 
THE AMOUNT OF DRUG RECOVERED FROM THE THROAT. THE DATA FOR DRUG DEPOSITED IN THROAT 
REPRESENTS MEAN ± STANDARD DEVIATION. THE DATA FOR PROPORTION OF PARTICLES BELOW 29 µm IS 
BASED ON SINGLE MEASUREMENT.  R2= 0.999 
 
 
6.3.4 Pre-separator deposition 
 
The number based particle size distributions of the material collected in the pre-separator, 
in terms of circular equivalent (CE) diameter, upon aerosolisation of the different 
formulations are summarised in Table 6.4. The d10 of the material collected in the pre-
separator for all the formulations were very similar. However, this was most likely related 
to the limit of detection with the use of the 5x magnification optic. The formulations with 
added fines had a lower d50 than the LH100 formulation. In terms of d90, clear 
differences between the formulations were characterised with decreasing d90 upon an 
increase in the fines content of the formulation. The CE diameter distributions of the 
material collected in the pre-separator are shown in Figure 6.6. The cut-off diameter of 
Stage 1 of the NGI when operated at 90 l/min is 6.48 µm (Marple et al. 2003a). Figure 6.6 
demonstrates that significant amounts of particles finer than this were collected in the pre-
separator from all the formulations. Clearly, these fines can either be fine lactose or drug 
particles. Therefore, at least some drug loss in the pre-separator can possibly be 
attributed to these fine particles depositing in the pre-separator.  
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Plotting the mass of drug recovered from the pre-separator from the different formulations 
against the number-based d90 of the particles collected in the pre-separator resulted in a 
linear correlation (R2=0.9996), as shown in Figure 6.7. These data indicate that the larger 
the proportion of coarse carrier crystals present in the formulation, the more drug was lost 
in the pre-separator. This result could be interpreted in two ways. Firstly, the advocates of  
the active site theory (El-Sabawi et al. 2006; Young et al. 2005) would attribute the larger 
proportion of drug lost in the pre-separator in the absence of lactose fines to the drug 
adhering to the high energy binding sites on the surface of the large carriers. The other 
school of thought, according to an interpretation by Podczeck (1998), would argue that the 
decreased drug deposition in the pre-separator in the presence of lactose fines was due 
to the drug being transported through the pre-separator as agglomerates with lactose 
fines, and thus depositing in the impactor stages rather than in the pre-separator.  
 
Unfortunately, the pre-separator deposition data from the current study cannot provide a 
definitive conclusion on the mechanism governing the pre-separator deposition. However, 
it was shown that a large proportion of particles finer than the cut off diameter of Stage 1 
(<6.48 µm) were also collected in the pre-separator from the formulation prepared with 
LH100. At least some of these fines are likely to be drug particles that for some reason 
have deposited in the pre-separator. Therefore, these data suggest that the active site 
theory (El-Sabawi et al. 2006; Young et al. 2005) is very unlikely to be the explanation for 
the decrease in the pre-separator deposition upon the addition of lactose fines.  
 
TABLE 6.4 THE 10TH, 50TH AND 90TH PERCENTILES OF NUMBER BASED PARTICLE SIZE DISTRIBUTIONS (D10, 
D50 AND D90, RESPECTIVELY) OF THE MATERIAL COLLECTED IN THE PRE-SEPARATOR FROM THE 
DIFFERENT FORMULATIONS IN TERMS OF CIRCULAR EQUIVALENT (CE) DIAMETER. THE DATA IS BASED ON 
THE ANALYSIS OF 3149 (LH100), 16086 (+20% LH210) AND 12657 (+20% LH300) PARTICLES DURING 
A SINGLE MEASUREMENT. 
Number based CE diameter (µm) 
d10 d50 d90 
LH100 2.45 7.97 39.01 
+20% LH210 2.21 3.40 20.74 
+20% LH300 2.29 3.77 9.61 
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FIGURE 6.6 NUMBER-BASED CIRCULAR EQUIVALENT (CE) DIAMETER DISTRIBUTIONS OF MATERIAL 
COLLECTED IN THE PRE-SEPARATOR FROM THE DIFFERENT FORMULATIONS. THE DATA REPRESENTS THE 
SIZE DISTRIBUTION OF 3149 (LH100), 16086 (+20% LH210) AND 12657 (+20% LH300) PARTICLES 
ANALYSED DURING A SINGLE MEASUREMENT. 
 
FIGURE 6.7 RELATIONSHIP BETWEEN THE NUMBER-BASED d90 OF THE CIRCULAR EQUIVALENT DIAMETER 
OF THE CARRIER AND THE AMOUNT OF DRUG DEPOSITED IN THE PRE-SEPARATOR. D90 IS BASED ON THE 
DISTRIBUTIONS REPORTED IN FIGURE 6.6. THE AMOUNT OF DRUG DEPOSITED IN THE PRE-SEPARATOR IS 
MEAN ± STANDARD DEVIATION, N=3. R2=0.9996 
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6.3.5 Stage 2 deposition 
 
The number-based and volume-converted CE diameter distributions of the material 
collected from the NGI Stage 2 from the different formulations are summarised in Table 
6.5. The table shows that, in number terms, a slight increase in the value of d10 was seen 
as the fines content of the formulations was increased. The cut-off diameter (the mean 
diameter of the material collected on the stage) of Stage 2 when the NGI is operated at 90 
l/min is 3.61µm (Marple et al. 2003a).  
 
Table 6.5 shows that the number based values of d50 measured for the formulations were 
close to this. Values of d50 did not exhibit a clear trend related to the fines content of the 
formulations. In terms of d90, an increase was apparent as the fines content was 
increased. The increasing particle size in the upper end of the distributions as the fines 
content was increased is clearly visible in Figure 6.8, where the number-based CE 
diameter distributions of the material collected on Stage 2 from the different formulations 
are presented.  
 
Table 6.5 and Figure 6.9, where the volume converted CE diameter distributions of the 
material collected on Stage 2 are shown, indicate that, in volume terms, the increase in 
the particle size in the upper end of the distributions was even more pronounced. These 
data suggest the material collected on Stage 2 became increasingly agglomerated upon 
increasing lactose fines content of the formulation.  
 
The particle shape of the material collected from Stage 2 is summarised in Table 6.5 in 
terms of mean high sensitivity (HS) circularity and convexity values for the different 
formulations. For both shape descriptors, a decreasing trend in the mean values was seen 
as the lactose fines concentration of the formulations was increased. Following the 
definition of these shape parameters (Willen 2008), the higher the value of the 
parameters, the more compact the shape of a particle. It is also known that agglomerates 
often exhibit less compact shape than primary particles (Huck 2007). Therefore, the 
decreasing trend in the particle shape descriptors upon the addition of fines indicated a 
simultaneous increase in the presence of agglomerates. The increasing degree of 
agglomeration in the presence of lactose fines as indicated by the larger particle size and 
less compact shape in the formulations was also reflected in MMAD of the drug collected 
from the formulations, as was shown in Table 6.1.  
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TABLE 6.5 NUMBER-BASED AND VOLUME-CONVERTED CIRCULAR EQUIVALENT (CE) DIAMETER 
DISTRIBUTIONS AND THE MEAN VALUES OF HIGH SENSITIVITY (HS) CIRCULARITY AND CONVEXITY OF THE 
MATERIAL COLLECTED ON STAGE 2 OF THE NEXT GENERATION IMPACTOR FROM THE DIFFERENT 
FORMULATIONS. THE DATA IS BASED ON ANALYSIS OF 7406 (LH100), 18361 (+20% LH210) AND 21551 
(+20% LH300) PARTICLES DURING A SINGLE MEASUREMENT. 
Number based 
particle size 
(µm) 
Volume converted 
particle size 
(µm) 
Particle shape 
Mean values 
d10 d50 d90 d10 d50 d90 HS Circularity Convexity
LH100 1.56 3.84 5.77 3.68 5.35 8.06 0.859 0.986 
+20% LH210 1.72 3.62 6.14 3.60 5.98 9.48 0.846 0.983 
+20% LH300 1.86 3.94 6.72 3.95 6.53 10.4 0.824 0.980 
 
 
FIGURE 6.8 NUMBER-BASED CIRCULAR EQUIVALENT (CE) DIAMETER DISTRIBUTIONS OF MATERIAL 
COLLECTED ON STAGE 2 OF THE NGI FROM THE DIFFERENT FORMULATIONS. THE DISTRIBUTIONS 
REPRESENTED ARE BASED ON ANALYSIS OF 7406 (LH100), 18361 (+20% LH210) AND 21551 (+20% 
LH300) PARTICLES. 
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FIGURE 6.9 VOLUME-CONVERTED CIRCULAR EQUIVALENT (CE) DIAMETER DISTRIBUTIONS OF MATERIAL 
COLLECTED ON STAGE 2 OF THE NGI FROM THE DIFFERENT FORMULATIONS. THE DISTRIBUTIONS ARE 
BASED ON THE SAME DATA AS THE DISTRIBUTIONS SHOWN IN FIGURE 6.8. 
 
 
The chemical composition of the material collected on Stage 2 was studied by Raman 
spectroscopy. The library spectrum of lactose is shown in Figure 6.10. Susi et al. (1974) 
reported the Raman spectra of α-lactose monohydrate in the crystalline state. The authors 
pointed out that lactose molecule has a low symmetry. Consequentially, the Raman 
spectrum of lactose exhibits 129 different vibrational modes. Due to the complexity of the 
spectra, the study did not present a detailed analysis of the different signals. However, the 
study concluded that the strong signals between 300 and 500 cm-1 were due to the 
different vibrations related to the glycosidic bond linking the galactose and glucose rings 
of the molecule. In the current study, these vibrations were used for visually distinguishing 
lactose from budesonide. Since the study by Susi et al., at least two studies have utilised 
Raman spectroscopy for characterising the polymorphic forms of lactose (Kirk et al. 2007; 
Murphy et al. 2005). The Raman spectra of lactose used in the current study as shown in 
Figure 6.10 is typical for α-lactose monohydrate, as reported in all three studies referred to 
here.  
 
The library Raman spectrum for budesonide is presented in Figure 6.11. The Raman 
spectrum of budesonide exhibited a very strong signal at a wavenumber of 1656 cm-1. 
This signal was used for distinguishing budesonide from lactose during visual inspection 
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of the spectra. This signal has been attributed to the stretching vibration of C=C bond in 
the aromatic ring of the steroid backbone of the molecule (Ali et al. 2007) The same study 
also attributed the weak signal at 1721 cm-1 to the stretching vibration of the C=O bond of 
the aromatic ring, and the signals at 1627 and 1602 cm-1 to the asymmetric ring vibrations 
of the aromatic C=C and C=O bonds (Ali et al. 2007).  
 
 
FIGURE 6.10 LIBRARY RAMAN SPECTRUM OF α-LACTOSE MONOHYDRATE 
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FIGURE 6.11 LIBRARY RAMAN SPECTRUM OF BUDESONIDE 
 
A 50x magnification field of view photomicrograph of material deposited on Stage 2 from 
the 20 wt-% LH300 formulation is presented in Figure 6.12. The photomicrograph clearly 
demonstrates that both primary and agglomerated particles were collected on Stage 2. 
Raman spectroscopical characterisation enabled the analysis of the chemical components 
forming these agglomerates. The Raman spectrum of the highlighted particle is displayed 
on the top right of Figure 6.12 and the library spectra of lactose and budesonide below 
that. The characteristic, strong signal of budesonide at 1656 cm-1 is present in the 
spectrum of the highlighted particle. Also the characteristic signal for lactose between the 
wavenumbers of 300 and 500 cm-1 is exhibited in the spectrum of the highlighted particle. 
The matching scores for the library spectra as allocated by the Morphologi G3-ID software 
for this particle were 0.681 for lactose and 0.635 for budesonide. Therefore, on the basis 
of matching scores and the visual inspection of the Raman spectrum, the highlighted 
particle could be characterised as an agglomerate of lactose and budesonide. Similarly, 
pure particles of lactose and budesonide could be characterised based on their Raman 
spectrum. This way, the chemical composition of approximately 1200 particles collected 
on Stage 2 were characterised for each of the formulations. 
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FIGURE 6.12 A 50X MAGNIFICATION FIELD OF VIEW PHOTOMICROGRAPH OF PARTICLES DEPOSITED ON 
STAGE 2 OF THE NGI, THE RAMAN SPECTRA OF THE HIGHLIGHTED PARTICLE AND THE LIBRARY SPECTRA 
OF α-LACTOSE MONOHYDRATE AND BUDESONIDE  
 
Following the Raman spectroscopic fingerprinting of the particles collected on Stage 2, a 
classification was set up according to whether the material was lactose, budesonide or an 
agglomerate of the two components. Proportions of the different chemical species in the 
different formulations are summarised in Table 6.6 and presented in Figure 6.13. These 
data show that, even for the formulation prepared with LH100 only, nearly 40% of the 
particles delivered to the impactor Stage 2 were lactose. With added lactose fines, the 
proportion of lactose delivered to the Stage 2 was even higher at approximately 80%. 
These data are in an agreement with previous studies, where it was reported that fine 
particle lactose is indeed delivered to the impactor stages (Guchardi et al. 2008; Karhu et 
al. 2000; Srichana et al. 1998b).   
 
Figure 6.13 and Table 6.6 demonstrate that the majority, nearly half of the particles, on 
Stage 2 from the LH100 only formulation were single particles or multiplets of budesonide. 
In contrast, the proportion of pure budesonide in the formulations with added lactose fines 
was very low, with 10% for the LH210 formulation and 6% for the LH300 formulation 
characterised as pure budesonide.  
 
Analysing the amounts of lactose and the drug particles delivered to the different parts of 
the impactor is straightforward by different chemical assays. However, when these 
techniques are used, addressing the possible presence of drug-lactose fine agglomerates 
is impossible. Using Raman spectroscopy for analysing the chemical composition of the 
particles collected on the impactor stages enables studying the possible agglomerate 
formation between two chemically different species. A previous study used Raman 
spectroscopy for qualitatively assessing the chemical composition of material deposited 
on the impactor stages (Kinnunen et al. 2009). The results showed co-deposition of 
Highlighted particle 
Lactose 
Budesonide 
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lactose and drug took place. The next step was taken in the current study by quantifying 
the proportions of drug-lactose agglomerates delivered to the impactor stage. Table 6.6 
and Figure 6.13 show, that the proportion of agglomerates of the drug and the lactose 
fines remained similar for all the formulations, with the proportion varying between 11.5 
and 17%.  
 
TABLE 6.6 PROPORTIONS OF BUDESONIDE, LACTOSE AND AGGLOMERATES OF THE TWO SPECIES 
DEPOSITED ON STAGE 2 OF THE NGI FROM THE DIFFERENT FORMULATIONS. THE DATA ARE BASED ON 
RAMAN ANALYSIS OF 1353 (LH100), 1095 (+20% LH210) AND 1156 (+20% LH300) PARTICLES 
COLLECTED. 
Lactose
(%) 
Budesonide 
(%) 
Agglomerates 
(%) 
LH100 37.4 48.8 13.8 
+20% LH210 79.0 9.5 11.5 
+20% LH300 77.3 5.7 17.0 
 
 
FIGURE 6.13 PROPORTIONS OF PURE LACTOSE AND BUDESONIDE AND THE AGGLOMERATES OF THE TWO 
COMPONENTS ON STAGE 2 OF THE NGI FROM THE DIFFERENT FORMULATIONS AS CHARACTERISED BY THE 
RAMAN FINGERPRINT OF THE PARTICLES 
 
To understand the underlying mechanisms for how the lactose fines alter the DPI 
performance, further analysis relating the in vitro deposition of the drug to the proportion 
of drug delivered to Stage 2 either as pure budesonide or agglomerates was performed. 
These data are summarised in Table 6.7. The total proportion of budesonide containing 
species (pure budesonide and agglomerates) was approximately 63% for the LH100 only 
formulation and approximately 20% for the formulations containing added lactose fines. 
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Because the proportions of agglomerates and pure budesonide of the budesonide 
containing species were known (Table 6.6), the amounts of budesonide in agglomerates 
and as pure budesonide could be quantified. This analysis revealed that interestingly, as 
shown in Table 6.7, the mass of the drug delivered to the Stage 2 of the impactor as pure 
budesonide remained constant from all the formulations. Meanwhile, the mass of 
budesonide delivered to the Stage 2 as agglomerates increased as the lactose fines 
content of the formulation was increased. For the 20% LH210 formulation the mass of 
budesonide in agglomerates was approximately four times as high as for the LH100 
formulation. For the 20% LH300 formulation, the mass of budesonide in agglomerates on 
Stage 2 was tenfold compared to the LH100 only formulation. These data show that 
agglomerate formation takes place upon the addition of lactose fines and consequentially, 
an improvement in the DPI performance is achieved. These results demonstrate that 
lactose fines have to be fine enough to be co-deposited in the impactor stages with the 
drug if an improvement in formulation performance is to be gained. Therefore, these 
results also explain why only the finest fractions of lactose fines are efficient in improving 
the DPI performance, as has been previously reported (Guenette et al. 2009; Louey et al. 
2003) 
 
TABLE 6.7 THE MEAN ± STANDARD DEVIATION (N=3)  AMOUNT OF BUDESONIDE RECOVERED FROM STAGE 
2 OF THE NGI, TOTAL PROPORTION OF SPECIES CONTAINING BUDESONIDE OF THE PARTICLES ANALYSED 
BY RAMAN FOR EACH OF THE FORMULATIONS AND THE AMOUNT OF PURE BUDESONIDE AND BUDESONIDE 
IN AGGLOMERATES ON STAGE 2 BASED ON THE RAMAN ANALYSIS. 
Budesonide on 
Stage 2 ± S.D. 
(µg) 
Total 
budesonide
(%) 
Budesonide in 
agglomerates 
(µg) 
Pure 
budesonide
(µg) 
LH100 3.37 ± 0.10 
4.78 ± 0.10 
9.82 ± 0.14 
62.6 0.7 2.6 
+20% LH210 21.0 2.6 2.2 
+20% LH300 22.7 7.4 2.4 
 
 
6.4 CONCLUSIONS 
 
The current study aimed to create a holistic picture of the mechanisms governing the 
regional drug deposition in the impactor by complementing the in vitro performance 
assessment of the formulations by using alternative analytical techniques in parallel with 
the in vitro analysis. The results from the complementary analytical techniques were 
successfully related to the in vitro deposition characteristics of drug from DPI formulations 
containing different concentrations of lactose fines.  
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The study demonstrated that the drug deposition in the USP induction port of the impactor 
was related to loss of fine particles in the throat. This was attributed to the drug depositing 
in the throat as agglomerates with the fine particle lactose. Also, the higher plume density 
in the presence of lactose fines may contribute to the higher drug losses in throat in the 
presence of fine particle lactose. The drug losses in the pre-separator were demonstrated 
to be related to the proportion of large carrier particles present in the formulation. 
However, large proportions of fine particles were also collected in the pre-separator. 
Therefore, evidence for the active site theory in governing the DPI performance in the 
presence of lactose fines (El-Sabawi et al. 2006; Young et al. 2005) is still very limited.   
 
Agglomerate formation and deposition in the impactor stages upon the increasing fines 
content was demonstrated with both the in vitro and the complimentary analysis 
techniques. In vitro analysis established an increasing trend in MMAD upon the increase 
in the lactose fines content of the carrier.  Morphological analysis demonstrated increasing 
particle size and less compact shape upon increasing lactose fines content indicating 
agglomerate formation. However, these analysis methods gave no information on the 
components forming the agglomerates. By means of Raman spectroscopy, proportions of 
pure budesonide and lactose and the agglomerates of the two materials delivered to 
Stage 2 could be quantified. Combining the results of the Raman and in vitro analysis 
revealed that the amount of pure drug delivered to the impactor Stage 2 remained 
constant from all the formulations. However, the amount of drug delivered to the Stage 2 
as agglomerates increased drastically upon the increase in the fines content of the carrier.  
 
The results of this study demonstrated that agglomerate formation between the drug and 
the lactose fines may be the dominant mechanism in how lactose fines improve DPI 
performance. The more fines were available within the carrier, the more drug was 
agglomerated with them and consequentially delivered to the impactor stage. The results 
also shed light on the question of why only the finest lactose fines are efficient in 
improving the DPI performance. This is because the lactose fines have to be fine enough 
to be co-deposited in the impactor with the drug particles. As a consequence, the results 
of the study highlighted why the proportion of fine particles present in the carrier is such a 
popular tool for predicting the DPI performance amongst formulators. 
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CHAPTER 7 GENERAL CONCLUSIONS AND FUTURE WORK 
7.1  ON THE PROCESS HISTORY OF THE LACTOSE FINES  
 
The role of lactose fines in improving dry powder inhaler performance was investigated 
during the current PhD project. Lactose fines with different process histories (milled and 
micronised) were used during the studies. It was seen that the micronised fines were very 
efficient in improving the DPI performance whereas milled fines had a less of an impact. 
These findings were attributed to the greater proportion of fine particle lactose (%<4.5 µm) 
present in the carrier blends prepared with the micronised fines. However, although not 
necessarily playing a significant role in improving the performance, addition of milled fines 
to DPI formulations may still provide the carrier blend with properties useful for the 
manufacturing process. For example, addition of milled fines may increase the cohesion 
of the carrier blend, and consequentially formulation, such that automated capsule filling 
equipment can be used during manufacturing. 
 
7.2 ON THE ROLE OF LACTOSE FINES IN IMPROVING DPI PERFORMANCE 
 
The main aim of the project was to determine the mechanism by which the fines improved 
the DPI performance. In Chapter 3 it was shown that the active sites theory is not likely to 
explain the improved DPI performance upon the addition of lactose fines.  Chapter 4 
indicated that the addition of lactose fines, independent of the process history, increased 
the cohesion of the carrier blends. However, this increase did not necessarily correspond 
to an improved DPI performance. Therefore, the increased cohesion theory is unlikely to 
be the sole explanation for the improved DPI performance in the presence of fine particle 
lactose. 
 
On the basis of SEM images, the improvement in the formulation performance was seen 
to correlate with agglomerate formation, either with drug only (Chapter 3) or between 
lactose fines and the drug (Chapter 4). In Chapter 6, further evidence for the agglomerate 
formation, and consequential drug-lactose co-deposition within the impactor was seen. 
The extent of co-deposition was quantified and it was shown that the more fine lactose 
particles were available, the more agglomerates of the drug and the lactose fines were 
deposited on the impactor stage 2. Therefore, the current thesis indicates that the drug-
fines agglomeration theory is the most likely explanation for the improved DPI 
performance in the presence of lactose fines. 
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7.3  ON THE PARAMETERS DESCRIBING THE LACTOSE PROPERTIES IN 
PREDICTING THE DPI PERFORMANCE 
 
The project also aimed to develop a universal model for predicting DPI performance on 
the basis of lactose properties, independent of the process history of the lactose. Linear 
correlations between lactose properties and DPI performance have been reported in the 
literature. However, it was shown in Chapter 4 that, when a diverse and large enough set 
of carriers is used, simple, universal, linear correlations between the carrier properties and 
the DPI performance are non-existent.  
 
In Chapter 5, statistical methods and artificial neural networks were applied for modelling 
the importance of different lactose properties in determining DPI performance in terms of 
fine particle fraction of emitted dose, mean mass aerodynamic diameter and the 
proportion of drug recovered in the pre-separator. It was shown that the proportion of fine 
particle lactose (%<4.5 µm) was the most important parameter for the networks modelling 
fine particle fraction of emitted dose and the proportion of drug deposited in the pre-
separator. However, this parameter only explained 57 and 45% of the variation in the 
data, respectively. For MMAD, the proportion of lactose particles finer than 15 µm 
explained approximately 75% of the variation. Therefore, other parameters, such as 
powder flow and fluidisation characteristics, although of less significance, are also 
important in capturing the variations in DPI performance. This finding most likely derives 
from the co-linear characteristics of lactose carriers, that on the other hand stem from the 
limited control over lactose properties during manufacturing process involving for example 
milling, sieving and air classification steps to control particle size post crystallisation. 
 
7.4  FUTURE WORK 
 
Micronised fines were seen to be efficient in improving DPI performance whereas milled 
fines had less influence. However, although the milled fines had very little influence on the 
performance, these fines still increased the cohesion of the carrier blends. Currently, 
micronised fines are not used in commercial products due to a short shelf life of half a 
year. Therefore, future work should involve developing more stable lactose fines with a 
particle size distribution similar to micronised fines and testing whether these engineered 
fines would still be effective in improving the DPI performance. The studies in the current 
thesis were conducted using capsule based devices. It would also be interesting to see 
whether similar trends would be observed with blister based devices, for which the 
deagglomeration mechanisms may significantly differ from capsule based devices. 
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APPENDIX I FLUIDISATION-DEFLUIDISATION CURVES OF THE 
FLUTICASONE PROPIONATE FORMULATIONS STUDIED IN 
CHAPTER 3 
 
LH100 
 
0.02% FP in LH100 
 
II 
 
0.05% FP in LH100 
 
 
0.08% FP in LH100 
 
 
 
 
 
III 
 
0.10% FP in LH100 
 
0.15% FP in LH100 
 
 
 
 
 
IV 
 
0.20% FP in LH100 
 
0.40% FP in LH100 
 
 
 
 
 
V 
 
1.00% FP in LH100 
 
2.00% FP in LH100 
 
 
 
 
 
VI 
 
SV010 
 
0.02% FP in SV010 
 
 
 
 
 
VII 
 
0.05% FP in SV010 
 
 
0.08% FP in SV010 
 
 
 
 
VIII 
 
0.10% FP in SV010 
 
 
0.20% FP in SV010 
 
 
 
 
IX 
 
0.30% FP in SV010 
 
0.40% FP in SV010 
 
 
 
 
 
X 
 
1.00% FP in SV010 
 
2.00% FP in SV010 
 
